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Abstract 
In this work lung cancer is introduced along with the current detection methods. The inadequacies 
of the current situation are highlighted along with the need for better detection technologies that 
would allow for a more rigorous testing regime to be implemented. Metabolism and metabolites are 
introduced as potential biomarkers. The advanced detection techniques mass spectrometry (MS) 
and differential mobility spectrometry (DMS) are introduced and discussed with regard to being a 
fieldable device. The methods applicable to processing data generated by these instruments are 
discussed. Finally the research objectives are highlighted. 
The science of breath sampling is discussed along with the considerations when engaging in breath 
analysis research. Sampling and trapping of volatile organic compounds (VOCs) is discussed with 
particular emphasis on the adaptive breath sampler which was used in this work. The benefits of a 
dual detector instrument allowing for analysis of a single sample using both MS and DMS are 
outlined. 
The design and implementation of a parallel, two detector system is outlined including the 
intricacies of balancing the two columns that operate at different pressures and developing a mount 
Processing DMS data currently lags behind the current hardware available as there are no methods 
that allow the full data surface to be utilised. This work outlines a method for transforming DMS 
data from three dimensions to two dimensions while retaining the full information contained within 
the data surface. This method was tested with generated data sets to show its’ utility and compared 
to the current standard processing method using real data sets. 
An understanding of all aspects of a clinical research project is vital to ensure the smooth running 
and completion of the project. The currently required documentation for an outside researcher to 
work within the NHS are detailed along with the expected timeframe for each step of designing, 
gaining ethical approval and implementing the research. The use of Gantt charts and work flow 
diagrams is highlighted and examples are given. 
An initial inspection of the data produced by a pilot study shows that there a several challenges that 
must be overcome, these are contamination and artefact peaks, retention time shifting, unresolved 
peaks, differing intensities in similar samples and the complexities of correctly identifying 
compounds found in breath samples. These are discussed and a workflow is highlighted. 
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“Not their application, certainly, but their principles you may; to learn is not to know; there 
are the learners and the learned. Memory makes the one, philosophy the other.” 
L’Abbé Faria 
The Count of Monte Cristo 
Alexandre Dumas, 1844 
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1 An introduction to lung cancer, current detection methods and applicable 
detection technologies for fieldable devices 
This thesis is based on the premise that there is a detectable difference between the breath 
of people with, and without, lung cancer. To study this difference a large range of 
techniques and skills are required. From collecting the sample through to processing the 
final data output from the instrumentation, it is important that each step is understood.  
This introductory discussion considers the underlying concepts of this research and 
necessarily, includes; 
 Lung cancer 
 Current detection techniques 
 The biochemical basis of cancer targets 
 Volatile organic compounds and lung cancer 
 Detection technologies 
 Fieldable devices – an alternate to imaging and biopsy 
 Data processing methods in VOC analysis 
The fundamental techniques that were used in this research, breath sampling, thermal 
desorption, gas chromatography, mass spectrometry and differential mobility spectrometry 
will be fully described in 2, although where appropriate they will be discussed here. 
1.1 Lung cancer 
In order to understand lung cancer and why there is a need for its’ early detection, it is 
important to have a basic understanding of the disease state. Cancer is a disease in which 
cells exhibit uncontrolled growth, invade neighbouring tissue and sometimes show 
16 
 
metastasis. Some, but not all cancers will form tumours. It is the invasive nature of the 
disease and its’ tendency to metastasise that separates cancer from benign tumours and 
makes it so dangerous. What is important to understand is that different cancers progress in 
different ways and this can affect both detection and treatment. The main types of lung 
cancer will be discussed, with an emphasis on identification, classification and method of 
treatment. 
1.1.1 Types of lung cancer 
The term lung cancer covers several different diseases that occur in the human lung. These 
are classified into three groups, with mesothelioma classified in isolation, Table 1.1. 
Table 1-1 Types of cancer and their group 
Type of Cancer Group 
Adenocarcinoma Non-small cell carcinoma 
Squamous cell carcinoma Non-small cell carcinoma 
Large-cell carcinoma Non-small cell carcinoma 
Small cell Carcinoma Small cell carcinoma 
Mesothelioma No applicable group 
All of these different cancers can be identified, but in terms of treatment the important 
information is the group to which the cancer belongs. The reason mesothelioma is not 
placed in one of the two main groups is because it is a very different disease to any of the 
others that fall under the term lung cancer. 
1.1.1.1 Adenocarcinoma 
Adenocarcinoma can be differentiated from other cancers as it originates from glandular 
tissue and so can sometimes be recognised by its’ attempts to form new glands. 
17 
 
 
Figure 1-1 Histopathology slide of the adenocarcinoma of the lung; HE stain [1]. 
Figure 1-1 shows a hematoxylin and eosin stain (HE stain) of a histopathology slide of 
adenocarcinoma. HE staining is a useful technique in histology. It uses hemalum, a mixture 
of aluminium and hematoxylin, to stain the nuclei of cells dark blue. This is followed by 
counterstaining with a solution of eosin Y, a fluorescent red dye, which colours eosinophilic 
structures different shades of red. Eosinophilic structures can be composed of protein, a 
large part of the cytoplasm is eosinophilic and red blood cells are stained intensely red. 
Adenocarcinomas can spread to the lymph nodes and eventually to the blood, which can 
lead to metastatic disease. Adenocarcinoma is the most common type of lung cancer seen in 
patients with no history of smoking and is the most common form of cancer seen in 
smokers. Adenocarcinoma tends to start in the periphery of the lung [2] and so occurrences 
of this type may be good candidates for surgery. It is a form of non-small cell lung carcinoma 
and so is less susceptible to radiation therapy compared to small cell lung carcinoma 
meaning surgery is the most likely treatment route. 
  
Adenocarcinoma cell 
stained blue
Red blood cell 
stained red
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1.1.1.2 Squamous cell carcinoma 
Squamous cell carcinoma is closely related to a history of smoking [3]. It is a non-small cell 
lung carcinoma making it less responsive to radiation therapy. This means that treatment 
options for squamous cell carcinoma are usually surgical. 
 
Figure 1-2 Squamous cell lung carcinoma. Adapted from [4]. 
This type of cancer most commonly develops in the major airways and from there can 
spread to the smaller airways and on to the lymph nodes and the blood, leading to 
metastatic disease. It may be preceded by squamous cell metaplasia, an irreversible 
changing of one cell type to another, which results in dysplasia, a change to an abnormal cell 
type, and finally forming a malignant neoplasia. Metaplasia is undetectable by x-ray. The 
hypothesis is that if different volatiles are released by squamous cell lung cancer cells they 
may be detectable by breath analysis. Earlier detection of this disease may improve survival 
rates and breath analysis could be a viable option as a diagnostic tool. While biopsy and 
analysis of the tissue allows for detection of this disease, it is a costly and invasive 
technique. Furthermore biopsy is usually only performed if another technique, such as CXR 
or CT scanning suggests the disease is present. By this point the disease has usually spread 
and can be fatal. 
Squamous cell carcinoma developed close to the bronchi
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1.1.1.3 Large-cell carcinoma 
Identified by its’ large cells, this cancer does not form any recognisable structures, unlike 
adenocarcinoma. They are most commonly found in smokers and can appear either within 
the lung or at the periphery. Like adenocarcinoma and squamous cell carcinoma, they 
spread to the lymph nodes and the bloodstream and can cause metastatic disease. 
 
Figure 1-3 Large cell carcinoma of the lung, HE stain [4]. 
A diagnosis of large cell carcinoma is made when adenocarcinoma, squamous cell carcinoma 
and small cell carcinoma have been excluded. There are several different types of large cell 
lung cancer, classification of which is based on the new World Health Organisation 
classification of lung tumours [5]. The cells show an absence of “salt and pepper” chromatin, 
granular chromatin in the cell nuclei, showing up as a grainy white and blue in a HE stain. 
Large cell carcinomas are composed of anaplastic cells, cells which show poor differentiation 
between each other, exemplified by the mass highlighted in Figure 1-3. 
1.1.1.4 Small-cell carcinoma (oat cell carcinoma) 
Small-cell carcinoma, sometimes called oat cell carcinoma due to the cell shape, is named 
due to its’ small, fragile cells. 
A section of a large 
cell carcinoma mass 
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Figure 1-4 Small cell carcinoma, HE stain [6]. The cells of the small cell carcinoma are stained dark blue. 
This form of lung cancer is most commonly associated with smokers and, like squamous cell 
carcinoma, it is most often found in the central part of the lung. Due to its’ tendency to be 
highly malignant it tends to progress quickly and, being more metastatic than non-small cell 
lung cancer, spread in its’ early stages. Small-cell carcinomas are thought to develop from 
Feyrter Cells, named for Friedrich Feyrter [7], in the bronchus. 
Small cell carcinoma is usually treated with combination chemotherapy and radiotherapy 
when the disease is limited stage, confined to the thorax, and just chemotherapy when it is 
extensive stage, metastasised to other parts of the body. This is the most aggressive form of 
lung cancer with an average survival time for sufferers of limited stage disease of 14-20 
months and approximately 20% surviving longer than 5 years and an average survival time 
of sufferers of extensive stage disease of 8-13 months with 1-5% surviving for 5 years or 
longer. This shows that catching this form of the disease in its’ earliest stage would be very 
beneficial and a method that can detect the disease before it is visible by imaging would be 
highly desirable. 
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1.1.1.5 Mesothelioma 
Mesothelioma is a tumour of the pleura, the membrane that surrounds the lungs and 
separates them from the chest wall. It is usually caused by exposure to asbestos and 
frequently causes a build up of fluid in the pleural cavity. 
 
Figure 1-5 Mesothelioma due to asbestos exposure [8]. 
As mesothelioma is a cancer of the lining around the lungs a breath detector may not be 
applicable in its’ diagnosis so it has not been considered in this work [9]. 
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1.1.2 Causes of lung cancer 
There are several causes of lung cancer, but the most widely recognised and publicised is 
tobacco smoking. There have been many, many studies linking tobacco smoking to lung 
cancer, and as smoking became more popular the number of lung cancer cases began to 
rise, leading deaths per one hundred thousand due to lung cancer to have more than tripled 
for both men and women since the 1950’s [10]. It has been estimated that ninety per cent 
of lung cancer deaths in the U.K. are due to smoking [11]. 
Cessation of smoking has been shown to reduce the risk of lung cancer, with Doll and Hills’ 
work over a 20 year study of British doctors showing that the death rate for those studied 
fell by 38 per cent, coinciding with over 50 per cent of them giving up smoking within the 20 
year study period while the death rate for men in the whole of Britain rose by 7 per cent, 
coinciding with an increase in smoking [12]. A clear benefit has been shown for smokers 
who give up smoking early, with the risk of lung cancer rapidly falling after just 5 years of no 
smoking and carrying on falling for over 20 years of no smoking, to a level just above non-
smokers. 
It has been shown that the more cigarettes a person smokes, the more likely they are to 
contract lung cancer, although the major factor is how long someone has smoked for [13]. 
This means that regular, long term smokers are much more likely to contract lung cancer, 
and form the highest risk group. 
Passive smoking has been indicated as increasing the chances of getting lung cancer, so the 
spouses/partners of smokers are at an elevated risk of contracting the disease. If their 
partner smokes more than 20 cigarettes a day their chances of developing lung cancer are 
doubled compared to someone whose spouse/partner is a non-smoker. It is estimated that 
11,000 deaths a year in the U.K. are caused by passive smoking. 
While smoking accounts for the large proportion of lung cancer cases, there are several 
other causes. Air pollution, vitamin A deficiency and exposure to asbestos have all been 
suggested as possibly increasing the risk of contracting lung cancer, with asbestos being the 
main cause of mesothelioma. 
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Exposure to radon gas is the second biggest cause of lung cancer behind smoking. Uranium 
occurs naturally in the Earth’s crust and as it decays it releases radon. Radon occurs as a gas 
under standard conditions, it is radioactive and because of its high density compared to 
other gases under standard conditions it can accumulate in poorly ventilated spaces such as 
attics and basements. When a person enters a location with an increased radon 
concentration they will breathe in the gas and it can damage DNA in the cells it passes 
through. This can lead to mutations in the cells which can then lead to cancer.  
1.1.3 Prevalence of lung cancer 
Lung cancer is the most common cause of death from cancer for both males and females. 
Twenty four per cent of UK male cancer deaths and twenty per cent of UK female cancer 
deaths are due to lung cancer [11]. This is coupled with extremely poor survival rates, with 
only twenty seven percent of male patients and thirty per cent of female patients in England 
and Wales surviving for one year after diagnosis and seven per cent of male patients and 
nine per cent of female patients surviving for more than five years [14]. 
Lung cancer is a disease of the developed world, with people living in the U.K. having the 
highest risk of developing lung cancer. People living in Africa have the lowest risk of 
developing lung cancer. There are approximately 34,500 deaths in the UK due to lung cancer 
each year [14]. 
Estimates for lung cancer prevalence for the world are available through the GLOBOCAN 
database from CANCERMondial [15] which allows users to see the cancer statistics by 
country for all cancer types.  A world map, Figure 1-6, generated from this shows the 
different mortality statistics using the standardised mortality rate (SMR). 
The SMR is calculated according to: 
    
 
 
     
Equation 1-1 
Where O is the total number of deaths observed in a specific population and E is the 
expected number of deaths if the population was subject to a standard set of age-specific 
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rates. In the case of the SMR E is the age specific mortality rates for the World. The SMR is 
expressed as a percentage of E and this means that the SMR can be used to compare a 
specific population to the World. 
25 
 
 
Figure 1-6 Maps coloured according to the SMR calculation to show the rate of lung cancer death in every country compared to the world average. 
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Figure 1-6 shows a shaded map giving the SMR for each country according to the colour key 
shown. From this map it is clear to see that, on the whole, the mortality rates are higher in 
the more developed regions of the world. The enlarged map of Europe shows the large 
differences in the morality rates between European countries. The statistics for Africa reveal 
a wide range of mortality rates that tend to follow the GNP trends seen at a Global level. But 
even so it should be noted that only the highest rates of mortality are above the World 
average. 
While lung cancer is mainly a disease of the developed world, the prevalence of the disease 
is beginning to spread. The World Health Organization (WHO) gives the expected increase in 
lung cancer incidence rates for different regions of the world. These rates have been 
challenged as underestimating the problem as cancer registration in developing areas is 
poor so many are extrapolated from neighbouring countries. Work by Nawi et. al. Suggests 
that the spread has been underestimated by as much as two point six times the 2003 WHO 
in sub-Saharan Africa [16]. This indicates that the incidence of lung cancer will steadily 
increase in areas where healthcare can be poor, and low-cost fast detection methods would 
be of a huge benefit here. 
Men are more likely to develop lung cancer than women with a rate of sixty point eight per 
one hundred thousand of the population compared to thirty seven point one per one 
hundred thousand of the population. Most lung cancer suffers are sixty or older with more 
than three quarters of deaths due to lung cancer occurring over the age of sixty five years 
old [14]. 
1.2 Current lung cancer diagnosis techniques 
The detection of lung cancer is a multi-disciplinary and multi-parameter procedure, and 
there is no single diagnostic test. There are several different diagnostic tests used to 
determine if a patient has lung cancer. These diagnostic tests are: 
 Spirometry, 
 Bronchoscopy, 
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 Chest x-ray (CXR) 
 Computed tomography (CT) scan, 
 Positron emission tomography (PET) scan and, 
 Biopsy. 
1.2.1 Spirometry 
There are many different spriometric tests. The two most common tests are: the forced vital 
capacity test (FVC); and, the forced expiratory volume in 1 second (FEV1). The FVC test 
measures the volume of air, in litres, that can be forcibly expired after full inspiration and 
the FEV1 test measures the maximum volume of air, in litres, that can be forcibly expired 
during the first second of expiration. Calculating the ratio of FEV1 to FVC can give a very 
good indication of a persons’ lung function. A value of 0.75 - 0.80 is expected for healthy 
adults while a value of less than 0.75 is expected for a person with obstructive respiratory 
diseases such as COPD or asthma; these diseases increase the resistance to higher flows in 
the lung . It is helpful to note that certain diseases can cause a reduction in both the FVC 
and the FEV1, which would result in a normal ratio between the two. While these tests are a 
good indicator of whether a person has impaired lung function, they cannot diagnose 
specific lung disease, only that lung function is impaired. To diagnose specific diseases other 
diagnostic tests are required. 
1.2.2 Chest X-ray (CXR) and X-ray computed tomography (CT) scan 
It is possible to identify tumours within the lungs by taking a Chest X-ray (CXR). There are 
many different things that can be identified using a CXR, although it can be difficult to 
conclusively identify a tumour. The simplicity of a CXR procedure means that it is usually the 
first diagnostic test used when lung cancer is suspected. Where the facilities are available, X-
ray computed tomography (CT) scanning is the usual next step if an abnormality is seen in a 
CXR. X-ray facilities are expensive to both install and maintain. They require skilled staff to 
operate and maintain them and they require a doctor to interpret them. They also require 
power services and a dedicated room in a building. This makes them unpractical for poor 
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communities in developing countries, particularly in rural areas with poor transportation 
links to local hospitals. A cheap, portable, point of care detector that requires minimal 
training and maintenance would be of real benefit in regions where x-ray facilities are too 
costly. 
CT scanning is an x-ray technique that can generate three dimensional images by processing 
a large amount of two dimensional images based on the principles of tomography. It is more 
useful than CXR as it can give a better view of the chest and allow for a better assessment of 
the analysis. Again, it cannot always give a conclusive diagnosis, and in this case a more 
invasive technique is needed to confirm the diagnosis of lung cancer. As with x-ray facilities, 
CT scanners are expensive and require trained personnel, power services, expensive 
consumables and a dedicated room or facility. This again makes them unpractical for many 
places where healthcare is poor. 
 
Figure 1-7 On the left is an abnormal Chest X-Ray showing a cancer in the patient’s right lung (blue arrow) and on the 
right is CT scan shows dominant pulmonary nodule (white arrow) in right lower lobe that proved at 
pathology to be adenocarcinoma (adapted from [17] and [18]). 
1.2.3 Bronchoscopy 
Bronchoscopy is a visualisation technique used to inspect the airways. The instrument used 
is a bronchoscope; a device that allows the operator to see the inside of the lungs. This 
means the operator can examine the airways for abnormalities such as tumours, bleeding, 
inflammation or foreign body. 
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Figure 1-8 Schematic of a bronchoscopy [19]. 
The bronchoscope will only allow the operator to see anything within the airways, which 
means that, in the case of lung cancer, only tumours that have formed within the airways 
can be seen. A bronchoscopy can be a useful diagnostic test to confirm findings from less 
invasive tests, such as CT scan, PET scan or chest x-ray. A skilled practitioner is required to 
perform a bronchoscopy along with sterile conditions. The bronchoscope is expensive and 
must be cleaned thoroughly between uses. A portable detector could be fitted with 
inexpensive one-use mouth pieces. This would remove the need for extensive sterilisation 
of equipment. 
1.2.4 Biopsy 
A biopsy is the removal of tissue for either the eradication of an unknown, an exclusion 
biopsy, or the removal of a small amount of tissue from an unknown to aid diagnosis, an 
inclusion biopsy. In the case of lung cancer, the biopsy is the most conclusive diagnostic test 
that can be performed for suspected lung cancer. It is, however, an invasive test and relies 
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on the tumour being of a sufficient size for the biopsy to be successful. This requires a 
skilled practitioner, expensive equipment and sterile conditions. As it is an extremely 
invasive technique it is only used to confirm findings from previous imaging diagnostics. As 
imaging techniques cannot detect many early stage cancers and require the patient to 
present themselves for testing it is likely that the disease will have progressed to a later 
stage by the time it is detected. This reduces the chances that treatment will be successful. 
1.2.5 The need for better diagnostic techniques 
The current diagnostic techniques really on imaging methods that are unlikely to detect 
early stage lung cancer as a starting point. This means that by the time the disease is 
detected it is likely that it has spread and cannot be treated. This is exemplified in the poor 
prognosis for most lung cancer sufferers. The statistics also show that the earlier the 
diagnosis can be made the more likely it is that treatment will be successful and the longer 
the sufferer is likely to survive. This highlights the need for better detection techniques that 
can diagnose the disease at an earlier stage. 
Diagnosis of lung cancer also relies on the sufferer presenting themselves for diagnosis. As 
smoking is the main cause of lung cancer, and is also a cause of many other respiratory 
diseases that have similar symptoms, it may be some time from the initial onset of the 
disease until the sufferer is aware of the onset of symptoms and presents themselves for 
diagnosis. This diagnosis then relies on techniques that are expensive and require skilled 
operators and interpreters of the data to successfully diagnose the disease. This is a limited 
work flow that can result in a disease being present for an extended period before 
diagnosis, increasing the likelihood that it will be fatal with a short time frame. 
A cheap, portable, point of care detector that can be operated and maintained with the 
minimal amount of training with the ability to detect disease at an earlier stage would be of 
major benefit in the diagnosis and treatment of lung cancer. The possibility of people at a 
high risk of lung cancer using the device regularly to monitor their health could be realised if 
all these criteria are met. The aim of this work is to establish a basis for this hypothesis, 
showing that cheap detection methods are applicable to the detection of lung cancer. 
31 
 
1.3 Biochemical basis of cancer targets 
To provide a biochemical basis for the biomarkers of cancer it is necessary to understand 
how cancer cells differ from normal cells. It is these differences that are expected to provide 
biomarkers of the disease that can be measured and used to develop diagnostic techniques 
that are capable of detecting the disease earlier than the current methods employed. 
Cancer cells do not function in the same way as normal cells. Cells follow a cell cycle which is 
divided into two main phases, the interphase and the mitotic phase, as shown in Figure 1-9. 
 
Figure 1-9 The cell cycle. Showing the four main stages: G1, the first gap phase. S, the synthesis stage. G2, the second 
gap phase and M, the mitotic phase. 
The cell cycle, shown in Figure 1-9, is divided into two main stages; 
1. The interphase. This phase can be divided into three growth sub-phases; 
i. The first gap phase, G1. During this phase the cell is growing by 
synthesizing proteins to produce cytoplasmic organelles. 
• The second 
gap phase.
• The mitotic 
phase. 
• The 
synthesis 
phase.
• The first 
gap phase.
G1 S
G2MCell division gives
two cells which
then follow the
same cell cycle.
Interphase
Mitotic phase
Cell can exit
the cycle to
G0 phase. Restriction point
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ii. The synthesis phase, S. During this phase, as well as growing in the 
same way as it is during G1, the cell copies its chromosomes ready for 
cell division. 
iii. The second gap phase, G2. During this phase the cell is growing in the 
same way it grows in the G1 and S sub-phases. 
2. The mitotic phase. It is during this phase that mitosis divides the nucleus and 
cytokinesis divides the cytoplasm, creating two cells. 
A population of cells increases as the cells divide. Normal cells follow a phenomenon called 
density–dependent inhibition of cell division. When normal cells reach a specific density 
they stop dividing and this can occur during the G1 phase. Just before the cell cycle passes 
from G1 to S a restriction point is reached. It is at this restriction point when it is decided if 
the cell will continue through the cycle and divide or if it will exit the cell cycle to the G0 
phase, the non-dividing phase. Whether a cell passes beyond the restriction point in the cell 
cycle is dependent on growth and nutritional status, the density of the cell population and 
the state of development the cell is in. The transition between phases is controlled by 
protein kinases which are in turn controlled by cyclins. 
Cancer cells divide excessively as they do not respond to the bodies’ normal cell cycle 
control methods. These cells can invade other tissues and, if allowed to continue, kill the 
organism they are present in. Cancer cells grown in culture will continue to divide and not 
enter the G0 phase as long as they have sufficient nutrients. An example of this is the HeLa 
cell culture, a culture grown from a cervical biopsy of Henrietta Lacks taken in 1951 that is 
still reproducing. 
Cancer cells are cells whose genes have undergone mutation, which causes them to ignore 
the control mechanisms that control their growth and division. The major cause of these 
mutations that cause lung cancer is the chemicals in tobacco smoke. Most cells that mutate 
are destroyed by the immune system, however if a cancerous cell is not destroyed it may 
proliferate and form a mass of cancer cells called a tumour. This tumour can be either 
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benign or malignant. Benign tumours can usually be removed by surgery and do not 
generally cause problems. Malignant tumours are tumours that can invade and impair the 
function of organs. It is the presence of malignant tumours that is classified as a cancerous 
disease. Cancer cells that form malignant tumours differ from normal cells in other ways as 
well as their uncontrolled proliferation. Differences in the cell surfaces allow them to detach 
and invade other tissues and separate from the tumour and enter the lymph and blood 
vessels. This transports the cells to other areas of the body and result in tumours growing in 
different tissue than the original tumour. This process is referred to as metastasis [20]. 
The metabolism of cancer cells may be different to that of normal cells and it is different 
volatile metabolites in cancer sufferers that can be used as biomarkers of disease. 
1.3.1 Metabolism and metabolites 
Metabolism is all an organisms’ chemical processes. A cells’ metabolism is made up of 
thousand of reactions that occur in the cell. Metabolism is specific to each cell type, 
although many of the same reactions will occur in different cell types. These reactions are 
arranged in “pathways”, a series of reactions that consecutively alter a molecule. These 
pathways are controlled by enzymes which accept specific substrates and convert them so 
they can be accepted by the next enzyme in the pathway. The pathways are used to 
regulate the material and energy resources of the cell. The regulation of energy is 
fundamental to all metabolic processes and must be managed by the cell. Metabolic 
pathways can be sub-divided into catabolic and anabolic pathways, energy producing and 
energy using pathways. It is these metabolic pathways that produce the volatile organic 
compounds that can be measured by breath analysis. 
1.3.1.1 Catabolism, catabolites and reactive oxygen species (ROS) 
Catabolism is the metabolic pathways that produce energy and this sub-set of metabolic 
pathways can be classified as catabolic pathways. Any pathway which results in the release 
of energy is a catabolic pathway and they involve the breakdown of larger molecules into 
smaller molecules to produce energy. Cellular respiration is the major source of energy 
production in a cell. In this process oxygen is used as a reactant along with complex organic 
compounds. Fats, carbohydrates and proteins are all used in this process which produces 
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carbon dioxide, water and heat which is used to drive the production of adenosine tri-
phosphate. Adenosine tri-phosphate is the main source of energy that drives cellular 
processes and this means its production and regulation is essential. The by-products of 
catabolism are referred to as catabolites and, as much of catabolism involves the 
metabolism of oxygen, many of these are reactive oxygen species (ROS). ROS are thought to 
play an important role in lung cancer based on the VOCs observed in breath samples from 
lung cancer sufferers. ROS are responsible for lipid peroxidation, the breakdown of 
polyunsaturated fatty acids into hydrocarbons such as pentane and ethane and aldehydes. 
These compounds pass from the cell into the blood and are excreted from the body via the 
transfer processes in the alveoli in the lungs. A possible reaction scheme showing lipid 
peroxidation by ROS with possible reaction products is shown in Figure 1-10. 
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Figure 1-10 Free radical mediated lipid peroxidation: Possible reactions and reaction products. Taken from Miekisch et. 
al. [21] R = CnHm, R1 = COOH, R2 = CnHm 
The role of oxygen free radicals in cancer development [22, 23] could explain an increase in 
ROS and this could explain an increase in the degradation products of lipid peroxidation. 
1.3.1.2 Anabolism and anabolites 
Anabolism is the opposite of catabolism. Anabolism uses energy to construct molecules 
from smaller units. Any metabolic pathway that uses energy can be classified as an anabolic 
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pathway. It is these pathways that are involved in the growth of cells. Different anabolic 
pathways exist in different cells depending on what the cell is required to do. It is these 
processes that will change in cancer cells and produce metabolites that are different to the 
metabolites found in normal cells. Identification of metabolites that are unique to or over-
expressed by cancerous cells will provide biomarkers for lung cancer. 
1.4 Volatile organic compounds and lung cancer 
Volatile organic compounds (VOCs) are organic compounds that, under normal conditions, 
form vapours from their condensed state either as a liquid or a solid. This makes them 
strong candidates for study as disease markers. The monitoring of VOCs is a widely used 
technique and has been employed to detect chemical weapons, narcotics, explosives and 
industrial contaminants as well as monitoring air quality [24-28]. The range of organic 
compounds that exhibit these properties is extremely wide, so this work focuses on those 
found in the breath. 
More than one thousand different VOCs have been observed in human breath [29], coming 
from both exogenous and endogenous sources. Detecting these compounds in the breath, 
using a range of different techniques, has been shown to allow discrimination between 
diseased and healthy participants in several studies [30-36]. It is the fact that volatile 
organic compounds can be detected in the breath that the technique of breath sampling is 
based on. This theme has been highlighted by several landmark papers that have progressed 
the research to the next stage. 
1.4.1 Landmark papers and studies in the characterisation of lung cancer volatiles 
1.4.1.1 In-vitro studies 
Several in-vitro studies have been carried out to characterise the volatiles released by 
cancer cells. Chen et. al. [37] studied the relationship between the volatiles found in breath 
and cells in vitro derived from tissue removed during surgery. The breath samples were 
collected using a Tedlar bag system where the participant was required to take a deep 
breath, hold it for one second and then exhale into the bag. The authors make the 
statement that as there are no plants or flowers in the room the VOCs in the samples can be 
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considered as originating from the participant themselves. As there are many sources of 
VOCs from perfumes and cosmetics to cleaning products, to assume that only flowers and 
plants will contribute to background VOCs is a flawed approach. The cell lines were sampled 
using solid-phase micro-extraction (SPME), a technique in which an adsorbent is exposed to 
a sealed headspace above a sample and the volatiles adsorb to the adsorbent. The breath 
samples were extracted from the Tedlar bags using a two bag system and SPME to pre-
concentrate the samples. This does not take into account any compounds which are 
adsorbed to the walls of the Tedlar bag which may not be removed and therefore not 
detected. The use of an adsorbent trap as both the sampling and pre-concentration step 
which eliminates the chance of these loses. The detector used in this work as a flame-
ionisation detector (FID). To identify components in the breath and cell line samples a set of 
standards were analysed and their retention time was used to identify the same compounds 
in the samples. This approach limits the research to identifying compounds which have been 
run as standards and in this case only those previously suggested as breath biomarkers. The 
authors note that breath samples contain approximately 200 compounds but their research 
is limited to only the eleven compounds selected. While they can still show the different 
compounds are changing in the different samples, the detector is non-specific and it is 
impossible to tell if any suspected increases are due to a single or multiple compounds. They 
have shown that it is possible to discriminate between lung cancer sufferers, healthy 
controls and participants with chronic bronchitis based on a principle component analysis 
(PCA) plot. The small number of samples means that these results cannot be extrapolated to 
a larger population but the results are encouraging. However, the limitations in the 
sampling methodology mean that a detailed study of the meta-data is required to validate 
the results. Something as simple as two different operators taking the samples from a single 
group while wearing a different perfume. This perfume could contaminate the samples and 
provide separation in the PCA plot if it were mistaken for or interfered with the peak 
produced by one of the chosen biomarkers. By using FID as the detector instead of mass 
spectrometry it is impossible to know if this has happened. 
Sponring et. al. [38] described work investigating the VOCs released by the lung cancer cell 
line NCI-H2087. 100 x 106 cells were cultured in-vitro in a sealed fermenter under controlled 
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ventilation using clean air. After sixteen hours a 200mL aliquot of the headspace was diluted 
1:5 with purified dry air to combat the high humidity of the fermenter. The VOCs in this 
headspace were sampled using an adsorbent trap packed with Tenax TA, Carboxen 569 and 
Carboxen 1000. It seems like an extra complicating step to dilute with dry air when the VOCs 
will be extracted from the headspace as while the concentration of water may be lower as 
the volume of gas is increased the amount of water that is passed through the adsorbent 
will still be the same. The authors have noted the problems with relying on a library 
searching programme for identifying compounds, particularly at low levels when 
background interference is high and have also used the retention time of standards to 
confirm identification. This is a move towards making the identification more rigorous but it 
also relies on the compounds being run as standards for comparison. There is no mention of 
any deconvolution of convoluted peaks, the splitting up of peaks that are composed of one 
or more compounds, although it is likely that these were present in the sample analysis. The 
results showed that twenty two distinct compounds were detected in the headspace of the 
cancer cell lines which were verified by comparison with the samples. These twenty two 
compounds provide an initial starting place for biomarker identification. Analysis of the data 
showed a reduction in five compounds when compared to the medium controls. This work 
highlights an important point. Biomarkers may not necessarily be compounds unique to lung 
cancer sufferers; they may be a change in the concentration of compounds present in all 
samples. 
Barash et. al. [39] sought to show that a more simple technology, gold nanoparticles, could 
be used to discriminate between Non-small cell lung cancer (NSCLC) versus medium. They 
identified 350-400 different compounds between the samples although after careful cross-
comparison forty common VOCs were identified that appeared in over eighty five percent of 
the cancer cell lines and the control medium. The authors make no mention of how they 
identified the compounds in each sample but it is likely they used an automated method. If 
this is so then this could highlight a problem with automated methods as pointed out by 
Sponring et. al. [38], that they can incorrectly assign compounds due to interference from 
background ions at low concentrations. They identified fifteen VOCs that were unique to 
NSCLC samples compared to the medium controls. Based on these results they developed 
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an array of 18 chemiresistors to detect NSCLC based on its headspace. They showed that 
they were able to separate out four groups, NSCLC headspace, control medium headspace, 
lung cancer breath and healthy breath in a principle component analysis plot. This shows 
that a fieldable device has the potential to detect lung cancer. These results add weight to 
the premise behind this research. It should be noted that the breath samples were taken 
from participants with stage 3 and stage 4 cancers. At this stage the cancer is likely to be 
advanced and a detection technology would need to be able to able to detect the disease at 
a much earlier stage to be of benefit in diagnosis. 
1.4.1.2 In-vivo studies 
Breath analysis has been discussed as a diagnostic technique since it was shown to be a 
viable technique for measuring compounds in the breath, first by Haldane but then 
furthered by L. Pauling. It was Pauling who first estimated that a breath sample can contains 
approximately two hundred and fifty compounds [40]. The limitation of this work was that 
there was no pre-concentration step so compounds that appeared at low levels such as 
parts per million or parts per billion were not readily detectable. It was Zlatkis et. al. [41] 
who first described the use of an adsorbent to pre-concentrate breath samples. They used 
the adsorbent to concentrate the volatiles from fifty breaths and then analysed these. They 
showed that based on the profile it was possible to distinguish the difference between 
breath samples from people with different substances in their mouths compared to those 
without the substance in their mouth. The compounds that accounted for the difference 
were never identified. 
The first study to identify compounds specifically related to lung cancer was carried out by 
Gordon et. al. [42]. This study aimed to identify differences between the VOCs found in the 
breath of lung cancer sufferers and healthy volunteers. They identified twenty different 
compounds that they used to develop a linear discriminate function that could distinguish 
between the breath of lung cancer sufferers and healthy controls for all twenty nine 
volunteers. This was the first study to show that breath analysis was a viable technique for 
disease detection. This work was extended in nineteen eighty eight when O’Neill et. al. [43] 
developed a computerised classification method for screening for the presence of breath 
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biomarkers in lung cancer. This showed that it was possible to automate the detection of 
lung cancer based on the volatiles seen in breath samples. 
Recently several papers from Michael Phillips have built on this initial work to show that 
detection of lung cancer by breath analysis is a valid option as an alternative diagnostic 
technique, not just for lung cancer but also other respiratory diseases [33, 44-46]. This has 
grown the area of breath analysis, exemplified by the number of reviews recently published 
on the subject such as those by Miekisch and Schubert [21, 47], Chan et. al. [31] and Cheng 
and Lee [48] and even a review article on the potential of a hydrocarbon breath test as a 
measure of lipid peroxidation [49] as discussed in 1.3.1.1. 
There has also been work on detection technology for breath analysis. Dragonieri et. al. [50] 
described an electronic nose for discrimination of patients with COPD and non-small cell 
lung cancer. Di Natalie et. al. [32] described a non-selective gas sensor array that could 
discriminate between lung cancer sufferers and healthy controls. These techniques are 
simple but they are also non-specific, they do not detect a specified molecules but a range 
of molecules that have an affinity for the chosen sensor. Of interest here is the work of 
Baumbach and co-workers who have used ion mobility as a detection technology for breath 
analysis and lung cancer [30, 51-53]. They have shown that it is possible to use ion mobility, 
a detection technique that can be tuned to specific compounds to detect volatiles from 
breath and discriminate between lung cancer sufferers and healthy controls [30]. This 
includes the development of a commercial ion mobility breath analysis device [54]. 
All of this work shows that the premise that there is a detectable difference in the breath of 
lung cancer sufferers and healthy controls is well grounded within the scientific literature. 
The current lack of any consensus on specific biomarkers for lung cancer needs to be 
addressed in the research. The identification of biological processes that may produce 
certain biomarkers, such as lipid peroxidiation, have been identified but this is currently 
limited to the action of reactive oxygen species which is non-specific. If certain lipids were 
identified as unique to cancer cells then it is possible that increases in particular volatile 
hydrocarbons would be able to discriminate lung cancer lipid peroxidation from other 
peroxidation, and the current literature suggests this may be the case with several papers 
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identifying methylated hydrocarbons as possible biomarkers for lung cancer, although this 
needs more rigorous investigation to confirm this. Add to this the work that has shown that 
relatively simple detection technologies such as electronic noses and IMS are viable as 
methods for breath analysis and the possibility of a fieldable device to detect lung cancer is 
a logical step in the future of this research. 
1.5 Fieldable devices – an alternative to imaging and biopsy 
The current standard for lung cancer diagnosis is the detection of the disease by one or 
more of the four following diagnostic techniques: 
 Chest X-ray (CXR), 
 X-ray computed tomography scan (CT-scan), 
 Bronchoscopy and, 
 Biopsy. 
All of these technologies have drawbacks. CXR and CT-Scans have limits of detection of 
approximately 1 cm3 [55] and cannot distinguish cancerous tissue from non-cancerous 
tissue. This relies on a skilled operator which experience and can still be inconclusive. 
Bronchoscopy can be used to visualise the airways and therefore can only detect cancerous 
tissue that can be seen from the airways. It also will only be carried out if the patient is 
suspected of having lung cancer, usually based on a CXR or CT-scan. Biopsy is an invasive 
detection method and will only be used to confirm that a mass found via an imaging 
technique is cancerous. This is because the imaging technique is needed to guide it to the 
suspected cancerous mass. 
The main limit for all of these techniques is that the patient must first visit present 
themselves for diagnosis and must then be referred for the relevant tests. As many people 
with lung cancer also suffer from other respiratory disease, and these diseases have very 
similar symptoms, it can be very difficult for someone to recognise that they may be 
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suffering from lung cancer. The high mortality rates observed for lung cancer patients show 
that most people are diagnosed when the cancer is relatively advanced [56] and this can be 
explained by the disease only being noticed at a late stage. 
The best method for lung cancer detection is regular diagnostic testing of high risk patients 
but this is impractical with the current diagnostic techniques. All of them are expensive, 
required a specialised setting and services and highly trained personnel to operate. This is a 
particular problem in rural areas and developing countries where the required diagnostic 
instrumentation is either too expensive or only located in urban areas which many people 
do not have access to. Add to this the limitations of these diagnostic techniques, as 
described in Section 1.2, and this shows that the current methods for detection of lung 
cancer are far from perfect. 
The perfect solution would be a device that is cheap, portable, sensitive and easy to use. A 
device such as the fictional “tricorder” in the Star Trek series is an example of a fieldable 
device. While this device is fictional there are real life examples of this type of device, one of 
which is particularly well known, the breathaylser. 
While Anstie made the first documented observation of alcohol being excreted in the breath 
[57], is was Emil Bogens’ 1927 paper [58] that made the first comparison between the level 
of alcohol within the breath and the blood, stating that “...the concentration of alcohol in 
the breath approaches a fairly constant relationship to that in the blood, since it passes 
through the lungs very easily.” The following work of Liljestrand and Linde [59] showed that 
1 mL of blood contained the same amount of alcohol as 2 litres of exhaled air at 31 oC. 
Testing for alcohol intoxication is a perfect example where an unintrusive, fieldable device 
can replace a more intrusive test, in this case taking a blood sample. The logistical problems 
of taking a blood sample compared to a breath sample show that the benefits of a fieldable 
analysis device are huge and these are now commonplace and date back to the first device 
intended for use by police officers, the drunkometer [60]. While this device was the first 
alcohol breath tester, its’ results were debatable and it was difficult to use. To combat these 
problems, R. F. Borkenstein developed the Breathalyser. This device was first described in 
the literature in 1961 [61]. The breathalyser works by passing the breath sample through a 
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glass ampoule containing 0.025% potassium dichromate in 50% sulfuric acid. This 
Concentration was calculated by Dubowski, as the initial concentration used by Borkenstein 
was too high for the low levels of alcohol present in breath [61]. As the breath passes 
through the dichromate solution, the alcohol is transformed to acetic acid. To measure the 
change in colour of the dichromate, the breathalyser used an incandescent light bulb 
arrangement on a moveable carriage that moved between a test and a reference ampoule, 
each with a separate photocell and blue filter. As the reaction causes a decrease in yellow 
colour of the dichromate, this causes a logarithmic increase in blue light transmittance 
according to the Beer-Lambert Law. By moving the light source to establish the null 
condition for the test cell, the movement is expressed in blood alcohol units (%w/v) in 
accordance with the movement of the light bulb carriage. 
The current technology is based on the same principle that the concentration of alcohol in 
the blood can be measured by measuring the concentration of alcohol in the breath, but the 
devices have changed considerably. The alcolmeter device series developed by Lion 
Laboratories uses a fuel cell; an electrochemical cell that converts a fuel to an electric 
current. This to tuned to selectively detect the alcohol in the subjects breath. These devices 
show that fieldable devices are a viable option for breath analysis. 
The detection technology used must be viable for the application. The technology must be 
capable of analysing VOCs in-situ. As it is unknown what the volatiles specific to lung cancer 
might be, although there are current suggestions, it needs to be capable of detecting a 
variety of compounds during the initial stages but also be capable of detecting a specific 
compound should this be required. It needs to be cheap to both purchase and run, easy to 
use and require as few services as possible. A device that is capable of operating as a stand-
alone instrument without any external services, such as a power or gas supply that can be 
re-charged and then used in the field would be ideal. For this work a differential mobility 
spectrometer, a device based on ion mobility, was chosen and the reasons for this will be 
discussed, however the other option that could be considered is a mass spectrometer. 
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1.5.1 Mass spectrometry as a fieldable device 
The main benefit of using mass spectrometry as a fieldable detection device is that it can 
identify unknowns. To use a mass spectrometer as a fieldable device there are several 
problems that need to be overcome. The size, cost and complexity of the instrumentation, 
along with the power required for operation, have previously limited mass spectrometers to 
laboratories. There has been much research into miniaturization of mass analysers [62-68], 
and this has led to miniature mass spectrometers being developed as the power and 
vacuum requirements are reduced. While this has led to a reduction in costs, the miniature 
turbo pumps are still expensive and this means that using mass spectrometers as fieldable 
devices is still an expensive option. 
These devices suffer from a reduced resolution compared to laboratory devices and, while 
cheaper than bench-top and floor-standing equivalents, are still expensive when compared 
to other techniques. They are also complex and contain fragile components that make them 
difficult to use as a fieldable device. While further development will improve these devices 
and bring them closer to being a viable fieldable detector option, they are currently too 
expensive to be considered. 
1.5.2 Ion mobility as a fieldable device 
While the breathalyser is designed to measure a single compound, ion mobility devices can 
monitor a wide range of different compounds simultaneously. Some of the areas where 
these devices are most commonly employed are in the detection of explosives, chemical 
weapons, narcotics and biological agents, several of which are usually abbreviated to CBRN 
(chemical, biological, radiological and nuclear). Several companies exist that make detectors 
for a variety of different applications. Smiths Detection makes a wide variety of detectors, 
from desktop detectors commonly used at airport security, to handheld devices for onsite 
detection and walkthrough detectors for security check-points [69-74]. General Dynamics’ 
JUNO detector is a small, personal detector that can identify a wide variety of chemical 
agents [75]. Environics is a “...Worldwide provider of CBRN protection solutions”, that 
manufactures portable, and fixed CBRN systems and specific biological detection systems 
[76]. These devices are designed to detect a particular set of molecules from a sample. 
Some of these devices, such as the JUNO, are constant air samplers which continuously 
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sample air through the device and analyse it for the specific compounds. These types of 
device are common as personal detection devices as they allow people to move about 
possibly contaminated areas while continuously alerting them to possible dangers. Desktop 
devices such as the IONSCAN systems from Smiths Detection are commonly found in 
airports and other places where the threat of people transporting narcotics, explosives or 
biological agents is raised. Hand-held detection devices, such as the ChemPro100i from 
Environics, are a portable detector that can be used on demand in any location to detect the 
specified compounds. 
These devices can also be used to monitor air in hazardous locations. The work by Eiceman 
et. al. [24] shows how an onsite IMS detection device can be used to monitor nicotine in the 
air. The major uptake of IMS devices has been the defence market, which has seen 10,000 
devices put into use in airports worldwide and 50,000 devices currently being used by the 
US military [77]. While these may be the main areas of interest in IMS research, there is a 
growing trend to extend the scope to which these devices are used. They are finding a place 
in the pharmaceutical industry [78] and research has been carried out using them as 
detectors in breath analysis [30, 51, 52]. 
Their use in breath analysis has huge potential benefits. As has been shown in other fields 
they can be developed into small, robust, portable detectors. A commercial ion mobility 
device for breath analysis is already available [54] and these devices can be developed 
further by tuning them to detect specific compounds, simplifying their operation and 
making them more applicable to the task. 
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1.6 Data processing 
The processing of the data generated in breath analysis is a complex task requiring several 
steps. The compounds found in the breath of the participants must be identified and then 
these must be carefully compared to highlight compounds that distinguish between the 
breath of healthy and diseases participants. This can be performed using the MS data. This 
data can then be used to tune the ion mobility device to detect the compounds of interest. 
The data collected from the DMS can be used to distinguish if there is a difference between 
the two groups of participants. This can be done using multivariate analysis techniques 
which look at the full data set to find patterns which distinguish between different groups. 
There are different stages to the data analysis, which are different for each detector, which 
must be carried out. These are; 
 MS data 
o Deconvolution of chromatographic data 
o Identification of compounds found in the breath 
o Cataloguing of compounds according to the diagnosis of the participant 
o Identification of potential biomarkers 
 DMS data 
o Conversion of data to acceptable format for multivariate analysis 
o Application of multivariate analysis techniques to determine if differences 
between groups are observed 
o Identification of data regions where differences are observed for device 
tuning 
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1.6.1 Current methods in data processing 
This section seeks to provide a brief overview of the data processing techniques that are 
used in the area of breath research carried out with mass spectrometry and ion mobility 
analysis methods. 
1.6.1.1 Mass spectrometry data processing 
1.6.1.1.1 Deconvolution of chromatographic peaks 
Deconvolution of peaks is when two or more analytes that co-elute from a separation 
medium are separated after detection. In terms of EI mass spectrometry this involves 
distinguishing which ions under the peak belong to which analyte. This is a difficult process 
and requires either a skilled operator to separate which ions belong to which analyte or 
reliance on a computer programme which does this automatically. 
Both techniques have advantage and disadvantages. Manual deconvolution requires a 
skilled operator to decide which ions under a single peak belong to which analytes. This is a 
long and laborious task. The operator must have the ability to recognise which ions belong 
to which component but it does allow the operator to manually decide which ions belong to 
which analyte to give a better analysis. The use of an automated method is much quicker 
than manual deconvolution. Employing this method has its pitfalls as it relies on the 
program to distinguish between analytes which may not always be accurate. 
There are few if any discussions of deconvolution of chromatographic data relating to 
breath analysis in the literature. Phillips et. al. [36] Make references to the use of library 
searching programs for identification of VOCs found in breath but no mention of how the 
data is deconvoluted first is made. An explanation for this would be that every peak in the 
data set is resolved, although this seems unlikely as the method used has an analytical run 
time of 33.83 minutes [29] during which they initially described an average number of VOCs 
detected per sample of 150-200. This would result in a peak width of approximately ten 
seconds per compound if all of the compounds were evenly spread across the 
chromatogram, and as can be seen in Figure 1-11 this is not the case. 
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Figure 1-11 Example chromatogram produced by the analytical method described by Phillips [29] 
A mixture of the two methods is the best approach but a manual method should be 
favoured in the initial stages of analysis. Establishing a method for this is an integral part of 
this work. 
1.6.1.1.2 Identification of compounds found in breath 
The identification of the compounds found in breath analysis is done against mass spectral 
libraries. As with deconvolution this can either be done manually or it can be automated. 
Automated methods will usually scan a mass spectral database and assign the most likely 
identification based on the match between your spectra and the library. This relies on the 
fact that the analyte is in the mass spectral library and it also relies on the fact that the top 
hit is actually the correct identification. As automated methods are much quicker, they are 
the method of choice for analyte identification. However, mass spectra are complex, 
particularly with the interference of background ions and co-eluting compounds and the top 
hit in the library may not always be correct. This means that a manual method is preferable, 
although it is time consuming. Being able to remove obvious contaminant ions that may 
have an influence over what the compound has been identified as is a large benefit. This can 
be a problem, especially towards the limits of detection. The main drawback of manual 
methods is the time it takes to assign each compound. When this needs to be done for 200 
compounds per sample for 50 samples this can become very time intensive. It does have a 
large benefit over automated methods in that it allows you to discard an identification if you 
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feel that the match to the library is not correct. The compound can then be manually 
annotated based on the ions present, either by its compound class or by specific ions of 
interest. 
1.6.1.1.3 Cataloguing of compounds found in breath 
Careful cataloguing of the compounds is required with particular attention paid to the meta-
data. Breath samples from lung cancer sufferers are difficult to obtain and this means that 
any samples that are obtained are extremely valuable and must be treated accordingly. 
Because of this it is unlikely large studies will be carried out in the early stage of this 
research so being able to cross-reference samples from different studies would be hugely 
beneficial. To make this possible careful cataloguing of the compound along with the 
sampling and analytical parameters and instrumentation must be carried out. Careful 
collection of metadata detailing aspects that may affect the volatiles in breath such as food, 
medication and other diseases the participant is known to be suffering from. These meta-
data can then be cross-referenced against each other when determining if a particular 
compound is a likely biomarker of disease. 
The construction of a library of volatiles found in breath, either kept in house or made 
available to the general research community would be very useful. Databases in other areas 
of research such as the HMDB [79] and METLIN [80] for metabolites and KEGG [81] for more 
general pathway analysis and genomic research have proved to be extremely useful tools 
and a similar database would be beneficial to breath analysis. 
1.6.1.1.4 Identification of potential biomarkers of lung disease 
The identification of potential biomarkers is the final step in the analysis of the data 
produced by analysing the samples using mass spectrometry. It makes use of all of the 
previous steps; 
 Deconvolution of the data to provide the best possible data set, 
 Identification of the compounds found so markers can be confirmed against 
standards, 
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 Cataloguing of the compounds to allow for cross-referencing of samples so 
compounds found either exclusively or at elevated or decreased levels in lung cancer 
sufferers can be identified. 
The possibility that it is not a single compound or even compounds that are exclusive to lung 
cancer sufferers that will allow for differentiation of lung cancer sufferers from healthy 
controls must be considered. This calls for even more careful cataloguing of the samples so 
that any possible biomarkers can be checked against a large “back-catalogue” of samples to 
add weight to their identification. Once identified these compounds can be used to develop 
instrumentation specifically to detect them and to give some idea of the biology that is 
taking place to produce them. 
1.6.1.2 Ion mobility spectrometry data processing 
This work involves the use of a DMS and for this reason only the processing of data 
produced by this instrument will be discussed. 
As a differential mobility spectrometer cannot provide identification of unknowns without 
running standards, the best method to process complex DMS data is by using a multivariate 
technique such as principle component analysis. The three dimensional data produced by 
the differential mobility spectrometer is a problem if multivariate techniques are to be used. 
These require two dimensional data, meaning that the data must be reduced in some way. 
The current methods for reducing the data are to decompose the data into its constituent 
wavelets [82] or to sum the data across the compensation voltage axis to reduce the data to 
two dimensions [46]. Both of these options reduce the information in the data set. This 
means that the full data set is not currently used in the data processing and this work aims 
to address this. 
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1.7 Research objectives 
In priority order the research objectives were: 
 To develop the dual detector mass spectrometry/differential mobility spectrometer 
analytical instrument set-up to increase the amount of information gained from the 
analysis of each sample,  
 Instigate new data processing methods to allow for three dimensional data sets to 
be inputted into multivariate analysis tools,  
 Outline a workflow for establishing a clinical trial between two research sites, an 
analytical facility and a National Health Service lung cancer clinic detailing the 
documentation, logistics and time frame required, 
 Give the initial data collected from a study into participants with lung cancer, 
including a list of compounds found in the breath of lung cancer sufferers. 
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2 An overview of breath analysis, a multidisciplinary combination of ethics, 
advanced instrumentation, in-vivo sampling and sophisticated data 
processing 
2.1 Introduction 
The hypothesis of this work is that there is a detectable difference in the breath of 
respiratory disease sufferers when compared to healthy controls. To test this hypothesis a 
multidisciplinary research programme was required. Figure 2-1 introduces the different 
aspects of this research and how they depend through a work flow diagram. 
 
Figure 2-1 Work flow diagram showing the different aspects of the research programme. There are three main strands of 
the research; clinical studies, instrument design and breath sampling. These three strands are all 
encompassed under the experimental design. Each strand is composed of several steps listed under the 
main strand heading. Separate from these strands is the final step of data processing. 
Each strand from Figure 2-1 will be discussed in detail, with the different aspects and how 
they interact with the other strands outlined. Challenges posed by the work and the 
solutions will be outlined along with a detailed discussion of the history and technology of 
the relevant steps. 
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2.2 Experimental design 
The experimental design must take into account all aspects of the research and deliver a 
scientifically credible balance between the conflicts inherent in the different factors in the 
project’s work flow. For example the sampling protocol must comply with the safeguards 
and restrictions necessarily specified in the project’s case for ethical approval while at the 
same time it must be compatible with the instrumentation. Further, data analysis must form 
an important element of the planning stages and often designs may require one hundred 
plus samples with biological and machine replicates; which may not be possible due to the 
limitations specified in the ethics case. Finally, destructive analysis may render machine 
replicates impossible. 
The instrument design and sample analysis must be carefully thought out. To extract the 
maximum amount of data possible from the samples collected a dual detector system was 
designed and set-up. The sample injection system used was a thermal desorber (Markes 
UNITY), split into two chromatography columns. One connected to a Varian quadrupole ion 
trap mass spectrometer and the other a Sionex S-VAC differential mobility spectrometer. 
This set-up allows for the DMS to be evaluated against the mass spectrometer. This means 
that with this set-up it is possible to determine if the DMS is capable of detecting the same 
changes in human breath samples as the mass spectrometer. 
These different detectors generate different data outputs that require different processing 
approaches. The mass spectrometry data sets require deconvolution programmes to refine 
the chromatographic peaks and enable individual compounds in complex and poorly 
resolved profiles to be identified. There are no data-processing systems available in the 
open literature or from commercial suppliers for DMS data, so an important element of this 
research was the development of a new pre-processing technique for GC-DMS data. 
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The three strands are; 
 Breath sampling 
 Instrument design and, 
 Clinical studies. 
2.3 Breath sampling 
2.3.1 A brief history 
Breath sampling in its modern from has a history that stretches back for over 100 years. The 
first breath sampler for collecting alveolar air was described by Haldane and Priestley in 
1905 [83]. This is shown in Figure 2-2. 
 
Figure 2-2 Haldane Priestley tube, described in and adapted from [83]. 
Initially the sampling tube is filled with mercury. The volunteer breathes normally through 
the mouthpiece for several minutes. At the end of a normal inspiration the volunteer 
exhales sharply through the tube and then blocks the mouthpiece with his tongue. To draw 
a breath sample the valve at the top of the tube is opened, the valve at the bottom is 
opened; the mercury flows out and draws the breath sample into the tube. The taps are 
then closed and the sample is taken for analysis. The concept of a haldane tube is still used 
by researchers in the field of breath sampling [84]. Breath testing for nitric oxide [85] as a 
marker for airway inflammation has been shown [86] and tests for hydrogen, carbon dioxide 
and methane as indicators in gastroenterology initially focussed breath sampling on this 
small range of gases. This was broadened to a wide range of volatile organic compounds 
Mouth-piece
Sampling Tube
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(VOCs) with the publication of work separating 200 compounds by gas chromatography in 
1971 [40]. This area is now extensively researched, with a particular focus on disease 
biomarkers being prominent. Work identifying possible biomarkers for lung cancer has been 
published [31, 36] and methods for detecting lung cancer have been described [32, 87] and 
the idea of a “breathalyzer” to aid lung cancer detection has even been discussed in a 
commentary in The Lancet [88]. 
There are two general approaches to breath sampling: direct analysis and archival sampling, 
for remote analysis. Direct analysis involves the participant breathing into an analytical 
instrument directly, from something as simple as a breathalyser to more complex set-ups 
such as the Breathspec IMS instrument from G.A.S. [54]. The work by Ruzsanyi et. al. [52] 
has shown that IMS systems are a viable set up for detecting human metabolites in breath. 
The main problem with current direct analysis methods is that they require the participant 
to force expire into the instrument which can be difficult for people suffering from lung 
dysfunction. There are other problems with this method that can make it problematic: 
 Equipment requires sterilising after use. This either means removing parts of the 
direct sampling system or having disposable parts that may increase costs. Infection 
control is essential and this means all parts that come into contact with more than 
one participant must be sterilised in between uses. This can be difficult with 
integrated instruments, 
 Daily validation and maintenance of the system requires an onsite member of staff 
to be trained or visits from maintenance engineers, 
 Installation of a dedicated sampling system requires a workspace and operators will 
require training, 
 The initial cost of the system may be expensive, particularly if it is not heavily used 
and, 
 Trace contamination by volatile organic compounds, and the subsequent 
decontamination of sensitive parts requires specialist systems (such as a vacuum 
oven) that may not be available on site or are expensive. 
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Archival sampling involves taking a sample that is analysed at a later time [35, 36, 46, 89-
93]. There are several approaches to archival sampling which tend to differ in trapping 
method and sampling protocol. The basic premise of archival sampling is that the sample is 
taken at one location, stored and transported to another location. This method allows 
researchers who are not based in a clinical environment to collect samples at a clinical site 
and transport them to another facility for analysis. This combats many of the problems 
highlighted for direct analysis. The equipment can be taken to the lab and sterilised, the 
instrument can be maintained by trained operators, portable sampling equipment means 
that there is little to no installation required, a single system can be used at multiple sites 
reducing purchase costs and decontamination of sensitive components such as any face 
masks used can be carried out in a dedicated facility. 
Sampling VOCs directly from the breath has been shown to be a useful tool for rapid 
detection of disease [94] and this work has led to the production of a miniaturised detection 
system being produced by Draper Laboratory. All this means that breath sampling could be 
used as a non-invasive monitoring technique in healthcare applications instead of invasive 
techniques such as blood sampling. 
2.3.2 Considerations in breath sampling 
VOCs are either endogenous or exogenous. This means that they are either a product of a 
process within the body or they are compounds that have entered the body, either through 
inhalation, absorption through the skin or consumed [95, 96], then exhaled in the breath. 
Exogenous compounds, studied in parallel with lung disease, can provide information into 
how these compounds affect people exposed to them. Endogenous VOCs can provide 
information on effects on metabolic pathways disease have, along with giving information 
of disease state and more general lung function markers. Some examples are changes in 
levels of Isoprene and other VOCs in COPD cases [97-99], and acetone as a marker for 
diabetes [100-102]. 
Exogenous compounds can be confounding factors in any analysis; they may influence 
results and cause false positives or negatives in statistical analysis. 
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There are other factors that should be taken into account. The concentration of VOCs is 
different in different places within the airways [21, 103] and so an ability to sample a 
particular portion of the breath profile is desirable. Patients suffering from some form of 
lung dysfunction may have difficulty using forced expiratory samplers and so development 
of sampling techniques that allow for normal breathing which can selectively sample a 
particular portion of the breath are desirable [104]. 
Human breath is a dynamic system. The Alveoli provide the location for rapid exchange 
between the blood and the air [105] and further VOCs can be added to this by volatile 
metabolism products other parts of the body such as the stomach. The dynamic range of 
compounds within the breath can also cause problems, with water being at a much higher 
concentration that any other compound found in the breath. Exogenous factors from 
perfumes, make-up and food can also influence the breath profile. These may also come 
from other people who are interacting with the subject, particularly researchers who are 
operating the sampling equipment. There are ways to limit these, using a full face mask and 
supplying purified air being effective [104], but their effects can still influence the data. 
The state of any sampling equipment used must also be considered. Regular cleaning by a 
standard process can help eliminate contaminant build up and also standardise any 
contamination introduced by these processes. 
These confounding factors are not always easy to control and any robust analysis must be 
able to take them into account to make it feasible as a point of care detection method. 
2.3.3 Sampling techniques 
The sampling of volatile organic compounds from breath can split into two categories in 
terms of the technique used; 
 Forced expiry and, 
 Non-forced expiry. 
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Forced expiry involves the volunteers forcibly expelling their breath to enable a sample to 
be taken. A non-forced expiry approach requires the volunteer participant to breath 
“normally” while samples are taken. There are four reasons why a non-forced expiry 
approach is preferable: 
 People suffering from lung dysfunction have a poor FEV1. 
The most likely candidates for breath detection are respiratory disease suffers. People 
suffering from respiratory disease tend to have poor lung function, which can make forced 
expiration a problem. Being able to take a breath sample from a volunteer who is breathing 
freely is therefore desirable. It is also possible that forced expiration may exacerbate a 
volunteers’ condition which as well as causing confounding markers to be over expressed, 
resulting in a poor analysis, may put participants at risk. 
 Sampling of larger volumes is feasible. 
For forced expiration methods it is usual to ask a volunteer to forcibly expire once to acquire 
a breath sample. This limits the volume sampled to the volunteers’ lung capacity. Non-
forced expiry methods allow the volunteer to breathe normally and selectivity sample 
portions of the breath profile, allowing for sampling of a theoretically infinite volume. 
 Blood pH changes during forced expiration and this alters the partitioning of volatiles 
between the blood and the air in the lungs. 
Reproducible sampling is a requirement of breath sampling and it is desirable to eliminate 
anything that may alter this. As it is extremely difficult to fully control forced expiration, 
particularly in people with respiratory dysfunction, the changes to the partitioning of the 
gases would not be consistent. A non-forced expiry method eliminates this problem. 
 Ventilation rates change during forced expiration causing a shift in the different 
volatiles’ equilibria between the blood and the air in the lungs. 
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This is another example of where forced expiration methods can change the composition of 
the expired gas that will be sampled. A non-forced expiration method helps to eliminate this 
as the volume of gas expired during normal breathing at rest is more consistent than that of 
forced expiration. 
Forced expiration methods are usually simple to perform and the apparatus is easier to 
maintain, but as outlined above, the benefits of non-forced expiration methods outweigh 
the benefits of forced expiration methods. 
2.3.4 Trapping volatiles 
There are 2 methods available for trapping volatile compounds from breath samples. They 
can either be trapped inside a container or on an adsorbent. Some researchers have 
advocated using Tedlar bags which are specified for several United States Environmental 
Protection Agency (US EPA) methods, including methods 3, 18 and 0040. Tedlar bags are 
composed of Tedlar®, a polyvinyl fluoride film, Made by DuPont™. Polyvinyl fluoride is 
suited for sampling bags because of its’ low vapour permeability, it’ general resistance to 
stresses and strains and resistance to most chemicals. A Tedlar bag can be formed from two 
sheets of Tedlar and a check valve. An example of commercially available Tedlar bags can be 
seen in Figure 2-3. 
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Figure 2-3 Example of Tedlar® Bags fitted with different valves [106]. 
While they are suitable for air sampling they do have some associated problems [107, 108]; 
 Recovery of VOC from Tedlar bags requires a secondary sampling step that results in 
a loss of efficiency and the introduction of selectivity into the sampling process.  
 They fail leading to leaks and punctures, 
 Ultraviolet degradation of the sample is a possibility, although black Tedlar is 
available, and degradation of the Tedlar can cause contamination and, 
 Adsorption of VOCs onto the walls of the bag can cause both losses from the sample 
and cross-contamination of the next sample if the bag is not fully cleaned before 
repeated use. 
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 Hydrolysis and oxidation artefacts can be created during sample transport and 
storage. 
 Diffusion of water vapour and other contaminants through the walls of the bag. 
Some may advocate sampling canisters which although robust suffer from many of the 
same drawbacks. 
The other method common in breath sampling is the use of adsorbents. Adsorbent based 
methods involve passing the sampled breath through a bed of active adsorbent (ca 100 mg). 
The VOCs undergo physical adsorption onto the surface of the adsorbent and are retained. 
Recovery is achieved by thermal desorption and this approach has advantages over Tedlar 
bags; 
 They are robust and easy to transport. 
 They are stable and samples can be stored without significant degradation. 
 Recovery of the trapped VOCs may be automated , 
 Thermal desorption provides close to 100% recovery of adsorbed VOCs from the 
adsorbent trap in a simple, reproducible procedure, 
 Hydrophobic absorbents can e used to minimise the water content of the samples 
and, 
 The opaque construction eliminates ultraviolet degradation. 
 Volatile enrichment is possible using thermal desorption as it is a two stage process. 
A sampling volume of 2.5L is desorbed from the adsorbent using 200mL of helium. 
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This is then refocused on a cold trap and desorbed using 200µL of helium. This leads 
to an enhancement of approximately 104. 
There are, however, disadvantages associated with active adsorbents: 
 Breakdown of adsorbents during thermal desorption process can cause artefacts in 
the analysis, 
 Sampled water is not easily removed prior to thermal desorption and, 
 Competitive adsorption can influence which compounds are most well retained. 
Of these problems the most easily controlled is competitive adsorption. As long as the 
break-through volume of the tube is not exceeded then competitive adsorption should not 
be an issue. The amount of sampled water is the major consideration, and while it may 
seem sensible to use a condenser arrangement in front of the trap this can remove 
compounds of interest at low levels and is not applicable. To combat the problem of water 
in the samples, careful selection of the active adsorbents is required. 
 
 
Figure 2-4 Example of an adsorbent trap fitted with end-caps supplied by Markes International and a schematic cross 
section of the trap showing the two different adsorbents and the end-caps fitted with PTFE ferrules. 
Ferrule
Swagelok end-cap
Tenax Carbograph
Adsorbent trap
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Figure 2-4 shows an adsorbent trap of the type used for this work. These were supplied by 
Markes International and are inert coated stainless steel tubes packed with Tenax TA and 
Carbograph 1TD. 
Tenax TA is a hydrophobic adsorbent with an approximate analyte range of C7 to C30 with 
boiling points of less than one hundred degrees centigrade for apolar compounds and one 
hundred and fifty degrees centigrade for polar compounds. It produces a low concentration 
of inherent artefacts (less than one nanogram) and is inert making it suitable for labile 
compounds.  
Carbograph 1TD is a non-specific carbon sorbent which can be used to trap a wide range of 
volatiles. This adsobent is hydrophobic which makes it a good choice for humid sampling, 
such as in breath analysis. It is generally used for trapping ketones, aldehydes, alcohols and 
apolar components making it a good choice for non-targeted work. It also produces a very 
low concentration of artefacts (less than 0.1 nanogram). Selecting the correct adsorbent for 
the purpose is vital as this can influence what compounds are trapped. In this work, as the 
compounds of interest are unknown, the adsorbents chosen were general purpose ones 
with hydrophobic properties. 
2.3.5 The adaptive breath sampler 
This work used the adaptive breath sampler that has been described previously [104]. The 
main features of the adaptive breath sampler are its non-forced expiry sampling method 
and its selective breath portion sampling ability. The adaptive breath sampler makes use of 
a non-vented full face mask so the volunteer is supplied with a controlled supply of medical 
air in an effort to control the levels of exogenous volatiles from the sample. As the air supply 
is constant, the volunteer is able to breathe normally while wearing the mask. Connected to 
this mask is an adsorbent trap via a tube assembly (shown in Figure 2-6) and a pressure 
sensor in the sampler control box by a silicon tube. This box contains a circuit (shown in 
Figure 2-7) that, along with a computer programme, monitors the volunteers breath profile 
and switches between two valves, both connected at one end to a pump and the other ends 
connected to the atmosphere for one valve and the adsorbent trap for the other. Depending 
on the settings for the computer programme these valves switch, drawing the breath of the 
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volunteer onto the adsorbent trap at specific points in the breath profile. This allows for the 
selective sampling of particular sections of the volunteers breath sample. A sample volume 
of 2.5 dm3 was collected following previous methods developed for this sampler.  
The breath sampler is composed of the following parts, which have been divided into 
sections: 
Face-mask set-up: 
 non-vented full face masks - ResMed 
 PTFE T-Piece – Custom made. Schematic shown in Figure 2-5. 
 One way disposable valves - Clement Clarke International Ltd Part No. 3122061 
(Blue) 
Adsorbent trap assembly: 
 PTFE luer capillary fittings – custom made, shown in Figure 2-6. 
 Steel capillary – ResTek UK 
 Markes stainless steel sorbent tubes (Tenax/Carbograph 1TD) with Swagelok 
Brass Cap for 1/4 in. Swagelok Tube Fitting B-400-C – Markes International 
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Figure 2-5 Schematic of the t-piece used to attach a one-way valve to the face mask and supply the purified medical air. 
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Figure 2-6 Adsorbent sampler assembly. The adsorbent trap (A) was connected to the sampling line through a 1/4’’ push 
fit connector sealed with a PTFE ferrule, (B). The other end of the trap was fastened into a 1/4’’ to 1/16’’ 
reducing union, (C), also with a PTFE ferrule (B). A shaped 5 cm MXT passivated stainless steel column 
was passed through the mask connector and reducing union so it was inserted into the top of the 
adsorbent trap (D). A 1/16’’ nut with a 0.53 mm Vespel™ ferrule sealed the capillary in place (E). The 
mask connector (F) was machined from PTFE with a male Luer fitting. The reducing union was held firmly 
in place while the capillary was threaded and positioned carefully inside the mask, before the Luer fitting 
secured the whole assembly. Taken from [104]. 
Pneumatic parts : 
 2002N-1B1-BX 2002-series (1/4") 1/4” NPT DPI auto drain BXE grade cartridge, 
2002N-1B1-DX 2002-series (1/4") 1/4” NPT DPI auto drain DXE grade cartridge, 
2002G-0A0 2002-series (1/4") 1/4” NPT no DPI drain plugged NO CARTRIDGE - 
Parker Balston Filters from KC controls 
 100-12-BX filter elements; box of 10, 100-12-DX filter elements; box of 10, CI100-
12-000 2002-series (1/4") adsorbent filter element; box of 1 
 Balston clamp kit C02-2091 x2 
 Silicon tubing – 4.8 mm bore, 6.4 mm bore, 3.6 mm bore – RS 
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Gas fittings for the sampler box: 
 SS Swagelok Tube Fitting, Zero Volume Reducing Union, 1/4 x 1/16 in. Tube OD 
Part No. SS-400-6-1ZV - Swagelok 
 2 x SS Swagelok ¼ tube x 1/8 pipe Part No. SS-100-R-4 – Swagelok 
 SS Swagelok union tee 1/16 in fittings Part No. SS-100-3 
Electronics: 
 Sampler Box – schematic shown in Figure 2-7 
 12v DC Power plug for sampler box - Farnell 
 Escort Elf personal pump - MSA 
 Laptop running windows 2000 with a pcmcia card slot 
 National Instruments DAQcard-6024E (for PCMCIA) 
 1.5m D25M – VHDCI M Cable 
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Figure 2-7 Schematic of the Breath sampler control box electronics 
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A schematic of the sampler set up is shown in Figure 2-8. This shows the connections 
between the main parts of the sampler. 
 
Figure 2-8 Schematic of the breath sampler set-up showing all of the major elements and their connectivity. 
2.3.5.1 Setting up the adaptive breath sampler 
To set the breath sampler up the following protocol should be followed: 
1. The adsorbent trap assembly, shown in Figure 2-6, is connected to one of the two 
Luer fittings on the face mask without a tube connected. 
2. A clement Clarke one-way valve is connected to the t-piece which is then connected 
to the face mask. 
3. The Balston filters are connected to the medical air supply at the wall outlet via a 6.4 
mm bore silicon tube at one end and then connected to the t-piece via another 6.4 
mm bore silicon tube at the other end. 
4. A 3.6 mm bore silicon tube is connected to the second Luer fitting at one end and 
the pressure sensor in the control box at the other. 
Pump
PC
Switch
Switch
Sensor
Trap
Face mask
Gas filters
T-piece
Control Box
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5. The escort elf personal pump is attached to the designated pipe fitting on the control 
box via a 4.8 mm bore silicon tube and another 4.8 mm bore tube is connected to 
the other pipe fitting. 
6. The sample box is powered by a 12v DC power supply and is connected to the laptop 
via a D25M – VHDCI M Cable to a PCMCIA card. 
7. Once the mask has been fitted to the participant and they are breathing comfortably 
an adsorbent trap is connected to the adsorbent trap at one end and to the 4.8 mm 
bore silicon tube previously connected to the pipe fitting on the control box at the 
other end. 
8. A 2.5 L sample of the participants’ breath is then taken. Once this has been done the 
tube is removed and sealed with Swagelok end-caps fitted with ¼ inch PTFE ferrules 
ready for transport. 
 
Figure 2-9 Photograph of the adaptive breath sampler in use. 
2.4 Instrument design 
The design of the thermal desorption – gas chromatography – mass 
spectrometry/differential mobility spectrometry system (TD-GC-MS/DMS) is integral to this 
work. Many of the volunteers involved in this work were too ill to request more than a 
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single sample from. This means that amount of data/information obtained from each 
sample must be maximised.  The rationale and specification of analytical systems and 
methods used is necessarily a compromise between sensitivity and resolution.  Data 
processing 
Once samples have been collected and analysed it is necessary to classify and characterise 
the data produced. This is perhaps the most important and challenging part of the work-
flow. Vast amounts of data can be produced rapidly, but with no methods to process and 
analyse the information such endeavours have little intrinsic value. The methods used in this 
research were: Baseline correction, normalisation, deconvolution, principle component 
analysis and discriminant function analysis. Further a new processing method for the 
analysis of dispersion field programmed differential mobility spectrometry was an important 
aspect of this research. 
2.4.1 Thermal desorption 
Thermal desorption (TD) is a technique commonly used to desorb volatile organic 
compounds from adsorbent traps such as those seen in Figure 2-4. The basic operation of a 
thermal desorption instrument is to heat the adsorbent trap to desorb the volatile organic 
compounds from the adsorbent surface and flush them from the trap with a flow of inert 
gas. The released volatiles are then concentrated in a cold-trap before injection, by flash-
heating onto a chromatography column. 
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Figure 2-10 The flow of analytes through an analytical system. 1) Shows the analytes flowing from the adsorbent trap to 
the cold trap. 2) Shows the flows of analytes from the cold trap to the gas chromatography column and 3) 
shows the volatiles flowing from the gas chromatography column to the analyser to produce a 
chromatogram. 
The cold trap contains a much smaller volume of adsorbent held at a lower temperature 
(usually -20 °C and 5 °C , depending on the adsorbent used). This results in the volatiles 
being re-trapped in the cold trap on this much smaller volume. The cold trap is then heated 
very rapidly resulting in the volatile organic compounds being injected as a much smaller 
volume, significantly improving sensitivity and chromatography. TD combined with cold 
trapping also has the benefit of enhancing the concentration of the sample. This can be 
shown by calculating the concentration enhancement (CE); 
   
  
  
 
Equation 2-1 
Where Dc is the detected concentration and Sc is the sampled concentration. If it is assumed 
that the sampled volatile organic compounds are completely desorbed, then the 
concentration is proportional to the volume and CE can be re-written as; 
1) 2)
3)
v
Adsorbent trap Cold Trap
Gas Chromatography column
Chromatogram
73 
 
   
  
  
 
Equation 2-2 
Where Sv is the sampled volume and Dv is the desorbed volume. With a sampled volume of 
approximately two and a half litres and a cold trap volume of approximately 100µL, the 
concentration enhancement is 2.5 x 104. This makes thermal desorption a very useful tool 
when analysing volatile organic compounds. 
Thermal desorption systems can be easily interfaced with gas chromatography columns 
making them an excellent choice of injector when adsorbent traps are being used. 
2.4.2 Gas chromatography 
Gas chromatography is a technique for separating complex mixtures of volatile compounds. 
The volatiles partition between a stationary phase, in the case of gas chromatography this is 
a thin film of polymer, and a mobile phase, the carrier gas. It is the activity of the analyte in 
the two phases that gas chromatography exploits to separate the analytes. In practical 
terms gas chromatography provides a way of separating out a mix of volatile compounds, 
such as a breath sample, before they reach the detector. This makes it easier to identify 
particular biomarkers. The key terms used in gas chromatography are listed in Table 2-1 
along with their definitions. 
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Table 2-1 The important terms in gas chromatography along with their definitions. 
Term Definition 
Column oven 
A programmable oven that can be used to control the 
temperature of the column contained inside. The 
Column oven has built in injectors (the injector type 
depends on the oven manufacturer) and mounting 
points for detectors. They also provide 
communication connections for any additional 
components such as external injectors and detectors, 
so they can be started/stopped by the column oven. 
Temperature programme 
A temperature programme is a pre-defined set of 
temperatures and times that dictate what 
temperature the column is at any point during the 
chromatographic run. 
Chromatographic run 
The chromatographic run is the time from when the 
sample is injected to when detection is finished. 
Gas chromatography column 
The gas chromatography column is a capillary column 
of a specific length and diameter. The inside surface 
of the capillary is lined with a liquid film stationary 
phase (which can be of different composition 
depending on the applications) that causes separation 
of the analytes as they pass through the column and 
partition between it and the mobile phase. 
Mobile phase 
The mobile phase is the gas which carries the analytes 
along the chromatography column. This gas is inert so 
as not to reach with the analytes and is usually 
helium. 
Internal column diameter 
The internal column diameter is the internal diameter 
of the chromatography column. A larger internal 
diameter increases the volume of the mobile phase 
and so changes the partitioning of the analytes. 
Film 
The film is the stationary phase. It is composed of a 
polymer that can be varied to interact more with 
specific analytes. Increasing the interaction between 
the film and the analytes increases the interaction 
between the two and so alters the partitioning of the 
analytes. 
Film thickness 
The film thickness is the thickness of the film applied 
to the inside of the chromatography column. 
Increasing this will increase the volume of the 
stationary phase and change the partitioning of the 
analytes. 
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Analysis of breath samples by gas chromatography raises four key challenges. All of these 
must be addressed as best they can when deciding upon the method to be used. These 
challenges are: 
 A wide range of unknown volatiles to be analysed, 
 The high water content of breath samples, 
 The stability of the chromatography system and, 
 The limitations imposed upon the system by the detectors. 
The selection of the column has a large influence on the separation of the analytes. There 
are a wide range of gas chromatography columns available for analysing volatiles. They 
differ in length, diameter, stationary phase film composition and stationary phase film 
thickness and all of these things have an influence over the separation of the analytes. As 
such a wide range of analytes is being investigated a “general purpose” column that is not 
targeted towards any particular analytes should be used. The column selected was 30 m 
long with an internal diameter of 0.25 mm. The stationary phase selected was a 95 % 
methyl:95 % phenyl with a film thickness of 0.25 µm. 
The high water content of the breath samples can cause problems for the analysis. The 
stationary phase of a gas chromatography column is degraded by water and high 
concentrations can cause damage which results in changes to the chromatography and can 
reduce the separating power of the column. To reduce the amount of water as much as is 
feasible when analysing breath it is important to select the compatible adsorbents for your 
adsorbent traps, described in 2.3.4. Also, using a hydrophobic cold trap in the thermal 
desorption unit and maintaining its’ temperature above zero degrees centigrade can help 
reduce the amount of water injected into the chromatography column. Careful monitoring 
of the intensity of the background contaminant levels in system blanks can help determine if 
the column is degrading. 
The stability of the chromatography system must be maintained over the course of the 
experiments. Deterioration of the column phase, changes in the carrier gas pressure and 
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fluctuations in the temperature programme can all cause problems. Monitoring the 
condition of the chromatography column using system blanks can again indicate if it is 
reaching the end of its’ useful lifespan. Another method of correcting for changes in the 
chromatography system is to use retention indices instead of retention time when 
classifying a compound. A retention index ladder can be created by running standards 
through the chromatography column at regular intervals. The retention time of each peak in 
the system can then be converted into a factor of the retention times of the standards, 
known as a retention index. As the column ages and the chromatographic properties change 
over time the retention time of the standards will change. Using the most recent standards 
retention time values to re-register the data converts them to retention indices and will 
make every run compatible. 
Limitations may be imposed upon the chromatographic separation by the detectors. In this 
work the DMS used dispersion field programming [109] which limited the analytical run time 
to one hour. Using a multi-step temperature gradient can help to focus separation on 
particular areas of the chromatogram and help overcome some of the limitations imposed 
upon the separation. 
2.4.3 Mass spectrometry 
Mass spectrometry as a technique began in nineteen hundred and six, when J.J. Thomson 
discovered the electron and determined its mass-to-charge (m/z) ratio which led to him 
constructing the first mass spectrometer in nineteen hundred and twelve [110]. There have 
been many advances in the technique since this first instrument leading to many different 
mass analysers, which have varying properties, but all still separate ions based on their m/z 
ratio. There has also been a large number of ion sources developed which are used 
depending on the type of analysis being carried out. There is a vast amount of literature on 
mass spectrometry, with many textbooks giving broad overviews or focussing on particular 
techniques or areas of application, so the descriptions in this section will focus only on the 
techniques used in this work. 
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2.4.3.1 Principles of mass spectrometry 
To measure the mass of a molecule in a mass spectrometer, the molecule must be ionised. 
The simplest method of this is electron ionisation; 
 
Equation 2-3 
Where M is a molecule and e is an electron. Ions of this form are likely to undergo 
fragmentation, because it is a radical, which can progress in two ways; 
 
Equation 2-4 
Where M
.+ is the molecular ion, OE
.+ is an odd ion fragment, R
.
 is a radical, EE+ is an even ion 
fragment and N is a new molecule. The two new ions formed have different properties and 
can themselves’ undergo fragmentation. A mass spectrometer will separate these ions 
based on their m/z ratio, detect them and give and output based on their abundance. 
Multiply charged ions can also occur in a mass spectrometer and they too are separated 
based on their m/z ratio. 
The mass analyser separates out the different ions based on their mass to charge ratio 
(m/z). There are six different types of basic analyser but in general terms they all do this 
same basic operation. All mass analysers make use of either an electric or magnetic field. 
This is why an analyte must be ionised be it enters the mass analyser. Neutral analytes are 
not affected by the electric/magnetic field and thus cannot be analysed. The mass analysers’ 
ability to distinguish between different ions is called the analysers resolution or resolving 
power. The resolution of a mass analyser can be defined by the following equation: 
                Equation 2-5 
Me
- .+ -2eM
EE
OE
R
N
M
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Where M is the m/z and ΔM is the full width at half maximum. In practice the higher the 
resolution the more able a mass analyser is to distinguish between two different ions. 
Resolution is limited by the instrumentation and its’ mode of action. For example a time-of-
flight instrument has a theoretically infinite mass range. This is because the ions are 
accelerated along a flight tube with the same energy and as such smaller ions will have a 
greater velocity and so will fly along the tube faster than larger ions. As separation is a 
function of the tube length, in an infinitely long tube all ions would eventually reach the 
detector. Of course in practice this is not possible. Limitations are imposed on the tube 
length as it must be maintained at constant temperature and under a high vacuum as 
changes in length due to heat expansion or contraction and any collisions within the tube 
would result in the ions reaching the detector at a different than expected point and 
produce a wrong result for the m/z. 
A benefit of certain analysers, such as a quadrupole ion trap, is their ability to perform MSn 
experiments. An MSn experiment is when ions are selected and fragmented, detected and 
then a fragment is re-selected and fragmented, detected and so on. These experiments are 
particularly useful for protein and peptide analysis but they are also useful for determining 
between isomeric compounds. They can also provide more information about a particular 
analyte when the resolution of the instrument is not capable of providing a monoisotopic 
mass. A monoisotopic mass is a mass that relates to a particular molecular formula 
composed of particular isotopes of each element. Instruments capable of measuring 
monoisotopic masses are usually limited to a certain point where it is able to distinguish 
between the different isotopic peaks for a single compound. As the mass of a compound 
increases the amount of different isotopes of the elements expected also increases and this 
results in extra peaks in the mass spectrum separated by very small amounts. When an 
instrument is no longer capable of distinguishing between two monoisotopic peaks they will 
be combined and ‘centroided’. Centroiding is when the average of the two peaks is 
displayed as a single bar in the mass spectrum. Fragmentation of analytes in instruments 
that are either incapable of achieving monoisotopic mass resolution or when the mass is 
above the monoisotopic mass limit of the instrument can provide structural information 
about the analyte and allow for identification without the need for an exact mass. 
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2.4.3.2 Quadrupole ion trap mass analyser 
The quadrupole ion trap mass analyser was first described by Paul and Steinwedel in 1953 
[111] and was modified by Stafford et. al. [112] of Finnigan company. A quadrupole ion trap 
analyser is made up of a circular electrode with two ellipsoid caps above and below it, 
shown in Figure 2-11. 
 
Figure 2-11 Schematic view of a quadrupole ion trap showing the ring electrode and the capping electrodes above and 
below it. 
The motion of the ions within the trap is three dimensional and controlled by the potentials 
applied to the electrodes. The three dimensions can be labelled as x, y, and z with the trap 
having a radius of r0, as shown in Figure 2-12. 
Capping electrodes
Ring electrode
Inlet from ion source
Outlet to detector
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Figure 2-12 Direction of the x,y,z coordinates and the distances z0 and r0 within the trap. 
As long as the coordinates of x and y never reach or exceed r0, and the coordinate z never 
exceeds z0, then the ions will have a stable trajectory. 
The ions within a quadrupole ion trap are held there by the RF frequencies applied to the 
two electrodes andcan be ejected from the trap in two different ways, ejection at the 
stability limit and resonant ejection. Ejecting at the stability limit is limited by the 
dimensions of the trap and the maximum value of V. Larger masses require a larger value of 
V to reach instability, this can be reduced by reducing the dimensions of the ion trap, but 
this would make the trap more prone to arcing. Resonant ejection can extend the mass 
range, as it is possible to calculate a particular frequency at which an ion, within the trap, 
will oscillate. By applying this frequency along the z-axis, an ions’ oscillations can be 
increased to a point where it is ejected from the trap along this axis. The main consideration 
with resonant ejection is fragmentation within the trap. If an ion within the trap fragments, 
it is possible that it will be ejected at a frequency that corresponds to a different ion, if V is 
being increased to scan across a range of ions. This will result in an artefact peak in the mass 
spectrum which corresponds to a different m/z than the fragments actual value. 
y
z 
x
z0
r0
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The resolution of an ion trap is determined by the scan speed. This means that the 
resolution can be increased greatly by reducing the scan speed of the ion trap, and 
resolutions of up to 30,000 have been reported [113], but this can greatly reduce the 
sensitivity of the instrument due to the increased scan time and is not typical. 
The main consideration when using a quadrupole ion trap is the ‘space charge effect’. If too 
many ions are present in the trap at any one time, ions oscillating closer to the electrodes, 
‘shield’ ions oscillating closer to the centre of the trap. This changes the frequency at which 
the shielded ions are ejected and introduces mass errors. One way of taking this effect into 
account is to monitor the total ion count (TIC). When this reaches a maximum value, 
specified by the instrument manufacturer, space charge effects are likely to be seen. An 
introduction to quadrupole ion trap mass spectrometry by R. March provides a good 
introduction to this topic [114]. 
2.4.3.3 Considerations when using ion trap mass spectrometry for breath analysis 
The use of ion trap mass spectrometry for breath analysis has some challenges. Space 
charging, as previously described in 2.4.3.2, can cause shifting of m/z peaks, poor 
chromatography can result in complex fragmentation patterns that are difficult to separate, 
the large orders of magnitude difference between the analytes can result in a loss of 
sensitivity and the high levels of water in the breath samples can cause degradation of the 
column and introduce large background artefact peaks. 
Poor chromatography, caused by increases in background noise and artefact peaks, can 
cause problems with accurately assigning an identification for analytes. Overlap of 
chromatographic peaks means that fragmentation patterns also overlap and these must be 
separated out so an analyte can be identified. The use of chemical ionisation (CI) may help 
with this but this would introduce more problems as not all analytes will ionise using CI, 
such as aliphatic hydrocarbons. This would also add the problem of ion suppression, with 
ions that are more likely to pick-up a charge ionising preferentially. 
The large difference in orders of magnitude of analytes in the samples can cause two 
problems: 
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1. Smaller peaks may be lost under larger peaks if they co-elute 
2. In the presence of space charging and combined with the challenges of 
deconvolution of complex chromatography the shifts in m/z can cause automated 
deconvolution programmes to assign m/z values as two different analytes when in 
fact they are due to a single analyte. 
The high levels of water in breath samples can increase the effect of several problems all 
ready described as well as creating some of their own. Water degrades the chromatography 
column resulting in causing large artefact peaks of siloxanes and high levels of background 
noise from increased column bleed, the gradual break-down of the column, in the mass 
spectra. This can increase the difficulty associated with deconvolution as well as increasing 
the likelihood of space-charging. As the compounds released by column damage tend to be 
higher weight compounds they can increase the need for trap cleaning and maintenance. It 
can be estimated that a two and a half litre breath sample contains approximately 0.16g of 
water, more water than adsorbent used. 
2.4.4 Differential mobility spectrometry (DMS) 
Differential mobility spectrometry (DMS) is a technique for separating gas phase ions. It can 
be coupled to a gas chromatography system [115] or used as an isolated sensor for 
detecting airborne volatiles [116]. As an analytical system it is small, low-cost and requires 
few laboratory services, compared to mass spectrometers. As an on-site analysis technique 
these features of DMS are highly desirable, this makes it an interesting candidate for 
evaluation for on-site breath analysis. It has already been demonstrated for breath analysis 
[117, 118] and research in this area is growing. 
The history of DMS begins, like mass spectrometry, with J.J. Thomson. His work on the 
mobility of ions in an electric field, first published in his book in 1903 [119], lead to him 
receiving the Nobel Prize for physics in 1906. His work relates to the linear form of ion 
mobility spectrometry (IMS). As a technique, IMS was primarily developed by E. W. 
McDaniel during the nineteen fifties and nineteen sixties, where he developed a drift tube 
and measured the mobility of H3+ and H+ ions in room air [120]. This method of IMS 
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measures the time taken for ions to drift along a tube against a buffer gas, under an applied 
low electric field. The equation for movement of ions in an electric field comes from 
Thomson’s work: 
      Equation 2-6 
Where Vd is the drift velocity of the ion in cm s
-1, K is the ions mobility constant in cm2 V-1 s-1 
and E is the applied field strength in V cm-1. As can be seen from this equation, for different 
ions to separate they must have a different drift velocity, and therefore must have a 
different mobility constant. The mobility constant of an ion is controlled by several factors 
and can be approximated by the newly reconsidered Mason-Schamp equation [121]: 
  
 
 
 
    
   
  
  
   
 
   
 
Equation 2-7 
Where M is the mass of the analyte, m is the mass of the gas, q is the unit charge on the ion, 
N is the number density of the drift gas, µ is reduced mass of the ion, k is the Boltzmann 
constant, T is the temperature of the drift tube and ΩD is cross-sectional area of the ion. 
This means that, as long as everything is kept constant, the time taken for an ion to reach 
the detector will be dependent on only the reduced mass and its collision cross-sectional 
area. 
A linear time-of-flight IMS drift tube is often composed of a series of field defining 
electrodes conductive rings separated by insulators which form an air-tight drift region, an 
ionisation source (typically 63Ni), separated from the drift region by an shutter grid, and a 
Faraday plate; used to detect any ions as leave the drift region. A schematic of an IMS tube 
can be seen in Figure 2-13. Neutral analyte molecules are introduced into the ionisation 
source and are held there by the shutter grid. Once ionised a packet of ions can be injected 
into the drift region by removing power to the shutter grid. This power is then restored to 
trap the next packet of ions. Without this shutter grid the ions would enter the drift region 
in a continuous stream and it would not be possible to separate them. A series of voltages 
applied across the field defining electrodes produces a linear voltage gradient across the 
field defining electrodes which accelerates ions through the drift region. A drift gas flows in 
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the opposite direction to the motion of the ions under the electric current. The action of the 
voltage on the ions combined with the collisions with the drift gas causes ions of different 
sizes to attain limiting velocities and so reach the detector at different times, separating 
different ion species. 
 
Figure 2-13 Schematic of an IMS device showing the ion source, the drift tube constructed of conductive and insulating 
rings, the ion gate, the Faraday plate and the inlets and outlets for the reactant gas, the drift gas and the 
carrier gas. 
DMS as a technique was first demonstrated by Buryakov et. al. in 1993 [122]. A schematic of 
a DMS instrument is shown in Figure 2-14. By applying a high frequency voltage to one 
plate, the ions’ trajectory is changed and moves towards the grounded plate. Application of 
a compensation voltage to the plates to counter the drift enables ions to be selectively 
filtered through the analyser and hence to the detector measured. 
Drift Gas inletGas outletGas inlet
Conductive ring
Drift Region
Insulating ring
Ion gate
Ionisation region
Flow of analyte 
in carrier gas
Faraday plate
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Figure 2-14 Schematic of a DMS system, showing the parallel plates which form the drift region , the waveform 
generator which provides the voltage to the bottom plate to separate the ions and the applied 
compensation voltage. Below this are two asymmetric waveforms with different semi-periods labelled as 
t1 and t2 for two different levels of voltage. Adapted from [123]. 
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From the nineteen eighty eight book by Mason and McDaniel [124] the simplified form of 
the mobility constant (K) according to electric field (E) when density of the drift gas (N) is 
constant can be given as: 
            Equation 2-8 
Where KE is the field dependant mobility at electric field strength E, K0 is the mobility 
constant at zero electric field and αE is the function for the mobility constant at electric field 
strength E at constant number density of drift gas. Buryakov et. al. [122] described the 
separation of a mixture of ions using the following equations: 
 
 
  
 
 
               
             
Equation 2-9 
where T is the field oscillation period and n is an integer not less than 1 describes a curve 
with period T = t1+t2 where the maximum field strength (Emax) during t1, the positive semi-
period is much greater than the minimum field strength (Emin) during the negative semi 
period t2. If t1 is much less than t2 this causes the ions to oscillate, for a short period, 
perpendicular to their flow in the drift gas during period t1 according to Emax, Emin and αE. 
This means that if Emax and Emin are constant, ions will be displaced perpendicular to their 
flow according to their αE values. By creating an electric field between the plates according 
to: 
                        Equation 2-10 
where Es satisfies the conditions of Equation 2-9, f(t) is the function which describes the 
form of the field, Es = max Es(t) and Ec is a constant voltage known as the compensation 
voltage. Specific selection of Ec, Es and F(t) make it possible to direct specific ions towards 
the detector, and variation of Ec with Es makes it possible to successively compensate for all 
of the ion species present, as shown in Figure 2-15. 
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Figure 2-15 How applying a compensation voltage, Ec, can allow an ion to traverse the drift region. A) shows the motion 
of the ion without the application of a compensation voltage and B) shows the motion of the ion with a 
compensation voltage. 
By varying the compensation voltage across a set range a final output from the instrument 
of signal intensity Vs. Ec can be created as seen in Figure 2-16. 
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Figure 2-16 Compensation voltage versus intensity plots taken from Rasulev and co-workers [122] showing the drift 
spectra of substances produced by (a) surface ionisation and (b) β-ionisation. 
This technology forms the basis of the Sionex Micro DMx chip, the DMS system used in this 
work. As a detection technique DMS exploits the ions change in mobility at different field 
strength to separate out complex mixtures of ions. In this way it differs from traditional IMS. 
This allows DMS to be used for continuous analysis methods without the need for ion gates 
that are present in IMS systems. This is because at a particular high field strength the point 
at which different ions reach the detector is dictated by the compensation voltage rather 
than drift time. 
As with mass spectrometry, DMS requires the molecules to be ionised before analysis. The 
method used in this work, and one of the more common methods is atmospheric chemical 
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ionisation (APCI) via a β-particle emitting 63Ni source. As with all APCI sources, several 
reactions can occur, depending on what molecules are present in the source at the time of 
ionisation. The main benefits of a 63Ni source are: 
 it produce positive and negative ions which can be measured simultaneously in a DMS 
system, 
 is stable and long lasting, 
 small, compact and easy to integrate into the inlet of an instrument and, 
 requires no external power. 
Reactant ions are generated by 63Ni ionisation of a gas stream, usually nitrogen or air. This 
description focuses on nitrogen, as this was used in this work. The following series of 
reactions describe the formation of the common positive reactant ions [125]: 
        Equation 2-11 
    
    
      Equation 2-12 
  
       
  Equation 2-13 
  
             
  Equation 2-14 
At this point it is important to note that water is required for all but one species of reactant 
ion, as N2
+ and N4
+ are high energy ions and will likely not survive as ions long enough to 
traverse the drift region [126]. The reactions proceed as follows: 
   
       
          Equation 2-15 
              
          Equation 2-16 
The only species of reactant ion that does not require the presence of water to form is: 
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            Equation 2-17 
The final reactant ion formed is: 
               
      Equation 2-18 
However it should be noted that both the nitrogen containing reactant ions were shown to 
cluster with water when they were identified by Karasek and co-workers [127], with the 
three reactant ions being H+.(H2O)n, NO
+.(H2O)n and NH4
+.(H2O)n, with the value of n being 
dependant on the temperature. It is the reactant ions. 
The reactant ions will form product ions with the analytes introduced, mainly of the forms: 
Protonated monomer - 
             
         Equation 2-19 
Hydrated protonated monomer - 
             
        Equation 2-20 
Proton-bound dimer - 
         
  Equation 2-21 
Hydrated proton-bound dimer - 
   
            
        Equation 2-22 
As well as adduct formation, charge-exchange ionisation also occurs, particularly with 
aromatic compounds. This involves a charge passing from an ion to a neutral molecule – 
          Equation 2-23 
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The maximum concentration of any ions formed is governed by the concentration of the 
reactant ions and any observed intensity due to product ions shows a corresponding 
decrease in intensity due to reactant ions. 
In the negative ion mode the formation of ions differs greatly from that of the positive ion 
mode. With clean gas systems, such as pure nitrogen, the negative charge carriers are the 
electrons. In air there are several reactant ions, identified by Spangler and Collins [128] 
mainly as O2
-, CO4
- and (H2O)O2
-. 
The ion clusters that are formed, which are dependent on: the amount of water present, the 
temperature of the instrument and the concentration of the analyte separate under the 
high field portion of the waveform. This is the effect that DMS exploits to separate out ions. 
However, as the size of the analyte molecule increases this effect becomes less pronounced, 
if the high field maximum remains the same, reducing the resolution of the instrument. 
While not much can be done about this if samples are directly injected to the instrument, 
combining DMS with front end gas chromatography means that it is possible to slowly 
increase the maximum field strength. As has been discussed, chromatography allows for 
separation of complex mixtures with a tendency for larger molecules to reach the DMS 
system later than smaller molecules. By programming the dispersion field to increase during 
the chromatographic separation it is possible to increase the analytical space to maximise 
the potential of the DMS system [109]. 
2.4.4.1 DMS as a detector for lung disease 
For this work a dual detector approach was decided on using both a DMS and MS. There are 
two reasons this approach was decided upon: 
 To extract the maximum amount of information possible from the breath samples 
and, 
 To test the utility of a DMS as a point of care instrument. 
The most important element in the design of the experimental protocol for collecting breath 
samples from people with serious lung diseases is their welfare. The time available for 
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sampling must be kept to a minimum and this limits the number of samples available to 
ensure adequate machine replicates running dual detectors from a single sample was the 
operational compromise sought. 
DMS is a strong candidate for development as a point of care instrument. DMS systems are 
small, robust, inexpensive to make, require few services and may be made easy to operate. 
By including in parallel with the mass spectrometry data evaluation of the DMS for breath 
samples was possible. 
One of the main considerations for using DMS as a point of care instrument is its’ ability to 
detect the compounds identified as biomarkers of disease. A DMS is capable of detecting 
volatiles as long as they can be ionised and understanding the ion chemistry in the 63Ni 
source is vital. 
2.4.5 Ion chemistry in differential mobility spectrometry 63Ni source for identified 
biomarkers of lung cancer 
63Ni ionisation chemistry is selective towards analytes with compatible ionisation 
behaviours, normally with proton affinities greater than that for the reactant ion peak, 
hydrated proton in this study. It is important to understand this ion chemistry and whether 
possible biomarkers for lung cancer will be ionised and detected in the DMS. Table 2-2 to 
Table 2-6 contain lists of potential biomarkers for lung cancer identified in the literature and 
whether they will be ionised by the 63Ni source. They have been split into compound classes, 
aromatics, alkanes, ketones, alcohols and other compounds, with each compound class in a 
different table. Chen et. al. [129] identified 1-butanol and 3-hydroxy-2-butanone as markers 
of lung cancer. The authors point out that at temperatures over 30 degrees centigrade 3-
hydroxy-2-butanone will be oxidised to 2,3-butanedione. The commonly accepted core 
temperature of the human body is 37.0 degrees centigrade as determined by Carl Reinhold 
August Wunderlich. While revisions have been made to this over time they are small and 
with this in mind it is questionable whether 3-hydroxy-2-butanone would survive to be 
sampled based on the authors’ conclusions. For this reason it is not included in Table 2-4, 1-
butanol is included as a possible marker. For an analyte to be ionised by the 63Ni source it 
must be able to accept a charge. Compounds classes such as alcohols, aldehydes and 
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ketones will be ionised along with benzene and its’ derivatives and cyclic hydrocarbons, as 
shown by G. A. Eiceman et. al. [123] Analytes that would not be ionised are compounds that 
are unlikely to form clusters such as saturated and unsaturated hydrocarbons. 
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Table 2-2 Aromatic compounds observed in human breath samples and the headspace of cell culture lines reported in the literautre. Adapted from [130] to include whether the 
compound will ionise in a 
63
Ni source, whether it is a sensible I.D. for a biological marker and any comments about its’ known uses. The in vitro studies are shaded grey. 
Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible I.D. 
for biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
Benzene x  x  x x     Y Y  
1,2,4-trimethylbenzene x  x        Y Y Petrol additive 
1,4-dimethylbenzene x          Y Y  
1-methylethenylbenzene x          Y Y  
1,1-(1,2-cyclobutanediyl)bis-benzene  x         Y Y Plasticiser 
1,1-[1-(ethylthio)propylidene]bis-
benzene 
 x         Y Y 
 
1,1-ethylidenebis[4-ethyl-]benzene  x         Y Y  
Ethylbenzene   x    x   x Y Y  
Trimethylbenzene   x        Y Y  
Propylbenzene x   x       Y Y  
1-Methyl-4-(1-methylethyl)-benzene       x    Y Y  
1-Methyl-2-(1-methylethyl)-benzene       x    Y Y  
1-Methyl-3-(1-methylethyl)-benzene       x    Y Y  
1-ethyl-4-(2-methylpropyl)-benzene          x Y Y  
(1,1-dymethylbutyl)-benzene          x Y Y  
1,3bis-(1-methylethyl)-benzene          x Y Y  
1,1-dimethylbutylbenzene          x Y Y  
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible I.D. 
for biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
1,2,4-trimethyl-5-(1methylethyl)-
benzene 
         x Y Y 
 
1-(1,1-dimethylethyl)-3-ethylbenzene          x Y Y  
1,2-benzenedicarboxaldehyde          x Y Y  
a` -hydroxybenzeneacetonitrile          x Y Y  
1,3,5-trimethyl-2-propylbenzene          x Y Y  
1-ethyl-3-(1-methylethyl)-benzene          x Y Y  
1,2-bis(1-methylethyl)-benzene          x Y Y  
(1,1-dimethylpropyl)-benzene          x Y Y  
Styrene x  x x   x   x Y Y  
Toluene   x   x x   x Y Y  
Xylenes (o-, -p, etc…)   x    x   x Y Y  
Phenol          x Y Y  
2,6-Bis(1,1-dimethylethyl)-4-
methylmethylcarbamate pieno 
      x    Y Y 
 
1H-Indene, 2,3-dihydro-4-methyl 
 x         Y Unlikely 
petrochemical 
compound 
Camphor 
 x         yes Unlikely 
Fragrance and food 
additive, used as a 
pasticiser, moth 
repellant 
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible I.D. 
for biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
Benzophenone  x         Y Possible  
Butylated hydroxytoluene (BHT) 
      x    Y Possible 
Antioxidant found 
in food, 
pharmaceuticals 
etc. 
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Table 2-2 give the details of all the aromatic compounds observed in human breath and lung 
cancer cell culture lines as reported in the literature [34, 36-39, 87, 131-134]. Many of the 
different compounds in Table 2-2 are isomers of each other. As all of the studies use 
electron ionisation sources it would be difficult to assign a specific isomer to a mass 
spectrum, as their fragmentation patterns would be very similar. So while 35 different 
compound identifications have been made this number may be lower. DMS would provide 
separation in the compensation field axis of isomers so would go some way to identifying 
what isomers are present if it were run in parallel with a mass spectrometer. All of the 
compounds in this table would be ionised by the 63Ni source and so are suitable for analysis 
in the DMS. Several of the compounds are found in exogenous sources that may influence 
the analysis such as 1,2,4-trimethylbenzene which is a petrol additive and BHT which is used 
as an antioxidant. Camphor has been labelled as an unlikely biomarker as it is used in many 
products that the participants may come into contact with. 2,3-dihydro-4-methyl-1H-Indene 
is also labelled as unlikely as it is extracted from oil by the petrochemical industry. 
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Table 2-3 Alkyl compounds observed in human breath samples and the headspace of cell culture lines reported in the literature. Adapted from [130] to include whether the compound 
will ionise in a 
63
Ni source, whether it is a sensible I.D. for a biological marker and any comments about its’ known uses. The in vitro studies are shaded grey. 
Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
2,2,4,6,6-pentamethylheptane x          N Yes  
2-methylheptane x          N Yes  
methylcyclopentane x          Y Yes  
1-methyl-2-pentylcyclopropane, x          Y Yes  
trichlorofluoromethane, x          Y No CFC-11 
Cyclohexane x          Y Yes  
3-methylnonane x          N Yes  
3-methyloctane x          N Yes  
2,4-dimethylheptane x          N Yes  
1,1,2-trichloro-1,2,2- 
trifluoroethane  x         Y No 
CFC-113 
2-methoxy-2-methyl-propane  x         Y unlikely Additive in petrol 
Decane x  x x       N Yes  
Undecane x   x    x  x N Yes  
Pentane   x   x   x  N Yes  
Heptane   x        N Yes  
Octane   x        N Yes  
Hexane         x  N Yes  
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
1,2,4,5-Tetroxane, 3,3,6,6- 
tetraphenyl-  x         Y Yes 
 
2-Methylpentane   x      x  N Yes  
Pentamethylheptane   x        N Yes  
Methylcyclopentane    x       Y Yes  
3-Methylhexane       x    N Yes  
3-Ethylpentane       x    N Yes  
2,3,4-Trimethylhexane       x    N Yes  
2,4-Dimethylheptane       x    N Yes  
4,7-Dimethylundecane       x    N Yes  
2,6,6-Trimethyloctane       x    N Yes  
3,3-Dimethylpentane       x    N Yes  
3,3-Dimethylhexane       x    N Yes  
2-Methylhexane       x    N Yes  
3-Ethylhexane       x    N Yes  
2,2,3-Trimethylhexane       x    N Yes  
Ethylidenecyclopropane       x    Y Yes  
4-Methyloctane       x    N Yes  
2,3,4-Trimethylpentane       x    N Yes  
2,3-Dimethylhexane       x    N Yes  
Isobutane      x     N Yes  
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
2,3-Dimethylbutane         x  N Yes  
3-Methylpentane         x  N Yes  
Methylcyclopentane         x  Y Yes  
2,3,4-Trimethylpentane         x  N Yes  
2,3,3-Trimethylpentane         x  N Yes  
4-Methylheptane         x  N Yes  
2,4-Dimethylheptane         x  N Yes  
2,3-Dimethylheptane         x  N Yes  
4-Methyloctane         x  N Yes  
EthylOxirane         x  Y Yes Carcinogen, mutagen 
3-ethyl-5-methyl-1-
propylcyclohexane         x  Y Yes 
 
1,5-diethyl-2,3-
dimethylcyclohexane         x  Y Yes 
 
Cyclopropylphenylmethane         x  Y Yes  
1-methyl-3-ethyladamantane 
        x  N Unlikely 
Pharmaceuticals, 
Petrol 
4,7-dimethylundecane         x  N Yes  
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Table 2-3 give the details of all the alkyl compounds observed in human breath and lung 
cancer cell culture lines as reported in the literature [34, 36-39, 87, 131-134]. As with Table 
2-2 there are several compounds in this table that are isomers of each other and it is 
unlikely that accurate isomeric identification of these analytes could be made using just 
mass spectrometry. This means that again the number of unique compounds identified may 
be less than is currently reported. There are two compounds listed as not being suitable 
identifications for biological markers in this table. They are trichlorofluoro-methane and 
1,1,2-trichloro-1,2,2,-trifluoro-ethane which are both CFCs’. 2-methoxy-2-methyl-propane 
and 1-methyl-3-ethyladamantane are listed as unlikely. These both occur in petrol and 1-
methyl-3ethyladamantane is an additive in pharmaceuticals. This means that both of these 
compounds are too likely to be exogenous and so can’t be considered. 
Very few of these compounds would be ionised in a 63Ni source and this is a gap in the 
current technology. Aliphatic hydrocarbons are unlikely to pick up a charge and form 
clusters and this is a problem for analysis with the DMS. They will be ionised in a mass 
spectrometer however and this will allow for identification using the TD-GC-MS/DMS 
system described. If any aliphatic hydrocarbons were identified as markers for lung cancer 
then, if DMS is to be used as a point of care detector, work would have to be done on the 
ionisation of hydrocarbons, possibly using a different method of ionisation. 
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Table 2-4 Ketones observed in human breath samples and the headspace of cell culture lines reported in the literature. Adapted from [130] to include whether the compound will ionise 
in a 
63
Ni source, whether it is a sensible I.D. for a biological marker and any comments about its’ known uses. The in vitro studies are shaded grey. 
Compound Reference Observed in Ionisable 
with 63Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
2,3-Hexanedione  x         Yes Yes Used as food additive 
3-Hexanone, 2-methyl-  x         yes Yes  
Bicyclo[2.2.1]heptan-2-one, 
1,7,7-, (Camphor) 
 x         yes No 
Fragrance and food additive, 
used as a pasticiser, moth 
repellant 
trimethyl-,(1S)-a` Isomethyl 
ionone 
 x          No Fragrance additive 
2,2,7,7-
Tetramethyltricyclo[6.2.1.0(1,
6)]undec-4-en-3-one 
 x          Yes  
2,5-Cyclohexadien-1-one, 2,6-
bis(1,1-dimethylethyl)-
4ethlylidene 
 x          Yes  
2,4,6-Tris(1,1-dimethyl-ethyl)-
4-methylcyclohexa-2,5-dien-
1-one 
      x     Yes  
2-Butanone       x  x   Yes  
2-Methyl-4,6-octadiyn-3-one       x     Yes Volatile seen in onions eur. 
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Jour. Plant. Path. 110: 371-
377, 2004 
3-Ethyl-3-methyl-2-
pentanone 
      x     Yes  
6,10-Dimethyl-5,9-
dodecadien-2-one 
      x     Yes 
Found in Gentiana genus of 
plants biochem. Sys. Ecol. 33, 
9, sept 2005, 938-947 
Acetone      x      Yes  
Ethanone, 2-hydroxy-1-
phenyl (HPE) 
         x  Yes  
2-(3-Methylbuta-1,3-
dienyl)cyclohexanone 
         x  Yes  
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Table 2-4 gives the details of all the ketones observed in human breath and lung cancer cell 
culture lines as reported in the literature [34, 36-39, 87, 131-134]. As can be seen from the 
comments column, several of the ketones are found in products and food stuffs. As these 
compounds have an exogenous source, identifying them as biomarkers of lung cancer is 
made more difficult as it can be difficult narrowing down exogenous sources. This is why the 
breath sampling system used in this work is designed to minimise exogenous sources of 
volatile compounds by using a full-face mask. Ketones will ionise in a 63Ni source so they 
would be seen in the DMS. 
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Table 2-5 Aldehydes observed in human breath samples and the headspace of cell culture lines reported in the literature. Adapted from [130] to include whether the compound will ionise 
in a 
63
Ni source, whether it is a sensible I.D. for a biological marker and any comments about its’ known uses. The in vitro studies are shaded grey. 
Compound Reference Observed in Ionisable with 
63
Ni source 
Sensible ID for 
biological marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
Hepatanal x          Y Y  
Hexanal 
x   x     x  Y Y 
Perfume additive, used in 
flavour industry 
Formaldehyde     x      Y Y  
Heptanal    x     x  Y Y Perfume additive 
Acetaldehyde 
        x  Y Y 
Occurs in coffee bread and ripe 
fruit 
2-
Methylpropanal         x  Y Y 
 
3-Methylbutanal 
        x  Y Y 
Product of 3-methyl-butanal 
reductase 
2-Methylbutanal         x  Y Y  
Benzaldehyde          x Y Y metabolite of amygdalin 
3-
ethylbenzaldehy
de          x Y Y 
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Table 2-5 gives the details of all the aldehydes observed in human breath and lung cancer 
cell culture lines as reported in the literature [34, 36-39, 87, 131-134]. As with the other 
compound tables, there are several aldehydes that can be identified as possibly coming 
from an exogenous source. Two of the aldehydes in Table 2-5 have been identified as 
products of metabolism. This highlights that it is perfectly reasonable for aldehydes to be 
proposed as biomarkers and the volatility of smaller aldehydes means that they can be 
sampled by breath analysis. Many aldehydes appear in foods naturally and this means that it 
again may be difficult to eliminate exogenous sources and careful collection and analysis of 
associated metadata along with using sampling methods that minimise the chance of 
exogenous interference are the best way to do this. 
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Table 2-6 Other compounds observed in human breath samples and the headspace of cell culture lines reported in the literature. Adapted from [130] to include whether the compound 
will ionise in a 
63
Ni source, whether it is a sensible I.D. for a biological marker and any comments about its’ known uses 
Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
p-menth-1-en-8-ol (alpha 
Terpineol) 
 x           
Perfum additive, flavour in 
Lasang Souchong 
Isopropyl alcohol  x         Y Y Cleaning solvent 
5-Isopropenyl-2-methyl-7-
oxabicyclo[4.1.0]heptan-2-ol 
 x            
2,2,4-Trimethyl-1,3-
pentanediol diisobutyrate 
 x          N Plasticiser 
9,10-Anthracenediol, 2-ethyl-  x          N 
possible metabolite of a 
9,10-anthracenedione 
based drug 
4-Penten-2-ol  x         Y Y 
Possible component of 
perfume 
Isopropanol     x x        
Ethanol      x x       
2-Ethyl-1-hexanol       x  x x  N 
causes diarrhoea and 
vomiting, nausea and 
headache 
2-Ethyl-4-methyl-1-pentanol       x   x  Y  
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
2-Propyl-1-pentanol       x     Y  
Methanol      x      Y  
1-propanol         x   Y  
Terpineol            Yes Fragrance additive 
1-hexene x   x        Y  
1-heptene x           Y  
1-(methylthio)-(E)-1-propene  x         Y Y  
5,5-Dimethyl-1,3-hexadiene  x         N Y  
Isoprene x  x x  x  x  x N Y  
1,3,5-Cycloheptatriene       x    N N  
1,3,5,7-Cyclooctatetraene       x     Possible Isolated from Fungi 
Bicyclo[4.2.0]octa-1,3,5-triene       x    N Y  
1,3-Pentadiene       x    N Y  
2,4-Dimethyl-1-heptene         x  N Y  
Naphthalene          x Y Y  
Azulene          x N Y  
1H-Indene, 1-methylene          x Y Y petrochemical compound 
2-propenylidenecyclobutene          x N Y  
1,2,3,4-tetrahydronaphthalene          x N Y  
Decahydro-2,6-
dimethylnaphthalene 
         x N Y  
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
Decahydro-1,5-dimethyl 
Naphthalene 
         x N Y  
Decahydro-2,3-
dimethylnaphthalene 
         x N Y  
Tricyclo[3.3.2.0(2,8)]deca-3,6-
diene 
         x N Y  
4-ethoxy-ethylbenzoate  x         Y Y  
Bicyclo[3.2.2]nonane-1,5-
dicarboxylate 
 x         Y Y  
2,2,4-trimethyl-3-
carboxyisoproplisobutylpentoa
te 
 x         Y Y  
2-methyl-,1-(1,1-
dimethylethyl)-2-methyl-1,3-
propanediylpropanoate 
 x         Y Y  
Dimethylether       x    Y Y Propellant and fuel 
2-[(2-ethoxy-3,4-dimethyl-2-
cyclohexen-1-ylidene)methyl]- 
 x         Y Y  
Vinylfuran          x Y Y  
Tetrahydrofuran          x Y Possible  
1,2,3,4-tetrahydro-9-  x         Y Possible Scintillator 
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Compound Reference Observed in Ionisable 
with 
63
Ni 
source 
Sensible ID for 
biological 
marker 
Comments 
[36] [87] [131] [132] [133] [134] [34] [37] [38] [39] 
propylanthracene 
2,3-dihydro-2-
methylbenzofuran 
         x Y Y  
Hydrazine-carboxamide       x    Y N  
Methylhydrazine       x    Y No Used as rocket propellant 
Hydrazine       x    Y No rocket fuel 
Carbonicdihydrazide       x    Y N  
Dimethylsulfide      x     Y Y 
indicator of bacterial 
infection in brewing, found 
in foods, e.g. Beetroot, 
cabbage maize 
Carbondisulfide      x     Y Y  
n-Butylacetate         x  Y possible 
Flavour additive in cheese, 
ice cream, candy etc. 
(p-hydroxyphenyl)phosphonic 
acid 
         x Y Y  
Methylbenzoate          x Y Y  
Benzoate hydrazide          x Y Y  
Acetic acid          x Y Y  
Nitrous oxide          x Y possible  
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Table 2-6 gives the details of all the other compounds observed in human breath and lung 
cancer cell culture lines as reported in the literature [34, 36-39, 87, 131-134] that do not fall 
directly under one of the other table contents. These compounds again have been 
suggested as biomarkers for lung cancer. Some of the compounds that have been suggested 
are not suitable identifications for biomarkers. Hydrazine and the four hydrazine containing 
compounds are inorganic compounds so would not appear in the human body. 2-ethyl-1-
hexanol causes diarrhoea, vomiting, nausea and headaches so it is unlikely that would be a 
biomarker for lung cancer. 2-ethyl-9,10-anthracenediol is possibly a metabolite of an 
anthrancenedione anti-cancer drug.  
As can be seen from Table 2-2 to Table 2-6, many of the compounds identified as possible 
biomarkers for lung cancer also occur from other, exogenous sources. While steps can be 
taken to eliminate exogenous compounds as much as possible, this cannot be completely 
guaranteed. Careful collection and analysis of metadata is important to make sure that once 
a biomarker is identified possible exogenous sources can be eliminated.  
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2.5 Clinical studies 
The clinical studies strand involves several different steps for it to be completed 
successfully. Taken from Figure 2-1 these are; 
 Ethical approval, 
 Study design, 
 Study implementation and, 
 Sample collection and transportation. 
2.5.1 Ethical approval 
Ethics is a philosophical discipline that seeks to discuss morality and associated ideas (for 
example good and evil, or right and wrong). In the context of this work, medical ethics are 
the values that are evaluated when deciding if an experiment on human subjects should go 
ahead. The Hippocratic Oath, believed to be written by Hippocrates around the 5th Century 
BC, is a document that outlines a set of ethical standards to be adhered to. There are two 
well known documents that have shaped modern medical ethics, the Nuremburg Code and 
the Helsinki Declaration. 
 
Table 2-7 A modern version of the Hippocratic Oath [135] 
1. I swear to fulfill, to the best of my ability and judgment, this covenant: 
2. I will respect the hard-won scientific gains of those physicians in whose steps I walk, 
and gladly share such knowledge as is mine with those who are to follow. 
3. I will apply, for the benefit of the sick, all measures [that] are required, avoiding those 
twin traps of overtreatment and therapeutic nihilism. 
4. I will remember that there is art to medicine as well as science, and that warmth, 
sympathy, and understanding may outweigh the surgeon's knife or the chemist's drug. 
5. I will not be ashamed to say "I know not," nor will I fail to call in my colleagues when 
the skills of another are needed for a patient's recovery. 
6. I will respect the privacy of my patients, for their problems are not disclosed to me that 
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the world may know. Most especially must I tread with care in matters of life and death. 
If it is given to me to save a life, all thanks. But it may also be within my power to take 
a life; this awesome responsibility must be faced with great humbleness and awareness 
of my own frailty. Above all, I must not play at God. 
7. I will remember that I do not treat a fever chart, a cancerous growth, but a sick human 
being, whose illness may affect the person's family and economic stability. My 
responsibility includes these related problems, if I am to care adequately for the sick. 
8. I will prevent disease whenever I can, for prevention is preferable to cure. 
9. I will remember that I remain a member of society, with special obligations to all my 
fellow human beings, those sound of mind and body as well as the infirm. 
10. If I do not violate this oath, may I enjoy life and art, respected while I live and 
remembered with affection thereafter. May I always act so as to preserve the finest 
traditions of my calling and may I long experience the joy of healing those who seek my 
help. 
The Nuremburg code was written as a direct result of the Doctors’ trial. The Doctors’ trial 
was the trial of twenty three people, twenty two men and one woman, for war crimes. All of 
the defendants were accused of being involved in Nazi human experimentation. The 
defendants had argued that what they did could not be described as illegal as there was no 
law declaring what was legal and illegal. In defence of medical research, Dr. Leo Alexander 
had earlier outlined six points in defence of medical research in his capacity as Chief Medical 
Advisor to Telford Taylor the Chief of Counsel for War Crimes during the U.S. Nuremburg 
Military Tribunals. The six points outlined by Leo Alexander and a further four points were 
adopted by the trial verdict and formed the “Nuremburg Code”. The ten points of the 
Nuremburg Code are; 
1. The voluntary consent of the human subject is absolutely essential. This means that 
the person involved should have legal capacity to give consent; should be so situated 
as to be able to exercise free power of choice, without the intervention of any 
element of force, fraud, deceit, duress, over-reaching, or other ulterior form of 
constraint or coercion; and should have sufficient knowledge and comprehension of 
the elements of the subject matter involved as to enable him to make an 
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understanding and enlightened decision. This latter element requires that before the 
acceptance of an affirmative decision by the experimental subject there should be 
made known to him the nature, duration, and purpose of the experiment; the 
method and means by which it is to be conducted; all inconveniences and hazards 
reasonable to be expected; and the effects upon his health or person which may 
possibly come from his participation in the experiment. 
The duty and responsibility for ascertaining the quality of the consent rests upon 
each individual who initiates, directs or engages in the experiment. It is a personal 
duty and responsibility which may not be delegated to another with impunity. 
2. The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and unnecessary 
in nature. 
3. The experiment should be so designed and based on the results of animal 
experimentation and a knowledge of the natural history of the disease or other 
problem under study that the anticipated results will justify the performance of the 
experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical and 
mental suffering and injury. 
5. No experiment should be conducted where there is an a priori reason to believe that 
death or disabling injury will occur; except, perhaps, in those experiments where the 
experimental physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the 
humanitarian importance of the problem to be solved by the experiment. 
7. Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death. 
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8. The experiment should be conducted only by scientifically qualified persons. The 
highest degree of skill and care should be required through all stages of the 
experiment of those who conduct or engage in the experiment. 
9. During the course of the experiment the human subject should be at liberty to bring 
the experiment to an end if he has reached the physical or mental state where 
continuation of the experiment seems to him to be impossible. 
10. During the course of the experiment the scientist in charge must be prepared to 
terminate the experiment at any stage, if he has probable cause to believe, in the 
exercise of the good faith, superior skill and careful judgment required of him that a 
continuation of the experiment is likely to result in injury, disability, or death to the 
experimental subject. 
The Helsinki Declaration was issued by the World Medical Association (WMA) as a set of 
principles for medical research involving human subjects. It was first issued in nineteen sixty 
four and has been amended six times, most recently amended in 2008 by the General 
Assembly of the WMA. Paragraph one of the Declaration states “The World Medical 
Association (WMA) has developed the Declaration of Helsinki as a statement of ethical 
principles for medical research involving human subjects, including research on identifiable 
human material and data.” The Declaration of Helsinki is probably the best known policy 
statement of the WMA. 
While the Declaration of Helsinki is not a set of legal guidelines it is often used to define 
what research is ethical and can be used when a case for research is presented to an ethics 
review board. The World Health Organization (WHO) state in their guidelines for 
contributors to their publications that “The World Health Organization publishes the results 
of research involving human studies only if it has been conducted in full accordance with 
ethical principles, including the provisions of the World Medical Association Declaration of 
Helsinki (as amended by the 59th General Assembly, Seoul, The Republic of Korea, October 
2008” [136] and as such has been used in this work to help guide the ethics application. 
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Two European directives exist, the Clinical Trials Directive and the Good Clinical Practice 
(GCP) Directive that influenced the Law in the United Kingdom with respect to medical 
research. Clinical trials of medicinal products are controlled by the Clinical Trials Regulation, 
but this does not control other types of medical research that have no direct legal 
regulation. These trials, including the clinical study in this work, are covered by a complex 
set of common law, clinical governance and professional guidance and ethics applications 
are approved by the Regional Board of the National Health Service (NHS) Research Ethics 
Committee for where the research will be taking place and the Local Board of the NHS 
Research Ethics Committee at the NHS institution where the study will take place [137-139]. 
The ethics board will consider several different aspects of the work when reviewing an 
application for their opinion and will ultimately weigh up the “risk/benefit” of the research. 
This means that they will consider the potential risk to the subjects, which can be examined 
by looking at any supporting data for the application, and compare this to any potential 
benefits the research may provide. This does not mean that research with limited potential 
benefits will be instantly discarded or that research with little to no risk will be approved, 
each application will be considered on its’ own merits. The key decision in this research was 
to investigate patients referred to the chest clinic and not specifically lung cancer sufferers. 
It was decided that this would be more likely to be granted ethics approval. This is because 
people with newly identified lung cancer will be under considerable stress and the 
treatment schedule can be very intensive. It was felt that it might cause undue stress to 
request that they participate in a study during this early period. By asking people to 
participate during their visit to the chest clinic no added stress would be incurred and there 
would be no disruption to their treatment schedule. 
There are several stages to an ethics application that must be completed and approved 
before a clinical study can be commenced. In addition to the ethics applications researchers 
also need to satisfy health and security vetting criteria before they will be allowed to work 
with volunteers; the research passport. These processes must be completed before research 
with human participants can commence. 
  
117 
 
2.5.2 Study design 
There are several different aspects that must be considered when designing a clinical study. 
The main challenge for researchers who are not working within the NHS is integrating into 
the NHS location where the research takes place and making sure this is possible is a large 
part of designing a successful clinical study. With this in mind the study should always be 
planned with the clinical lead. Access to volunteers and hospital sites is key to any clinical 
study and the clinical lead is best placed to provide this. 
The study design should outline every aspect of the clinical study. These are: 
 The aims of the research, 
 The procedures involved in the research, 
 The number of participants required for the study, 
 The data analysis to be carried out and, 
 The expected outcomes of the research. 
All of these should be covered in the study documentation that is submitted to the Regional 
NHS ethics review board for approval. The study design allows all of the people involved in 
the research to be aware of what the basis for the clinical study is and how it should be 
carried out. 
Clearly without ethics approval the research programme fails and the decisions about when 
and where to sample needed to reflect the clinical work-flow and possible impacts on 
individuals who may be gravely ill. It was decided that volunteers would be sought from 
individuals attending “the two week wait clinic”, rather than specify people with lung 
cancer. It would involve the taking of two breath samples per participant for twenty 
diseased participants and twenty healthy participants. Twenty participants in each group 
were decided on as this would give a wide range of biological variation, so any identified 
differences would be more likely to be markers of disease, but was a suitably small number 
of samples to collect in the time frame. These breath samples would be analysed at 
Loughborough University with a view to characterising the differences in breath samples 
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observed in the sampled cohorts. Identification of a suitable sampling site was the first and 
probably most important aspect of the design. To start with the sampling procedure must 
be: 
 comfortable for the participants and; 
 provide reproducible samples for an extended period. 
See Section 2.3 for details on the breath sampler and technique used. 
2.5.3 Study implementation 
The implementation of the study is critical to the research. While the study will have been 
well-planned it needs to be a living thing and able to change if there should be a problem. 
With this in mind there should be a back-up plan for the different aspects of the study 
protocol. A second location for taking samples, different methods for recruiting participants 
(these would require ethical approval) should recruiting prove problematic, back-up 
sampling equipment in case there are problems with it and more than one person trained to 
use it should the operator be taken sick are all vital if the study is to proceed as planned. 
A Gantt chart [140] is a useful document for following the planning and implementation of a 
study as is a flow chart that can provide quick reference to how each different aspect of the 
study interacts and these should be used by the study leader to maintain the smooth 
running of the work. 
In general the study should be fairly straightforward to implement as it will follow the 
agreed and ethically approved programme. In the case of work such as that described here 
that is carried out between two sites constant communication between both sites is 
essential to ensure the study runs smoothly. Simple things such as making sure that the 
clinical researcher taking the samples in the clinic has sterile sampling kits of the right size 
for participants can prevent appreciable delays, particularly if sampling only occurs on a 
single day per week. Every effort should be made to avoid this. 
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2.5.4 Sample collection and transportation 
Sample collection and transportation is the most important aspect of the study. Collection 
of the samples must be done under controlled conditions. Sampling in the same location, 
using the same air supply and sampling equipment is vital to maintain the consistency of 
sampling. The operator needs to make sure they are not contributing to any exogenous 
contamination of the samples or sampling kit. This means refraining from wearing perfumes 
and other scented cosmetics and using hand-creams and other products that may contain 
volatile compounds. 
As the samples are volatile in nature all efforts should be made to ensure their fast 
transport to the laboratory for analysis. The volatile analytes are adsorbed onto the 
adsorbents in the adsorbent trap. To maintain this adsorption the samples should be 
transported at zero degrees centigrade to reduce the chance of more volatile analytes being 
lost. 
2.6 Data processing and analysis methods 
The main consideration when processing data is the avoidance of introducing bias to the 
analysis - something that is surprisingly easy to do, either intentionally or unintentionally, 
and this must be carefully monitored. While the obvious points where an analysis can be 
biased are easily dealt with, such as performing the same processing techniques to all the 
data sets, there can be more subtle effects that can go unnoticed and produce artefacts. For 
example: normalisation of the data set can remove relevant concentration effects between 
samples, while alignment of peaks can force peaks to align that are not actually equivalent. 
It is necessary and helpful to justify the use of each data processing step and describe fully 
the effect of each processing technique on the data. 
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Three different data processing methods were used: 
 Baseline Correction, 
 Normalisation, 
 Euclidian distance transformation and, 
2.6.1 Baseline correction 
The noise in the analytical instruments signal is subject to day-to-day drift and this can result 
in a variation in different baseline values between analyses. To account for this a baseline 
correction on the data is performed subtracting the value of the minimum data point in the 
data set from every point. This means that every sample produced by a detector will have a 
comparable baseline. An example of this process is shown in Figure 2-17. 
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Figure 2-17 Two plots A) and B) of two breath samples before and after baseline correction. Plot A) shows the two 
breath samples plotted as the raw data produced by a Varian Ion Trap 4000 mass spectrometer. In this 
plot the baseline of T123PH1 has been artificially adjusted so the process is easier to visualise. Plot B) 
shows the breath samples after they have been baseline corrected. These two samples now have a 
comparable baseline. 
  
A)
B)
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2.6.2 Normalisation 
Normalisation refers to rescaling the intensity of data against a specified range; most often 
on a scale zero to one. This can either be done for each sample or the sample set as a whole. 
This means that either each sample is scaled from zero to one individually or the sample set 
is viewed as a whole and largest and smallest values set at one and zero respectively, with 
all the other values adjusted accordingly. 
The main consideration with normalisation is that concentration effects can be hidden both 
within and between samples.  
2.6.3 Deconvolution 
As analytes flow through the chromatography column they separate. If they completely 
separate then the peaks produced be the mass spectrometer will be due to one single 
analyte and can be identified. If they do not completely separate then this leads to 
convoluted peaks, peaks which overlap each other. If this happens they must be separated. 
This would usually be done based on the underlying mass spectrometry data. 
2.7 Data analysis methods 
2.7.1 Multivariate analysis 
Multivariate analysis is the application of multivariate statistics, where more than one 
statistical variable is simultaneously observed. It is applicable to mass spectrometric data 
and differential mobility spectrometry data as both techniques measure a large number of 
variables in each run. There are many different multivariate statistical methods available for 
the investigation of variance in the data.  
2.7.2 Principal Component Analysis (PCA) 
Principal component analysis is a technique that reduces the dimensionality of a data set 
composed of a large number of interrelated variables while retaining as much as possible of 
the variation. It does this by transforming the data to a new set of uncorrelated variables; 
called principal components. Principal component analysis is an unsupervised method of 
data analysis that uses no prior knowledge of the samples. 
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Each principal component is calculated successively to account for the maximum amount of 
variance in the sample set. This means that the first component will account for the largest 
portion of the variance in the sample set, the second for the second largest portion and so 
on. Principal components are calculated by transforming the axes of the original plot so that 
the new axes lie along the maximum variance of the data. Figure 2-18 shows the first two 
principal components for the example data set shown. As can be seen in Figure 2-18, the 
first principal component lies in the direction of the maximum variance of the sample set, 
the second lies in the direction of the next highest variance and so on and so on. 
 
Figure 2-18 Example of the first two principal components projected onto a data set. 
The scores for each principal component are the distance the point is from the origin after 
projecting the data points onto the principal component, as shown in Figure 2-19. This 
means that the points can now be plotted on a new set of axes according to the principal 
component scores to look for patterns in the data. Any observed patterns may be due to 
any number of factors and so it is necessary to fully investigate a data set. 
PC1 – Accounts for
the largest Variance
of the data
PC2 – Accounts for the second
largest variation of the data.
Usually, but not always, at right
angles to PC1
x1
x2
x3
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Figure 2-19 Example of how scores are calculated for each data point. 
To fully investigate a data set the points can be plotted in terms of class. The class is the 
label applied to the points in the data set. This can include any meta-data as well as the 
initial sample classes, such as diseased and healthy or the date the samples were taken or 
analysed. 
The number of principal components calculated is determined by the person doing the 
analysis. It is important to remember that the percentage of variance each component 
contains decreases for each successive component. This means that real differences 
between classes are most likely observed in the earlier principal components and it is 
possible that differences observed in the later principal components are due to artefacts for 
the analytical process and this must be considered when interpreting the results[141]. 
2.7.3 Discriminant Analysis (DA) 
Discriminant analysis is a supervised method that uses a priori knowledge to classify 
samples to a specific group. It is broken down into linear discriminant analysis (LDA) where 
the grouping variable has two categories and multiple discriminant analysis where the 
grouping variable has more than two categories. Because it is supervised, discriminant 
analysis can test a prediction by observing if samples are assigned to the expected groups 
[142]. 
PC1
PC2
Dotted lines show projections onto the PCs’, the
scores for each data point are based on their
projections distance from the origin
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3 A dual channel thermal desorption gas chromatograph with differential 
mobility spectrometric and mass spectrometric detection. 
3.1 Introduction 
This work focuses on exploring the differences in breath between asymptomatic 
participants and participants with unambiguously defined lung disease. In doing this testing 
the utility of using differential mobility spectrometry (DMS) for the in-clinic analysis of 
breath was also an important task. In short, was it possible to establish a DMC-based 
method for detecting and identifying compounds found in breath samples. 
The current “gold-standard” for analysing breath samples is gas chromatography - mass 
spectrometry (GC-MS) [35, 62, 85, 104, 129, 143-148]. This allows for separation of complex 
mixtures of volatile organic compounds (VOCs) and identification of the analytes. DMS 
cannot give identify unknown compounds without reference to known standards or 
comparison to mass spectral data. Pairing it with MS enables better characterisation of the 
DMS responses as well as the identification of compounds.   
The challenge in this approach was to use both detectors for the analysis of every sample. 
There are advantages to running the detectors in series, such as the IMS-TOF instruments 
made by TOFWERKS [149], the SYNAPT series made by Waters [150] or the FAIMS adaption 
for Thermo mass spectrometers [151]. This approach was not available in this work as the 
DMS system employed, the Sionex S-VAC, cannot be combined in series with a Varian 4000 
quadrupole ion trap mass spectrometer. An important additional consideration is that 
running the instruments in series would mean that the ionisation would be fixed on APCI, 
and the complementary information from electron impact ionisation would not be available.  
A significant element of this study involved the modification of a commercial GC-MS to 
accept a DMS to run in parallel from a single sample and this chapter describes the 
modifications and protocols designed and undertaken to build a TD-GC-DMS/MS. 
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3.2 Instrumentation 
3.2.1 Overview of instrument set-up 
As a quick reference guide an overview of the system set-up is given. Consumable parts for 
connection of the separate components are given along with part numbers. The description 
is given from the sample injection point, the thermal desorber, to the detection point, the 
mass spectrometer and the differential mobility spectrometer. 
1. A Markes International UNITY thermal desorber was connected by its transfer-line 
through an empty injection port on a Varian 3800 Gas Chromatography oven to a 
VSIS-2 inlet splitter (SGE part No. 123632) via a GVF/004 (SGE part No. 072663) 
ferrule. 
2. Two Agilent J&W DB-5ms (I.D. 0.25 mm, 30 m, 0.5 µm Agilent part No. 122-5536) 
analytical columns were connected to the VSIS-2 inlet splitter via a GVF2/004 (SGE 
part No. 072662) ferrule. 
3. Both of the columns were connected to a SilTite™ mini-union via an 85 per cent 
Vespel/15 per cent graphite 0.1-0.25 mm I.D. ferrule (SGE part No. 072696). 
4. The DMS was connected to the SilTite™ mini-union via a length of deactivated fused 
silica capillary (SGE part No. 0624431), this length was determined as required to 
keep the SilTite™ mini-union inside the Varian 3800 gas chromatography oven. The 
capillary column was connected to the DMS using a 1/32” Valco adaptor ferrule 
(Thames Restek part No. 20137). The fused silica capillary was passed through the 
annular heat pipe in the DMS mount. 
5. The MS was connected to the SilTite™ mini-union via a length of deactivated fused 
silica capillary (SGE part No. 0624431), this length was determined as required by the 
length of the transfer-line heater to the mass spectrometer. The fused silica capillary 
is connected to the mass spectrometer through the transfer-line via a 85 per cent 
Vespel/15 per cent graphite 0.1-0.25 mm I.D. ferrule (SGE part No. 072696). 
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3.2.2 Adsorbent trap conditioning 
All adsorbent traps used in this work were conditioned before use. This was done at 280oC 
in an adapted gas chromatography oven for at least 8 hours. During conditioning nitrogen 
was passed through the tube at 150 mL min-1. After conditioning all tubes were analysed by 
TD-GC-DMS/MS to check they were blank before being shipped for samples collection. 
3.2.3 Outline of the instrumentation system. 
The instrument design enabled two detectors to be operated in parallel from the sample 
that was split onto two GC-columns immediately after injection; one column per detector, 
see Figure 3-1. 
 
Figure 3-1 A flow diagram to show the flow of analyte through the parallel system. All transfer lines between each part 
of the system are heated. 
This system was based on: Varian gas chromatograph (GC 3800); an ion trap mass 
spectrometer(Varian 4000) with a Markes International UNITY thermal desorber. A 1:1 
splitter (SGE part No. 123632) was fitted to the end of the transfer line form the thermal 
desorption unit as it entered the gas chromatography oven. A panel was removed from the 
top of GC and a detector mounting port was modified to receive a heated transfer line and a 
Sionex S-VAC differential mobility spectrometer. 
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3.2.4 Differential mobility spectrometer mount 
There is no specific mount or fitting to connect the Sionex S-VAC unit to the Varian GC-3800 
so a mount was designed to connect these two units, Figure 3-2 - Figure 3-4. 
The mount was designed for the detector interfaces on the top surface of the Varian GC-
3800 and the Sionex S-VAC DMS system. The Varian GC-3800 has several threaded holes to 
allow for mounting detectors above the oven, and holes through to the oven to allow GC 
columns to pass through to the detectors. A plate was machined to fit across the top of the 
Varian Detector outlets and anchor at four of the threaded mounting holes. Two threaded 
holes were cut in the plate to allow mounting rods to be secured in the base plate. These 
mounting rods allow connection of the Sionex S-VAC DMS unit to the base plate. A 44.3 mm 
hole was cut to allow an annular heat pipe assembly to be mounted to the base plate. 
The length of the mounting rods was set by the dimensions of the S-VAC unit and the 
annular heat pipe. The mounting rods were machined from stainless steel. A 3 mm diameter 
13 mm threaded stainless steel rod was screwed into a 5 mm deep threaded hole and glued 
in place. Using a separate rod, rather than turning down the original rod, makes for a 
stronger mounting point. These threaded rods allow the S-VAC to be secured on top of the 
mounting rods using a nut. PTFE spacers were used between the housing of the S-VAC and 
the mounting rods to minimize heat transfer from the oven and heater block assembly 
attached to the mounting plate. A stainless steel cylinder was machined along with a circular 
plate with a mounted screw thread. The underside of the cylinder was threaded to match 
the mounted screw thread on the plate. This allowed the cylinder to be mounted on the 
base plate. Two holes were drilled through the stainless steel cylinder with the same 
diameter as that of the annular heat pipe and the cartridge heater. A small recess was 
drilled for a thermocouple to be placed inside, as part of the heater controller for the 
heating cartridge. 
Drawings of the machined parts that make up the DMS mount and the annular heat pipe 
can be seen in Figure 3-2 and Figure 3-3. 
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Figure 3-2 Base plate for the differential mobility spectrometer mount. This was designed so that it would fit on the 
detector mountings of the Varian GC-3800. 
Figure 3-2 shows a scale drawing of the base plate of the DMS mounting. The plate can be 
easily attached to the top of the Varian GC-3800 with no modification of the GC required. All 
other machined parts are attached to the base plate by screw threads, this means that they 
can be removed and the base plate can be left attached to the GC oven, should the DMS 
unit be removed. 
 
Figure 3-3 The machined parts that fit to the base plate of the differential mobility spectrometer mount. Drawing not to 
scale. 
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Figure 3-4 shows the machined parts connected to the base plate. All of the parts were 
machined from stainless steel. The mounting rod is shown with the threaded rod inserted 
into the drilled hole, to show the complete rod. This was done to improve the strength of 
the mounting point. 
 
Figure 3-4 Differential mobility spectrometer mount. The blue arrows indicate parts that are fitted together on the 
mounting of the differential mobility spectrometer. A = anchoring screws, B = differential mobility 
mounting poles, C = thermocouple, D = cartridge heater, E = PTFE spacer, F = heater block, G = annular 
heat pipe, H = base plate. The whole mount is retrofit and requires no modification of the Varian 3800-GC 
to fit. 
Once all the parts were machined, the mount was assembled as shown in Figure 3-4 and 
fitted to the top of the GC. A deactivated fused silica capillary column (0.25 mm I.D (Supelco, 
USA)), connected to the end of the analytical column, was fed through the annular heat pipe 
and connected to the Sionex S-VAC DMS. A transfer-line was used rather than the column to 
maintain the whole length of both columns at the same temperature. This would not have 
been possible if the column was connected directly to the DMS unit as the annular heat pipe 
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was not capable of reaching the same temperatures as the 3800-GC oven; this was to 
protect heat sensitive components within the Sionex system. The mounting points on the S-
VAC were then placed over the threaded inserts in the end of the mounting poles and PTFE 
washers and 3 mm nuts were used to lock the unit in place. The heating block and annular 
heat pipe were wrapped in Superwool 607 max blanket (RS part No. 417-6713) and this was 
taped in place on the heating block and held in place on the annular heat pipe using 25.4 
mm I.D. black heat-shrinkable tubing wrap (RS part No. 700-4668). The whole block was 
grounded through the earth point on a mains cable. 
Figure 3-5 shows a photograph of the base plate, with the S-VAC unit attached, connected 
to the top of the GC. The main parts have been labelled with letters corresponding to the 
drawing in Figure 3-4. 
 
Figure 3-5 Photograph of the differential mobility spectrometer mount assembled on top of the Varian GC 3800 with a 
temperature controller and a Sionex S-VAC attached. Labelling kept the same as Figure 3-4 for ease of 
identification. 
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The parts list for the DMS mount and the heating assembly is given below: 
 DMS mount 
o Annular heat pipe - (Pipcar Ltd, Unit 4B Valley Industries, Hadlow Road, 
Tonbridge, Kent, TN11 0AH. England. Tel (UK) +44 (0)1732 851807. Fax (UK) 
+44 (0)1732 850255). 
o Baseplate and mounting poles - (Produced externally) 
o PTFE spacers - (Produced by the University of Manchester Institute of Science 
and Technology workshop) 
o Heat pipe mount with threaded base - (Produced by the University of 
Manchester Institute of Science and Technology workshop) 
o 3mm thread mounting screws - (internal stock) 
 Heating assembly 
o Tempatron On/off temperature controller, 0-200 deg C type K. RS stock No. 344-
546 
o PTFE insulated J welded tip thermocouple. RS Stock No. 621-2142 
o Bi-metallic NC thermostat. RS stock No. 339-724A 
o 300W Cartridge heater 6.5 x 100mm. RS stock No. 376-1685 
Figure 3-6 shows the DMS mount in place on the GC oven. 
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Figure 3-6 The DMS mount set up with the DMS in position. 
3.2.5 Splitting the sample 
A fixed ratio inlet splitter was used to split the thermal desorption profile between the two 
capillary columns. The thermal desorber transfer line was connected to a VSIS-2 inlet 
splitter, Figure 3-7, (SGE part No. 123632) with GVF/004 (SGE P/N 072663) ferrule for 
connection of the thermal desorber fused silica capillary and a GVF2/004 (SGE P/N 072662) 
ferrule for connection of two Agilent J&W DB-5ms (I.D. 0.25 mm, 30 m, 0.5 µm Agilent part 
No. 122-5536) analytical columns inside the gas chromatography oven. 
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Figure 3-7 Column splitter 
3.2.5.1 Mitigation of differences in transfer line temperatures. 
The heated transfer line to the mass spectrometer was specified at higher and more 
precisely maintained temperatures than the annular heat pipe. To avoid temperature 
effects on retention times between the two channels deactivated, fused silica capillary 
column was used to connect the DMS to the main capillary column, using a SilTite™ mini-
union GC capillary column connector (SGE Part No. 073550) with two 85 per cent Vespel/15 
per cent graphite 0.1-0.25 mm I.D. ferrules (SGE Part No. 072696). This fused silica column 
was passed through the annular heat pipe with the SilTite™ mini-union maintained inside 
the GC oven. This fused silica column contained no stationary phase so analytes would pass 
along it without any partition effects. This meant that while there would be a difference in 
temperature between the two, the analytes would move quicker through the deactivated 
column compared to the main capillary columns and so reduce any differences in retention 
times. The same set-up was used for the mass spectrometer. 
3.2.5.2 Balancing flows. 
Engineering a precise 1:1 split between the two columns was not straightforward. The 
priority focus was to deliver a flow of 2 mL min-1 through the mass spectrometry column for 
two reasons; 
1. Low pressure at the end of the capillary column damages the stationary phase and causes 
contamination of the mass spectrometer, and a minimum of 1 cm3 min-1 should be 
maintained and, 
2. As the mass spectrometer provides identification of the analytes and this can be 
confirmed with retention time against a standard, every effort should be made to keep 
this as consistent as possible when prospecting for biomarkers. 
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In order to balance the flow in this way the deactivated capillary retention gaps to the two 
detectors were trimmed to the lengths needed, and this in turn meant that the effects of 
temperature on column flow were not identical in each of the channels. This meant that the 
flow through the DMS column was unlikely to exactly match the flow in the MS column, it 
was still raised at the same rate during each analysis and the results between the detectors 
were directly comparable. 
3.2.5.3 Calibrating the flow through the columns 
To achieve the specified flow of 2 cm3min-1 over the specified temperature range, 
measurements were made at 10oC steps from 30 to 310oC at varying pressures to produce a 
series of charts; an example is shown in Figure 3-8. 
 
Figure 3-8 An example of the charts produced to show how flow varied with pressure at a constant temperature.  
Figure 3-8 shows the change in flow to be linear with respect to pressure at a constant 
temperature. To show that the change in flow was also linear with respect to temperature 
at constant pressure, another series of charts were plotted, an example of which is shown in 
Figure 3-9. 
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Figure 3-9 An example of the charts produced to show how flow varied with temperature at a constant pressure. 
Figure 3-8 and Figure 3-9 show that the variation of flow is linear with respect to both 
temperature and pressure. This means that the equations of either line can be used to 
calculate the temperature and the pressure required to maintain the flow at a constant 2 
cm3 min-1 for any time point in a GC programmed run. Figure 3-10 shows a plot of pressure 
against temperature to give a flow of 2 cm3 min-1 at each temperature point that 
measurements were made. 
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Figure 3-10 Chart showing the pressure required to maintain a 2 mL min
-1
 to the mass spectrometer. 
The equation of the line in Figure 3-10 allows for the calculation of the pressure required for 
a flow of 2 cm3 min-1 at any temperature within the range measured. 
As can be seen in Figure 3-8 and Figure 3-9, the flow through the DMS column is lower than 
that through the MS column. This means that the same analytes will reach the two different 
detectors at different times, highlighting one of the problems with a parallel column 
approach. This must be taken into account and corrected for. This can be done using a 
retention index ladder. While this difference exists it will be constant across all of the 
samples analysed and so they will still be comparable. 
This procedure needs to be carried out each time a column is replaced as slight differences 
in the two columns may change the pressure required to drive the correct flow through 
them. 
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3.2.6 System operating parameters 
The system operating parameters are given in Table 3-1, Table 3-2, Table 3-3 and Table 3-4. 
These are the parameters used for the analysis of all breath samples in this work. 
Table 3-1 Thermal desorber settings 
Parameters Settings  
Primary desorption flow 50 cm3min-1 
Primary split splitless  
Primary desorption temperature 300 oC 
Primary desorption time 5 minutes 
Cold trap temperature -10 oC 
Secondary desorption flow 20 cm3min-1 
Secondary split Splitless  
Secondary desorption temperature 300 oC 
Secondary desorption time 5 minutes 
Trap heating rate 100 oC min-1 
Transfer line temperature 140 oC 
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Table 3-2 Gas chromatography settings 
Parameter Settings   
Column 
95% methyl 5% phenyl 30m x 0.25mm I.D x 
0.25um film thickness 
  
Carrier gas Helium   
Flow 2 cm3 min-1   
Total run time 60 minutes   
Temperature 
program 
Temperature/ oC Rate/  oC min-1 
Hold / 
minutes 
 40 3.3 - 
 90 2.5 - 
 140 10.0 - 
 310 0.0 8.85 
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Table 3-3 Mass spectrometer settings 
Parameter Setting 
Scan type Full 
Mass range m/z 40-450 
Ionization time Electron ionization (EI) 
Emission current 10 µA 
Scan time 0.82 s 
Transfer line temperature 270oC 
Trap temperature 150oC 
Manifold temperature 50ºC 
Table 3-4 Differential mobility spectrometer settings 
Parameter Settings 
buffer gas High purity nitrogen 
Flow buffer gas 270 cm3min-1 
Temperature 100ºC 
Compensation field scan rate 3.6 s scan-1 
Dispersion field scan rate (dispersion 
field programming) 
322 V cm-1s-1 
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4 Processing GC-DMS data surfaces. A new Euclidian-based approach 
4.1 Introduction 
The data generated by GC-DMS are difficult to process in multivariate analysis, and this 
challenge was a vital part of this study if DMS devices are to be used in this field. DMS data 
is a plot of compensation voltage versus intensity, but when a DMS instrument is attached 
to a GC system an extra axis is introduced creating a data surface, and including data from 
multiple samples results in a data cube. Multivariate techniques, such as principal 
component analysis or principal component – discriminant function analysis are the 
favoured approach in such instances; however the difficulty with working with GC-DMS data 
is that multivariate techniques can only be applied to one dimensional data. It is possible to 
reduce DMS data to one dimension by integrating across the compensation field, but this 
removes any separation information generated by the instrument in the first place. For 
complex data sets such as breath samples this lost information may be vitally important. 
This chapter therefore describes a method that was developed to register the three-
dimensional output generated by a GC-DMS experiment as a two-dimension array amenable 
for multivariate processing. 
4.2 DMS data processing  
IMS has been developed for applications where analytes are specified and their behaviour 
within the instrument is characterised extensively [69-76]. Subsequently the instrument’s 
parameters are optimised to detect the specified compounds. In contrast in this study DMS 
was used to detect unknown VOCs in a complex mixture, and the instrument was configured 
to record as much information as possible with the greatest possible sensitivity. At the end 
of the campaign the data were to be modelled to enable differences in the sample sets to 
be evaluated as predictors of disease. This is a “classic” multivariate problem with small, yet 
significant, differences embedded in highly complex and variable data sets [26, 46, 82, 152, 
153]. 
This study generated many thousands of time resolved spectra, described in three 
dimensions by: 
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Compensation field (V cm-1 ); 
Signal intensity in (V) and;  
Retention time (s) or dispersion field (V cm-1) strength, which correlated to retention time as 
the dispersion field was being programmed [109]. 
The first step in processing such data is to reduce the dimensionality of the data structure 
for example: 
Sum the data across the compensation field axis [46, 152], this removes the separation 
given in the compensation field and can combine peaks that were resolved,  
or, take strips through the data at specific compensation voltages [153]. For complex data 
sets this either means reducing the amount of data or the complementary processing of a 
very large number of strips, 
Or, to use wavelet analysis to pick out peaks of interest and process these [154]. This can 
also reduce dimensionality of the data as peaks below the limits set in the analysis may be 
missed. 
Summed method approaches integrate across one of the dimensions of either retention 
time or compensation field, and in recent approaches the preferred factor has been 
compensation field [46, 152, 153], a schematic of how this is done is shown in Figure 4-1. 
This approach removes chemical information contained within the differential mobility 
dimension and necessarily excludes the reactant ion peak. This is a significant omission, for 
earlier studies with neural network analysis of mobility spectra indicated that significant 
information is contained in the fragment ions associated with the RIP [155]. Therefore 
intentionally excluding this element of the experimental response is to remove a significant 
source of information from the data analysis. 
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Figure 4-1 Representation of how the summed method transforms the data from three to two dimensions. The raw data 
is summed across each compensation field sweep and the resultant data is used. 
Ideally the data structure needs to be simplified while retaining as much of the information 
as possible. One approach may be to employ a Euclidian approach; whereby multiple 
dimensions may be replaced with single vector. 
4.3 Developing the approach 
4.3.1 Euclidian distance method 
The Euclidian distance method represents the vectors of compensation field and retention 
time by a single vector. For a three-dimensional response surface of N values of 
compensation field and H values of retention time then any point on the surface may be 
represented by the single vector Zx (Where x is the specific point on the surface) and I, 
which is the intensity of the signal at the specific point. This vector is calculated according to 
Equation 4-1, and a schematic detailing how a point is identified is shown in Figure 4-2. 
          
  Equation 4-1 
Here, ni is the scaled value of the compensation field between 0 and n and hj is the 
corresponding scaled retention time increment between 0 and h. 
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To enable this approach to work, two-additional data processing operations are required to 
take into account the original “scaling” of the data set and “equivalent-value” Euclidian 
vectors that result. 
 
Figure 4-2 Schematic showing how each point is identified on a surface for the Euclidian transformation. 
4.3.2 Data scaling 
The “raw” data are defined by the experimental parameters (compensation voltage and 
retention time). Combining data scales with contrasting numerical ranges generates a 
matrix that is disproportionately skewed towards one of the variables, with the associated 
reduction in information. Further, the inclusion of un-scaled positive and negative 
compensation field values would result in nonsensical outcomes. Consequently the data are 
scaled from zero to N and H in single integer series, where zero is the lowest value of the 
measurement scale number and N and H are the highest values of the measurement scale, 
N being associated to the compensation voltage scale and H being associated to the 
retention time scale. 
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4.3.3  “Equivalent value” Euclidian vectors 
The mapping of a surface using Euclidian distance will produce a series of equivalent-value 
vectors. The number of equivalent value Euclidian vectors points will depend on the data set 
and the scaling increments used. This is addressed by adding a point number when sorting 
the Euclidian/Intensity pairs. As the Euclidian distance for each point is calculated, a point 
number is assigned to each distance. The distances are calculated across the compensation 
voltage axis beginning at the origin and proceeding across the axis until every point in this 
compensation voltage sweep has been assigned. This is then repeated along the retention 
time axis. By sorting by Euclidian distance first and then point number, features that appear 
first in the data set will appear first in the reassigned set. The sorted pairs are then 
reassigned against a single integer series, ranging from 1 to M (M=N×H) when one is the 
smallest distance and M is the largest distance. This enables the full information of the set 
to be retained. 
4.3.4 Five peak demonstration test set 
An idealised data surface consisting of five peaks was created using a two dimensional 
Gaussian function; 
         
  
      
 
    
 
      
 
    
 
 
Equation 4-2 
Where A describes the amplitude of the peak, x0 and y0 describe the centre of the peak and 
σx and σy describe the x and y spread of the peak. These will be referred to as the peak 
parameters. As an example of how these factors affect the shape of the peak several plots 
have been produced in Figure 4-3 with their peak parameters listed in Table 4-1. 
Table 4-1 The peak parameters for the different peaks seen in Figure 4-3. 
Series number Intensity (A)/AU Peak location (x0 or y0)/AU Peak spread (σx or σy)/AU 
1 1 0 3 
2 2 0 2 
3 4 -4 2 
4 5 0 1 
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Figure 4-3 Plots of the Gaussian peaks whose parameters are listed in Table 4-1. This shows how altering these 
parameters affect the size, shape and position of the peak and can be manipulated to created peaks for 
testing the Euclidian transform method. 
Figure 4-3 shows one dimensional Gaussian function plots. In two dimensions the plot has 
two more variables which dictate the spread and location on the second axis. An example 
plot is shown in Figure 4-4. 
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Figure 4-4 An example plot of a single three dimensional Gaussian peak. 
The peak seen in Figure 4-4 has the same location and spread along both axes of the plane 
to produce a symmetrical peak. This can be used to create test DMS data files or insert 
simulated test peaks into DMS data files. 
Five separate peaks were created using Equation 4-2. Their locations were chosen so that 
two pairs of peaks were unresolved in the retention time axis and analogously, two were 
unresolved in the compensation field axis. The final peak was placed exactly in the middle of 
the two pairs. This can be seen in Figure 4-5. 
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Figure 4-5 Plot of the five peak test set created using the two dimensional Gaussian function. 
Although the five peaks are resolved two of them, B and C, have equivalent-value Euclidian 
distances and four of them (A, B, C and D) are aligned in pairs with respect to compensation 
voltage (A, C and B, D) and retention time (A, B and C, D). Integration with respect to either 
compensation field or retention time will yield three peaks, integration with respect to 
compensation voltage shown in Figure 4-6, with the associated loss of information. 
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Figure 4-6 Five peak test set after transforming from three dimensions to two dimensions using the summed method 
with respect to the compensation voltage. Only three peaks are observed with two being enlarged. The 
peaks are labelled to show which peaks from the original test set make up which peak. 
Unfolding using Euclidian distance, data scaling and sorting enables the complete 
characteristics of all five peaks to be recorded in a two dimensional plot. The smaller peaks, 
labelled WA, WB, WC, WD.and WE in Figure 4-7 record the peak width and as such enable the 
full nature of unresolved signals to be included in subsequent data processing operations. 
This enables more of the complexity of the original data to be captured in the transformed 
matrix. Note that their position along the “reassigned distance” axis is due to their distance 
from the origin in the original data set, and co-located features may not normally be 
assumed to be close to one another in the original response surface, see features B and C in 
Figure 4-7 for example. 
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Figure 4-7 Five peak test set after transforming from three dimensions to two dimensions using the Euclidian transform 
method. Each separate peak is due to a single intensity point in the original data. i) shows the full 
transformed data set, ii) shows an enlarged view of the reassigned distance region 1727 to 1902. In this 
region it can be seen that peaks B and C are fully resolved. Peaks labelled Wx are the coded width of the 
peaks, where x is the peak label. 
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4.3.4.1 Evaluation of the five peak test set 
The five peak test set sought to demonstrate the Euclidian transform approach to data 
reduction of GC-DMS data. The test set was constructed with overlapping features that 
would be obscured by a summing/integration approach or by taking sub-samples. This effect 
can be seen in Figure 4-6 with the first and third peaks both containing pairs peaks which co-
elute in the time axis. Any attempt to use summing approaches would lose these details in 
the subsequent data models. An alternative approach, wavelet analysis, “picks peaks” and 
sets limits based on pre-determined parameters. While the operator may be very careful 
this method still reduces the data sets and may exclude important information. Methods 
where strips are taken through the data have also been used but this means complimentary 
processing of many strips depending on the complexity of the data set and may not take 
into account multiple changes in different strips. The Euclidian distance method was applied 
to the five peak test set; this produced the data set plotted in Figure 4-7. All five peaks can 
be seen and they are all fully resolved. Smaller peaks are also observed and these are due to 
the width of each peak. As all the data points in the plot are single signal intensities from the 
original data matrix there has been no false combination of any components as opposed to 
the data resulting from using the summed method. 
Preserving the intensity of the original signal is discussed in more in section 4.5.1, but as can 
be seen from the discussion of the combination of peaks in the same compensation field 
sweep, it is difficult to assign a peak area to a single peak using this method, especially with 
real data when background noise will be summed as well. 
4.3.5 Dispersion field sweep data set 
The dispersion field sweep data set consisted of ten dispersion field sweep blanks recorded 
on consecutive days. The data was generated on a thermal desorption – gas 
chromatography – differential mobility spectrometry instrument platform, see chapter 3 for 
instrument details. 
The dispersion field sweep data set was produced using the parameters summarised in 
Table 4-2. The sample set was produced by running the instrument without any sample 
injection. Each data set was collected in the morning after the instrument had been 
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validated. The ten samples were collected on ten consecutive days and were visually 
checked before processing. 
Table 4-2 Differential mobility spectrometer settings 
Parameter Setting value Units 
Start compensation voltage -43 V 
End Compensation Voltage 10 V 
Number of Compensation voltage steps 100  
Compensation Voltage Scan duration 3600 ms 
Start dispersion field voltage 500 V 
End dispersion field voltage 1500 V 
Number of dispersion field steps 100  
Sensor temperature 80 °C 
Flow rate 300 cm3 min-1 
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4.3.5.1 Comparison of the effect of using the Euclidian-based approach against a 
summation method with the summed method to analyse dispersion field 
programmed data 
The method was applied to a dispersion field sweep data set to contrast the Euclidian 
distance method and the summed method with straightforward data, in essence an 
instrument blank 
 
Figure 4-8 Data from the dispersion field sweep data set. The positive channel is displayed on the left and the negative is 
displayed on the right. The only signal observable in both plots is due to the reactant ion peak. 
The dispersion field sweep data set is shown in Figure 4-8. There is only one feature present 
in both the negative and positive channels and this is due to the reactant ion peak. Note 
how the intensity of the signal reduces with increasing field strength, due to wall losses, and 
how the intensity of the RIP in the negative mode is less than the positive mode, transport 
gasses were dry nitrogen. 
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Figure 4-9 Comparison of the final output after converting the positive channel of a single dispersion plot using the summed method and the Euclidian distance method. 
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The difference in the information content of the two methods is striking, see Figure 4-9. The 
summed method gives a single line plot that follows the intensity of the reactant ion peak 
and any underlying water/ammonia features as attenuation of the reactant ion peak with 
the increasing wall losses associated with increasing dispersion field strength. There are 100 
data points in the series, each point being due to a whole, summed, compensation field 
sweep. The intensity given starts at 12.35 V and falls to 11.7 V. the Euclidian distance 
method gives a plot where each individual intensity is plotted, and as such is a much larger 
data set with 10,000 points. The signal due to the reactant ion peak and any underlying 
peaks are grouped together in the centre of the plot. Figure 4-10 shows an enlarged view of 
the main response area of the Euclidian distance transform plot. 
 
Figure 4-10 Enlarged view of the main response area in the Euclidian distance transform plot of the positive channel. 
The decrease in signal intensity in the summed method occurs more quickly in the negative 
channel data set. The intensity varies from 10.62 to 10.23 V and the data set is the same size 
as the positive data set. Again, in the Euclidian distance method transformed data we see a 
grouping of peaks that is more central, although slightly offset to the left, between 
reassigned distance 2000-4500. The data set is the same size as the positive data set and the 
signal intensity varies from 0.11 to 0.24 V. 
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Figure 4-11 Comparison of the final output after converting the negative channel of a single dispersion plot using the summed method and the Euclidian distance method. 
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An enlarged view of the Euclidian transformed negative channel data is shown in Figure 
4-11. The data is less complex than the positive channel data and the transformed features 
are readily discernable, see Figure 4-12. 
 
Figure 4-12 Enlarged view of the main response area in the Euclidian distance transform plot of the negative channel. 
4.3.5.2  PCA of dispersion field sweep data sets 
The ten sets of summed and Euclidian processed dispersion field data were analysed by PCA 
and the first two principal components were calculated with the data plotted as individual 
principal component values. The data sets were labelled as either positive or negative. This 
can be seen in Figure 4-13. 
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Figure 4-13 Plot of the individual values of the first and second principal components calculated from the data set after 
transformation using the summed method. 
As can be seen in Figure 4-13, when using the summed method for transforming the data, 
full separation of the data is only observed in the second principal component. Figure 4-14 
shows the single principal component plot for the first two principal components calculated 
from the data after it has been transformed using the Euclidian distance method. Full 
separation can be seen in both principal components. 
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Figure 4-14 Plot for the individual values of the first  and second principal components calculated from the data set after 
transformation using the Euclidian distance method. The names on the x axis are the channels from the 
differential mobility spectrometer. 
Figure 4-15 shows the plots of the first two principal components against each other after 
transforming the data using both the summed method and the Euclidian distance method. 
Full separation can be seen in both data sets, but the data that has been transformed using 
the Euclidian distance method shows improved separation and grouping. 
 
Figure 4-15 Plot of the first principal component values (on the y-axis) against the second principal component values 
(on the x-axis) calculated from both data sets after transformation using the summed method (left) and 
the Euclidian distance method (right). 
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4.3.5.3 Dispersion field sweep data sets 
In day to day evaluation of data separating positive mode and negative mode data does not 
require PCA analysis for the position of the reactant ion peaks, the only signal in the data 
sets, is very reproducible. 
The reproducibility of a plot is important in chemometric techniques for data analysis. In this 
instance these dispersion field sweeps are blanks, there is very little, if any, change in the 
position of the reactant ion peak. In contrast, features in non-blank data sets can drift, and 
consequently require complex pre-processing of the data sets before chemometric analysis. 
In this study such pre-processing was avoided to enhance the efficiency of the work and 
avoid any chance of favouring one or the other transform method.  
Figure 4-13 shows the individual principal component plots for the first two principal 
components of the dispersion plot data set after transformation using the summed method. 
Although the separation of the positive and negative mode responses is a trivial exercise at 
one level it may be seen that separation is still not seen in the first principal component. In 
contrast, Figure 4-14 shows separation in both the first and second principal components if 
the Euclidian approach is adopted; see also Figure 4-15 that emphasises why this is the case. 
The Euclidean plots have retained their obvious differences and the principal component 
analysis has separated the groups, and generated precise clusters in the first principal 
component, with significantly improved discrimination when the first two components were 
plotted against each other. 
4.4 Evaluation and testing the approach with modelled data. 
Six tests were devised to test the Euclidian transform method. These six tests were based on 
the ways the peaks in a data set can change. The first three tests were designed to test that 
the method would work as the intensity of the peaks that differ between sets decreases. 
Two of the final three tests were designed to show that the method would work when only 
one peak differed between sets and when two peaks were unresolved with one set showing 
slightly more resolution. The final test was designed to show how the method performed 
when a peak within the data set drifted. To create the data files for these tests, a single data 
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file from the set described in 4.5.2 data set was selected and then modified to produce 
simulated responses in the following ways: 
1) The average noise for the section -43 to -31.87 volts and 0 to 19.203 seconds was 
calculated for the selected file. Based on this average value the intensity at every 
point in the plot was changed in one of two ways: 
2) A random number between zero and one and a half times the average value was 
added to every point to increase the amount of noise in the data set. Or, 
2) The average noise signal was divided by four and subtracted from every point. A 
random number between zero and the divided average value was then added to 
every point. This method was used to adjust the noise in each sample while but 
increasing it. This method slightly reduces the average noise in the samples. This 
will be referred to as the adjusted noise method. 
3) And 4) Gaussian peaks of differing values were created and inserted into the 
selected file to create new data sets with controlled differences. These peaks can 
be described in terms of compensation voltage location, retention time location, 
the spread of the peak in retention time and compensation voltage and the 
intensity of the peak. The compensation voltage location dictates where along the 
compensation voltage axis the peak maximum will be. The retention time location 
dictates where along the retention time axis the peak maximum will be. The 
spread of the peak in the compensation voltage and the retention time dictates 
the overall shape of the peak and the intensity dictates the maximum intensity 
which falls at the point where the compensation voltage location and the 
retention time location meet. 
5) The file was cropped to exclude the RIP and areas where there were no peaks 
observed. The original file axes were -43 to 15 volts compensation voltage and 0 
to 348.828 second and this was cropped to -9.61 to 7.97 volts and 79.875 to 
280.063 seconds. This resulted in a surface of 31 points by 199 points. 
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These are the modifications that were made to every file created for the six tests. Figure 
4-16 shows how the original file changed as these modifications were made. Details of the 
test data are included in Appendix I. 
 
Figure 4-16 The DMS surface at different stages of modification. 1) Shows the original data file. 2) Shows the original file 
with the noise increased. 3) Shows the extra peaks (in this case five) that will be inserted into the file. 4) 
Shows the original data file with the noise increased and the new peaks inserted. 5) shows the original 
file with the noise increased and the new peaks inserted after it has been cropped to remove the RIP and 
the sections of the surface where no peaks appear. 
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The additional noise was recalculated every time a new file was created. This is because the 
same file is used as the base for each file created. If this was not done clustering of files in 
any analysis may have been artificially improved as the background noise pattern of every 
file would be the same. 
For each of the six tests two sets of files were created, set A and set B, with the noise 
modified in one of the two ways described previously. Ten peaks, differing in retention 
time and compensation voltage, were inserted into every file. 
The peaks inserted for each test were as follows: 
4.4.1.1 Test 1 High intensity differences in half of the discriminant data.  
Ten resolved peaks were generated into two sets of data (set A and set B). Each set of data 
contained noised replicates with five common peaks  shared between the two sets and five 
peaks associated with the set These peaks had an approximate intensity of four times the 
maximum peak intensity of the original file. The noise was increased by 150 % of the 
average noise of the source file, see Figure 4-17. Where the intensity of the ten inserted 
peaks was approximately four times the intensity of the largest peak in the original data set. 
The noise was increased by one and a half time using the method described previously. The 
tables containing the details of the inserted peaks are Table 1 and Table 2 in Appendix I. 
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Figure 4-17 Plots of a single file from each set in Test 1. A is a plot of data file A1 and B is a plot of data file B7. 
After the peaks had been inserted each data file was processed using the Euclidian 
transform method, and the two dimensional data transferred to Minitab 15 Statistical 
Software. A principal component analysis was performed extracting the first ten principal 
components. The first two principal components were then plotted against each other for 
all of the samples. This plot can be seen in Figure 4-18. 
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Figure 4-18 Plot of the first two principal components calculated for the transformed data files in Test 1. This shows a 
clear separation and grouping of the two sets, A and B. 
A clear separation and grouping of the two sets, A and B, can be seen in Figure 4-18. This 
shows that the Euclidian transform method is able to differentiate between the two sets of 
data files described. This is not a rigorous test for the approach but provides a useful and 
encouraging starting point. 
As an initial test five of the peaks in both sets were the same and the other five differed 
between sets. The results of the PCA show that it is possible to separate the two sets based 
on these differences. This is to be expected as the differences in the data sets can be visually 
distinguished. As highlighted by Figure 4-17. While this separation could have been done 
manually, for a larger number of data files per set, this could be a time consuming process, 
especially if the differences were not so obvious. This test has shown that the Euclidian 
transform method is a viable option for three dimensional data sets when a large number of 
differences are present. 
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4.4.1.2 Test 2 Medium intensity differences in a small proportion of the discriminant 
data. 
The data sets were created in the same way as Test 1 but the intensity of the peaks was 
changed to between one and two times the maximum peak intensity of the original file and 
only two peaks differed in location, examples of the two sets are shown in Figure 4-19. The 
tables containing the details of the inserted peaks are Table 2 and Table 3 in Appendix I. 
 
Figure 4-19 Plots of a single file from each set in Test 2. A is a plot of data file A8 and B is a plot of data file B5. 
These data were processed and analysed as for Test 1 and the resultant plot of the first two 
principal components may be seen in Figure 4-18. 
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Figure 4-20 Plot of the first two principal components calculated for the transformed data files in Test 2. This shows a 
clear separation and grouping of the two sets, A and B. 
The separation and grouping of the two sets, A and B, shows the effect of increasing the 
noise and decreasing the proportion of peaks that varied. 
Test 2 was designed to test the Euclidian transform method when two sets of data that 
were similar to the sets in Test 1 but with the seeded peaks being a lower intensity were 
analysed. This represents sets that show large differences but not as great as Test 1 and 
therefore harder to distinguish. Again, the PCA was able to provide grouping and separation 
of the two sets based on the first two PCs, again showing that the Euclidian transform 
method is a viable option for data sets where there are large differences, but these 
differences are not as great as those tested in Test 1. A result of these differences being 
smaller is a wider spread within the groupings in the plot of the first two PCs, as show in 
Figure 4-20. As with Test 1, while the differences in Test 2 may be distinguishable by eye, for 
large, complex data sets an automated, multivariate analysis method is favourable and this 
shows that the Euclidian transform method is a viable option. 
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4.4.1.3 Test 3 Low intensity differences in a small proportion of the discriminant data. 
The data sets were created in the same way as Test 2 but the intensity of the peaks was 
changed to less than one times the maximum peak intensity of the original file. In addition a 
third data set of ten surfaces was included in this test. An example of each set can be seen 
in Figure 4-21. Set A and set B contain 8 peaks that are the same and 2 peaks that are 
different. Set C contains ten peaks that are all different from set A and set B. The intensity of 
the inserted peaks was less than the intensity of the largest peak in the original data set. The 
noise was increased by one and a half time using the method described previously. The 
tables containing the details of the inserted peaks are Table 5, Table 6 and Table 7 in 
Appendix I. 
169 
 
 
Figure 4-21 Plots of a single file from each set in Test 3. A is a plot of data file A4, B is a plot of data file B7 and C is a plot 
of data file C8. 
Euclidian processing followed by PCA gave the result in Figure 4-22. 
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Figure 4-22 Plot of the first two principal components calculated for the transformed data files of set A and set B in Test 
3. This shows separation of the two sets, A and B. 
This was a more demanding test and the separation of sets A and B in the first two PCs was 
satisfactory albeit with greater scatter evident in the clusters. Comparison of these two sets 
with the third set required three PCs to be evaluated as can be seen in Figure 4-23. 
 
Figure 4-23 Plot of the first three principal components calculated for the transformed data files in Test 3. This shows 
separation of the three sets A, B and C. 
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Unsurprisingly Figure 4-23 shows the greatest separation between the third set and the first 
two sets; which had smaller differences between them. To show this more clearly a PCA was 
carried out on sets A and C. A plot of the first two PCs of this analysis can be seen in Figure 
4-24. 
 
Figure 4-24 Plot of the first two principal components calculated for the transformed data files of set A and set C in Test 
3. This shows separation of the two sets, A and C. 
A much clearer separation between A and C can be seen when compared to Figure 4-22 
which shows the separation for sets A and B. This is because the data files in set C are more 
clearly different to sets A and B than set A is to set B. 
Test 3 was designed to test the Euclidian transform method when two sets of data files were 
given increased overall noise and seeded with peaks of a maximum intensity of less than 
that of the most intense peak in the original data file. This was to test whether the Euclidian 
transform method is a viable option for real data files as none of the seeded peaks would be 
more intense than those expected to be produced by an instrument. The PCA was able to 
give separate grouping of all three sets from each other as shown in Figure 4-23. As would 
be expected, set C is more separated from the other two sets than set A is from set B. As the 
differences between these sets are much less than the differences observed previously in 
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Test 1 and Test 2, the spread of the sets across the two PCs would be expected to be larger 
and the separation of the two groups less well defined and this is seen for sets A and B in 
Figure 4-22. With a greater number of differences, separation of sets A and C in a PC plot 
would be expected to be greater than the separation of sets A and B in Figure 4-22 and this 
can be seen in Figure 4-24. This shows that the separation seen between sets is reliant on 
the difference in the data files of the sets and is independent of the Euclidian transform 
method. 
4.4.1.4 Test 4 Intensity difference in a single peak. 
Ten resolved peaks were inserted into set A and set B. Nine of the peaks were identical in 
both sets. The tenth peak had the same retention time and compensation voltage location 
in both sets but a different intensity. The intensity of every peak inserted into the two sets 
was less than the maximum peak intensity of the original file. The noise was altered using 
the adjusted noise method as described previously and examples are shown in Figure 4-23. 
The tables containing the details of the inserted peaks are Table 8 and Table 9 in Appendix I. 
The results of the PCA after Euclidian processing are presented in Figure 4-26. 
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Figure 4-25 Plots of a single file from each set in Test 4. A is a plot of data file A5 and B is a plot of data file B4. 
 
Figure 4-26 Plot of the first two principal components calculated for the transformed data files in Test 4. This shows a 
clear separation and grouping of the two sets, A and B. 
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A clear separation and grouping of the two sets, A and B, can be seen in Figure 4-26. Test 4 
was designed to test the Euclidian transform method when a single peak changed in 
intensity in one of the two data sets. This test was designed to mimic the simplest of 
changes possible, such as a single biomarker in a diseased sample set that being slightly up-
regulated compared to the controls. As Test 3 proved that the method was capable of 
distinguishing changes at an analytical level in data files with greatly increased noise, it was 
decided to use a different method to alter the noise, the adjusted noise method. Figure 4-26 
shows the plot of the first two PCs from the PCA performed on the two sets created for Test 
4. Separation can be seen between the two sets showing that the Euclidian transform 
method can be used to process data sets for analysis that have the smallest possible 
changes, a change in intensity of a single peak, and would be a viable method for research 
aimed at discovering biomarkers. 
4.4.1.5 Test 5 Differences in resolution 
Eight resolved peaks and two unresolved peaks were inserted into A and B. Eight of the 
peaks were identical across both sets, and two peaks were not fully resolved. Resolution is a 
measure of the separation of two overlapping peaks. The greater the separation between 
the two overlapping peaks the greater they are said to be resolved. The resolution of the 
two non-resolved peaks differed between the two sets with the peaks in set B being slightly 
more resolved than the peaks in set A. This was achieved by inserting the peaks in set B one 
unit further apart in the time axis. The noise was altered using the adjusted noise method as 
described previously. The tables containing the details of the inserted peaks are Table10 and 
Table 11 in Appendix I. Example data and the PCA analysis are presented in Figure 4-27 and 
Figure 4-28 respectively. 
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Figure 4-27 Plots of a single file from each set in Test 5. A is a plot of data file A3 and B is a plot of data file B6. 
After the peaks had been inserted each data file was processed using the Euclidian 
transform method. After every file had been converted the resultant two dimensional data 
was transferred to Minitab 15 Statistical Software and a principal component analysis was 
performed extracting the first ten principal components. The first two principal components 
were then plotted against each other for all of the samples. This plot can be seem in Figure 
4-28. 
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Figure 4-28 Plot of the first two principal components calculated for the transformed data files in Test 5. This shows a 
clear separation and grouping of the two sets, A and B. 
Test 5 was designed to show that using the Euclidian distance method could be used to 
transform two data sets that contain two unresolved peaks at slightly different levels of 
resolution. This test is particularly important as it has been shown previously that current 
methods for transforming three dimensional data sets will not maintain the separation of 
peaks that fall at the same retention time but different compensation voltages. Figure 4-28 
shows that when performing a PCA on two data sets where the only difference between the 
two is a different resolution of two unresolved peaks in the compensation voltage axis a 
clear separation between the two sets is seen in a plot of the first two PCs. This shows that, 
unlike the current methods, the Euclidian transform method can be used to convert data 
files from three dimensions to two dimensions and maintain the full information of the data 
file. 
4.4.1.6 Test 6 Drifting phenomenon. 
Ten resolved peaks were inserted into each file. Eight of the peaks were the same in both 
sets. In each set the compensation voltage and retention time of one peak, a different one 
for each set, was varied to mimic drifting. In the other set this peak did not drift. The tables 
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containing the details of the inserted peaks are Table 12, Table 13, Table 14 and Table 15 in 
Appendix I. The noise was altered using the adjusted noise method as described before. See 
Figure 4-29 and Figure 4-30 for examples of the data and the PCA results respectively. 
 
Figure 4-29 Plot of a single file from each set in Test 6. A is a plot of data file A3 and B is a plot of data file B10. 
Figure 4-30 shows slight separation and grouping of the two sets. However, the spread of 
the data files in each set is considerably larger than before and some cross-over of the sets 
is seen. 
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Figure 4-30 Plot of the first three principal components calculated for the transformed data files in Test 6. This shows 
slight separation and grouping of the two sets, A and B, but a wide spread in the set grouping with some 
cross-over. 
Test 6 was designed to test how drifting peaks would affect the results of the PCA after the 
data files had been transformed using the Euclidian transform method. Drifting peaks is a 
problem in many areas of analysis, as can be exemplified by the large amount of research 
into and software available for aligning different types of analytical data. As the Euclidian 
transform method works on the basis of calculating a distance from the original of the data 
to every point on the DMS surface, slight changes in either compensation voltage or 
retention time could have an effect on the analysis. This was tested using two data sets that 
contained eight peaks with the same location and two peaks that were shifted to simulate 
drifting, with one peak drifting in each set. Figure 4-30 shows some grouping and separation 
of the two sets but there is cross-over of the two sets. This shows that alignment of the data 
is an important consideration and one that will still be needed with this approach. 
4.4.2 Evaluation and testing with a spiked system. 
A surrogate biogenic VOC profiles was generated using a complex mixture of VOCs, diesel 
headspace. The diesel standard was spiked with a single compound of known concentration 
at six different concentrations. These data files arose from another piece of research 
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involving the study of labels and impurities in fuel. The compound is an intelligent fuel tag. It 
was chosen to produce a known response, increase the sensitivity for specific analytes, in 
the samples. The exact nature and concentration of this compound was withheld (the data 
comes from another research project and so the nature of the compound is necessarily 
secret.) with them samples being split into 6 known groups. This provided a opportunity to 
test the new processing methods’ ability, combined with the analytical systems used, to 
distinguish between the different sample sets. The compound was added at six different 
concentrations to produce six different data sets. These 6 concentrations provided 6 groups 
containing the following number of samples; 
Table 4-3 Surrogate biogenic VOC profile groups along with sample numbers and known compound concentration 
Data sets Number of replicate analyses 
A 5 
B 4 
C 5 
D 4 
E 5 
F 7 
All these samples were analysed randomly using dynamic headspace – gas chromatography 
– differential mobility spectrometry and Figure 4-31 is an example of data surfaces 
obtained. Three surfaces are shown, ranging, from left to right, from the lowest to the 
highest concentration of the added compound. The highlighted regions show some of the 
most visually obvious changes that occurred as the concentration of the added compound 
was increased. This provided a set of samples that mimicked the expected differences in 
breath samples from healthy and diseased participants and the changes investigated in the 
previous six tests described in 4.4.1.1 - 4.4.1.6, particularly the increasing concentration of 
particular peaks, which mimics the expected changes due to increased lipid peroxidation 
[49]. 
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Figure 4-31 Three data surfaces generated from the positive DMS data. From left to right they show an increasing level of addition of the unknown compound. Highlighted is the region of 
the data surface that that shows the most change due to addition of the compound. While these are the most obvious visual changes others changes will be present which 
are not brought out by the colour shading. 
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This data set was baseline corrected and transformed from a three dimensional set to a two 
dimensional set using the summed method and the Euclidian distance method. 30 principal 
components were calculated for each data set. Initially plots of the principal components 
were examined to see if any separation of groups could be observed. As no separation was 
observed in the principal component plots, PC-DFA was performed on both data sets. The 
results of this analysis can be seen in Table 4-4. 
The data processing was performed with Microsoft Excel 2007. The data surface was 
cropped and extraneous features such as labels and axes removed. The data were baseline 
shifted, important because the Euclidian transform programme determines the end of a row 
by looking for a zero in the data. Plots of the raw differential mobility data were produced in 
Igor Pro Version 5.0.1.0. A programme was written in Visual Basic 6.0 to perform the 
Euclidian distance transformation. The code for this programme is included in Appendix II. 
This programme was written to calculate the Euclidian distance for each point in the data 
series, order them, assign them a cell number and save the Excel file as a new, corrected 
file. Two dimensional plots of data after transform were plotted in Microsoft Excel 2007. 
Principle component analyses and plots of the principal components were carried out in 
Minitab ® 15.1.1.0. The principal component analysis (PCA) of each data set was carried out 
using a correlation matrix. In a correlation matrix each variable has a variance of one so that 
the total possible variance is equal to the number of variables. As the first components 
extracted contain the most variance, plotting these against each other can show grouping of 
similar data sets and so is a good method for analysing the data in this work. The maximum 
number of principal components that can be extracted is equal to the maximum number of 
variables. The analysis in this work was confined to the first few principal components as 
these are the ones most likely to contain the variance caused by real differences in the data 
sets. 
Principal Component - Discriminant Function Analysis (PC-DFA) was used when no 
separation was seen in the principal component plots. PC-DFA is an a priori technique. This 
means that some knowledge of the samples is provided beforehand, in this case which set 
they belong to. With this knowledge the analysis seeks to minimise within set variance and 
maximise between set variance to assign the samples into their correct group. It uses the 
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PCs previously calculated to assign samples into sets. Increasing the number of PCs provided 
to the PC-DFA increases the amount of variance the PC-DFA has to differentiate between 
the sets. The more variance the PC-DFA has to use the more likely it is that it will be able to 
assign the data files to the correct group. Overtraining is a problem with PC-DFA and it is 
important to note the amount of variance being supplied to the PC-DFA as the more 
variance being used the more likely the data will be over-trained or assigned based on 
variation that does not represent real differences. The PC - DFA was carried out using a 
linear discriminant function on first seven principal components of the two dispersion field 
data sets analysed. 
The PC - DFA was carried out using a linear discriminant function on the first seven principal 
components of the two dispersion field data sets analysed. 
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Table 4-4 The summary of the PC-DFA results from processing the data generated by applying the summed method of 
transforming. 
Summary of PC-DFA classification using summed method data 
 True Group 
Put into Group A B C D E F 
A 5 0 0 0 0 0 
B 0 4 0 0 0 0 
C 0 0 5 0 0 0 
D 0 0 0 4 1 0 
E 0 0 0 0 4 1 
F 0 0 0 0 0 6 
       
Total N 5 4 5 4 5 7 
N Correct 5 4 5 4 4 6 
Proportion Correct 1 1 1 1 0.8 0.857 
 
N = 30   N correct = 28 Proportion Correct = 0.933 
First 7 PC's used describing 97.3 per cent of the variance 
  
184 
 
Table 4-5 The summary of the PC-DFA results from processing the data generated by applying the Euclidian distance 
method of transforming. 
Summary of PC-DFA classification using Euclidian distance method data 
 True Group 
Put into Group A B C D E F 
A 5 0 0 0 0 0 
B 0 4 0 0 0 0 
C 0 0 5 0 0 0 
D 0 0 0 4 0 0 
E 0 0 0 0 5 0 
F 0 0 0 0 0 7 
       
Total N 5 4 5 4 5 7 
N Correct 5 4 5 4 5 7 
Proportion correct 1 1 1 1 1 1 
 
N = 30   N correct = 30 Proportion correct = 1 
First 7 PC's used describing 93.3 per cent of the variance 
Table 4-4 shows the results of the principal component – discriminant function analysis 
results for the summed method transformed data set. Using the first seven principal 
components for the analysis, which describe 97.3 per cent of the variance, correctly assigns 
90 per cent of the data sets to their correct group. Table 4-5 shows the principal component 
– discriminant function analysis results for the Euclidian distance transformed data set. 
Using seven principal components, the same number as used in the summed method 
analysis, which describe 93.3 per cent of the variance, correctly assigns 100 per cent of the 
data sets to their correct group. 
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4.5 Discussion 
4.5.1 Comparison of the two methods when applied to a real data set 
The first trial of a Euclidean approach was the analysis of dispersion data containing only the 
reactant ion peak described in 4.3.5. This simple preliminary test was chosen to test the 
data modelling approach on a trivial problem that nonetheless represented an increasing 
complexity over the five peak illustration, with the introduction of background noise into 
the system. Comparison of the outputs from the two transform techniques used was 
straightforward and interpretation of the responses would be. 
Figure 4-9 and Figure 4-11 show the plots of the positive and negative channels after both 
transform methods have been applied to the original data set. The first thing to note is the 
size of the different outputs. The output from the summed method has one hundred data 
points, this is equal to the number of Rf steps there were in the original data set. Compared 
to the ten thousand data points seen when using the Euclidian distance method this is a 
very large loss of information. The size of the data set seen with the Euclidian distance 
method is dictated by the number of data points in the original set. That is to say, every data 
point in the original set is seen, nothing is combined. This means that while you see a single 
trend in the summed method data, an intensity decreasing as the intensity of the reactant 
ion peak decreases, the full data set is seen using the Euclidian distance method, with 
background noise being distinguished from signal. 
In the plots for the Euclidian distance method the data corresponding to the reactant ion 
peak signal is contained mainly within the reassigned distance range four thousand to five 
thousand for the positive channel and two thousand to four thousand five hundred for the 
negative channel. This is due to the position of the reactant ion peak in the original data set 
and this peak is easily distinguished from the background noise signal. In the plots for the 
summed method the reactant ion peak cannot be distinguished from the background noise. 
In fact, without reference to the original data set it is very difficult to see where the reactant 
ion peak ceases to be present in the data. The only really discernable fact about the data 
from these plots is that the intensity of the signal due to the reactant ion peak decreases as 
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the Rf increases. The shift of the reactant ion peak, due to the increasing Rf, is not preserved 
using the summed method, whereas it is using the Euclidian distance method. 
Preserving the intensity of the original signal is not possible using the summed method. This 
is shown in Figure 4-9 and Figure 4-11. The original data set has intensities ranging from 
approximately 0.1 to 0.35 v. using the summed method gives a summed intensity for each 
compensation field sweep which ranges between 12.35 and 11.7 V for the positive channel 
and 10.62 to 10.23 V for the negative channel in Figure 4-9 and Figure 4-11 respectively. 
This would make any quantitative analysis very difficult. In contrast, by using the Euclidian 
distance method quantitative analysis of the data is possible. Each distance can be traced 
back to the data point in the original data set. This means that it is possible to find every 
peak in the Euclidian distance data set that is due to a single component, and these 
intensities can be combined for quantitative analysis of the data. 
The enlarged views in Figure 4-10 and Figure 4-12 show the full, rich data set that is 
available using the Euclidian distance method. As every point is plotted, the full profile of 
the reactant ion peak is observed. Due to the way the Euclidian distance method works, 
whole peaks are kept together. This is most easily seen in Figure 4-7, where the five peaks 
are fully coded in a small reassigned distance area, but is also seen in Figure 4-9 and Figure 
4-11, where the reactant ion peak is kept within a finite region of the plot and maintains 
some of its’ shape. This is the benefit of using a Euclidian distance method over purely 
unfolding the data. By maintaining the data structure in this way it is also easier to isolate 
and remove specific areas of a data set, such as the RIP, peaks or areas from of information. 
This would be much more complicated if the data was unfolded. 
There are other benefits over just unfolding the data. This work covers combining retention 
time and compensation voltage but it is also possible to combine positive and negative data. 
This can be done by inverting one of the data sets and subtracting the intensity of each 
point to create a “difference surface” or by adding each matching point on the two surfaces 
to create an “additive surface”. Another method to combine the two data sets would be to 
treat them as a continuous surface by combining them and then to read across both data 
sets for the transform in the same manner as for a single channel. This would maintain and 
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separate the structure of both data sets, although it would increase the file size and 
processing time. 
As long as a common reference point can be found it should also be possible to include 
other information, such as mass to charge (m/z) ratio of the peak analysed in a mass 
spectrometer. This means peaks that occur at the same compensation voltage but have a 
different mass could be differentiated. The addition of underlying MS data could add a new 
level of complexity to the data and improve any analysis. It also eliminates the need for 
separate analysis of the MS and DMS analysis, both increasing the analytical power of the 
data and decreasing the amount of time and effort required to process it. 
The high complexity of the data shown for the Euclidian distance method is due to two 
factors; 
That the whole data set is transformed, including the large areas where nothing appears 
except background noise and, 
That there has been no pre or post-processing of the data set. 
The reason that no pre or post-processing was carried was so that any comparisons 
between the two techniques could be made directly, without fear that any pre or post-
processing would bias the data towards either technique. A noise filter can be applied to the 
data either pre or post-processing, and this will reduce the complexity of the data set. 
4.5.2 Surrogate biogenic VOC profiles 
The next level of testing the Euclidian method involved a more complicated set of data and 
again the results were compared against analysis by a summation method. A set of highly 
complex mixtures were prepared to act as surrogate biogenic VOC samples. Into these 
mixtures a single component was added at six different concentrations to provide six 
different groups for the analysis. All of the data sets were visually checked for consistency 
before any processing was carried out, and the only pre-processing performed was baseline 
shifting of the raw data sets. This was to ensure the possibility of unintentionally introducing 
188 
 
bias into the data and method towards either approach was minimised. The assumption was 
performing the two alternative transforms on the same baseline corrected data would 
ensure that any differences seen in the outcomes would be representative of data 
processing outcomes.  
After both transforms had been applied the first ten principal components were calculated 
for each data set. This was carried out in Minitab using The NIPALS method. The first four 
components were plotted against each other and singly to see if any separation could be 
seen. As no separation was seen it was decided to proceed to a principal component – 
discriminant function analysis of the data sets. 
The principal component – discriminant function analysis was used as a method to test the 
differences between the two data sets. It was initially carried out using only the first 
principal component and then successive components were included in the analysis until 
the data sets for one method were fully assigned. This point was reached for the Euclidian 
distance transformed data using seven principal components. At this point the samples from 
all six groups were correctly assigned for the Euclidian distance set but only ninety per cent 
of the samples were correctly assigned for the summed method. 
The variance contained within the seven principal components is significant. The less 
variance used to assigned samples to their respective groups means the more likely it is that 
the groups are being separated on real differences. The first seven principal components 
produced by the summed method contain ninety seven point three per cent of the variance 
whereas the seven principal components produced by the Euclidian distance method 
contain ninety three point three per cent of the variance. This means the assignment 
observed in the Euclidian distance set is more likely to be due to a real difference in the 
samples. 
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4.6 Conclusions 
Several conclusions can be drawn from this work: 
Applying a Euclidian transform method is a viable option for converting a three 
dimensional data set to a two dimensional data set. 
Using the Euclidian transform method over other reported methods maintains all the 
information contained within the data set. 
The Euclidian transform method has been shown to allow for better separation and 
grouping of data sets in a PCA when compared to the current methods used. 
Initially it was necessary to show that the Euclidian-based method would transform a data 
set in a viable way, both maintaining the full information set but also maintaining the peak 
structure, something that purely unfolding the data cannot achieve. Once it was established 
that this method was viable a comparison of this method to the current standard of 
summing the data across the compensation voltage axis needed to be made to show that 
the Euclidian-based method was an improvement. After this was established using the 
dispersion field sweep data set, 4.3.5.3, a rigorous test of the method using data sets 
exhibiting the smallest likely differences between the samples was used to show the 
method was capable of supplying a data-set which could differentiate based on these 
changes. The method was then compared to the current standard again when applied to a 
real data set to show it was an improvement. 
The main benefit of this method is its ability to maintain all the information contained 
within a sample. For complex data sets containing a large number of peaks a loss of fidelity, 
such as that which occurs when summing across the compensation voltage axis, may mask 
peaks of interest. The current situation is that the added benefit of the compensation 
voltage separation is lost. The technology is ahead of the data processing and this method 
aims to bring the data processing in-line with the current detection technology allowing 
researchers to utilise the full information contained in the data sets for advanced data 
processing methods such as PCA and PC-DFA. 
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Drifting of peaks is the next issue that needs to be tackled. 4.4.1.6 shows that this could be a 
major issue, although if the drifting can be limited by careful experimental control of the 
analytical instrument it may not present a huge problem. Alignment software exists for 
protein gels [156, 157] and similar system for DMS data may drastically improve the data 
analysis possible and should be an aim of those working in improving these processing 
techniques. 
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5 Design and implementation of a collaborative clinical campaign within 
the National Health Service (NHS) 
5.1 Introduction 
The development of a clinical breath sampling collaboration within the NHS, in this case 
Royal Preston Hospital, was key to this work as samples were to be collected within the NHS 
and analysed at Loughborough University. Developing this collaboration from the initial 
meeting with the clinical lead to the collection of the final samples and subsequent data 
processing, everything must be pre-planned and approved both by the clinicians whose 
knowledge of the workings of their NHS site are vital, but also by the appropriate ethics 
board. 
To satisfy the ethics board several pieces of documentation are required and developing a 
process to ensure speedy delivery of these documents is vital to ensure that the research is 
not delayed. As well as satisfying all of the ethical requirements imposed upon any clinical 
research, there are several key parts of the research that must be discussed, such as breath 
sampling locations, the required services for sampling and the logistics of transferring the 
breath samples from the clinical site to the samples analysis site. 
Breath sampling is a new field of research, and this means that it is unlikely that there will 
be a vast amount of experience both at the clinical site and at the samples analysis site. This 
means that education of both the clinical team as to what the requirements of the sampling 
are and conversely, education of the analytical team as to what can and cannot be expected 
of volunteers and clinicians within the NHS is important to allow for smooth completion of 
the research. 
This chapter will describe the steps that were taken, the documents that were produced 
and the decisions that were made to ensure this research progressed in a timely fashion and 
any delays could be promptly dealt with. 
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5.2 Initial discussion with the Clinical lead 
An initial discussion was held with the clinical lead at Royal Preston Hospital, Dr Stephen 
Fowler to discuss the research idea of taking breath samples from volunteers attending the 
two week wait clinic. This clinic is where NHS patients are referred by their general 
practitioner (GP) when a diagnosis of lung cancer is suspected. At this meeting the decision 
was made to collect samples from 40 volunteers, 20 diseased and 20 control. This was felt 
to be a sufficiently large cohort for this initial study. It was decided that patients would be 
recruited at their first outpatient visit. The initial inclusion criteria were decided upon and 
these were: 
 Volunteer referred to the chest clinic with suspected lung cancer. 
 Diseased – lung cancer confirmed 
 Control – lung cancer excluded 
 Age > 18 years 
These were chosen to be as wide ranging as possible as any diagnostic test must be 
applicable to a wide range of subjects. 
The exclusion criteria were also decided upon and these were: 
 Co-morbidities that are likely to significantly affect metabolic status, i.e. diabetes 
mellitus, chronic liver failure, chronic renal failure. 
 Other active malignancy 
The co-morbidities were included as each produces a distinctive smell on the sufferers 
breath and as such it was felt this could significantly influence any breath analysis test. 
5.3 Required documentation 
There are several pieces of documentation required for a clinical study within the NHS. All of 
these were completed and submitted to the appropriate bodies. 
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5.3.1 Ethics documentation 
Any study that involves interaction with NHS patients or their medical records requires 
ethical approval. For this work a research protocol was produced (Appendix VI) and this was 
submitted along with the online forms for ethical approval. The research protocol details 
the planned study and the justification for the research. This document outlined who was 
involved, the aims of the research, the methods to be used and the expected results. Patient 
information, consent and questionnaire forms were also submitted for approval. This was 
reviewed by the ethics board for the Lancashire Hospitals Trust at a review meeting that the 
researchers attended to answer any questions. On the basis of this documentation ethical 
approval was given for the study. 
5.3.2 Researcher documentation 
There are several documents required for researchers, both within and out with the NHS, 
based on the part of the work they will be carrying out. All researchers submitted a CV along 
with the ethics documents. For researchers external to the NHS interacting with participants 
a research passport was completed. This included a Criminal Records Bureau (CRB) check 
and an occupational health assessment. Once this research passport was completed an 
honorary contract was issued by Royal Preston Hospital allowing the external researcher to 
work unsupervised within the NHS. 
5.4 Identification of sampling site 
The requirements for the sampling site are detailed in Appendix VI. Two different sampling 
sites were identified based on these requirements with a third possible site also identified. 
The primary sampling site, an unused surgical suite in the Accident and Emergency 
department was used for the duration of the study, with the other two identified sites kept 
in case sampling had to be moved. 
5.5 Transport logistics 
The transportation of the adsorbent traps both to and from Royal Preston Hospital was 
carried out in two different ways. When a researcher was visiting from Loughborough 
University blanked tubes were carried with them at less than 0oC in a polystyrene box on 
ice-packs. These were then transferred to a fridge until needed. Collected samples were 
194 
 
then returned to Loughborough University in the polystyrene box on ice-packs at less than 
0oC. When a researcher was not visiting all samples were sent via next day delivery on ice-
packs at less than 0oC in a polystyrene box to Loughborough University and blanked tubes 
were returned in the same fashion. 
5.6 Installation and testing of breath sampling equipment 
To make the breath sampler portable all of the components were stored in a wheeled 
suitcase and stored in a locked office. Once a sampling site had been identified based on the 
criteria set out in the research protocol Appendix VI, the sampling equipment was tested 
both mechanically and electronically to ensure it functioned correctly. Test samples were 
collected and analysed at Loughborough University to ensure the sampling equipment was 
functioning properly. 
5.7 Training of hospital staff 
To ensure that samples could be collected as and when participants were available, two 
members of hospital staff were trained to set up and operate the sampling equipment as 
well as train others. This meant that researchers from Loughborough University would not 
need to be present on every sampling occasion and that site at Royal Preston Hospital could 
be self-sustaining as new researchers could be trained to operate the sampling equipment. 
5.8 Changes to the initial ethically approved study plan 
During the study areas were identified where the protocol was lacking. The aim to recruit 
participants on one visit to the hospital and ask them to return for a second visit to give 
samples was found to be unsuccessful. To rectify this the protocol was changed to allow the 
usual 24 hour waiting period to be waived if the participant agreed so that samples could be 
collected during their initial visit to the chest clinic. This change was submitted to the ethics 
board and approved. 
It was also decided that samples would be collected before diagnosis and only mention of 
general lung disease would be made in and patient information sheets with all references to 
lung cancer removed. As not every patient attending the two week wait chest clinic is aware 
that they may be suffering from lung cancer it was felt that an mention of the specific 
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disease would cause undue stress to participants, particularly as their Consultant would, 
most likely, not have discussed this with them yet. This change was submitted to the ethics 
board and approved. 
5.9 Flow diagram and Gantt chart 
During the course of planning and implementing this study two documents were produced 
to guide this, a flow diagram Figure 5-1 and a Gantt chart Figure 5-2. The flow diagram 
details all the steps that must be carried out to ensure that the study can start and the Gantt 
chart outlines time the main steps should be expected to take. 
5.10 A guide to setting up a collaborative clinical study within the NHS 
A more complete guide is given in Appendix VII. This guide is aimed at researchers with no 
previous experience in collaborative clinical studies and will guide them through each step 
and all of the documentation that is required as well as highlighting where possible delays 
may occur. 
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Figure 5-1 Flow diagram outlining the steps that need to be taken to implement a clinical campaign within the NHS as an external researcher. 
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Figure 5-2 “Idealised” Gantt chart outlining the time each objective should take and when each objective should be started. 
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6 Exhaled Breath of Participants attending a chest clinic: a Pilot Study - An 
initial inspection and development of a workflow. 
6.1 Introduction 
VOCs in an individual’s breath reflect the dynamics of their: environment, metabolism and, 
catabolism. Changes in exogenous factors, such as exposure to contaminants in inspired air 
[95, 161] may be controlled to some extent in a study. Dietary effects may be mitigated 
slightly by persuading participants not to eat or drink anything, other than plain water, for a 
period before sampling. Other criteria often require participants not to smoke. Keeping a 
record of diet in the week prior to sampling may be helpful in the subsequent analysis of 
data. 
It is possible to identify non-biological exogenous components in breath profiles, based on 
complementary air sampling. Endogenous factors are more difficult to identify and control. 
For example, an individual’s gut flora are difficult to regulate. Knowledge of the participants’ 
recent bowel movements may help, but this assumes some homeostasis in human breath, 
not just intra-subject, but also inter-subject as it assumes gut flora will be the same across 
participants. At the moment it is sensible to record as much appropriate metadata as 
possible so any identified biomarkers can be evaluated against possible exogenous and 
endogenous contaminant sources. Such information will be invaluable in future comparative 
studies and one would hope meta-studies yet to be undertaken. 
The variability of human breath makes searching for biomarkers of a particular disease 
problematic. It is not possible to purely group diseased and control subjects separately and 
compare them for differences, careful analysis of the meta-data is also required. One 
method of reducing the complexity of the task is to create a human breath database, 
containing all compounds that can be found in human breath. By carefully recording what 
compounds are found in both control and diseased subjects and the level they are found at, 
common compounds can be more easily discarded. While work exists that has detailed 
many compounds found in human breath there is no list that is continually updated and can 
be easily accessed by researchers from different groups. Similar lists in the fields of 
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metabolomics, such as METLIN [80] and The Human Metabolome Database (HMDB) [79], 
proteomics, such as Swiss-Prot [162], lipidomics, such as LIPID MAPS [163] and genomics, 
Such as the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [81], have shown to be an 
invaluable resource in these areas, and a database for compounds found in human breath 
would be very useful for breath analysis. 
Certain information must be recorded with compounds, such as retention time, the 
diagnosis of the participant whose breath the compound was found in, the concentration 
the compound was found at and the m/z value for the most intense ions. This means that 
once a compound has been found, if it is again seen in another subject of a different 
diagnosis, this should be included in the database, meaning the knowledge base it provides 
is continually growing and being refined. As the database grew it would become easier for 
researchers to eliminate common compounds and focus on unique or uncommon markers 
that may be representative of a specific disease. 
The first stage to establishing such a database is the collection, analysis, processing and 
logging of the compounds found in many breath samples from a variety of subjects. A 
complete clinical description of the participant is paramount, as the possibility of different 
diseases showing similar markers, particularly of oxidative stress, has already been shown 
by Phillips et. al. [36]. 
Obtaining the best possible chromatographic and mass spectrometric data from the 
instrumentation and careful data processing is required when assessing breath data. A 
single breath sample can contain many hundreds of compounds [40] many of which may not 
be resolved by the chromatography. The use of computer packages developed specifically to 
aid in the deconvolution of complex peaks such as AnalyzerPro from Spectralworks [164], 
Intellixtract from ACD labs [165] and the Automated Mass Spectral Deconvolution and 
Identification System (AMDIS) [166] from the National Institute of Standards and 
Technology (NIST) [167], makes this work possible. Where it is not possible to assign an 
exact compound, logging the most intense ions means that it can still be entered in the 
database with a tentative assignment and so can still be included in the knowledge base. 
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The aim of this study was to create a compound database by generating a list of every 
compound found in the breath samples collected from participants attending a chest clinic. 
This initial work outlines the difficulties associated with it and seeks to outline a workflow by 
which the data from this initial study can be processed. 
The focus of this initial inspection is on the mass spectrometry data. This is because at the 
time of writing there were not enough samples available to do a preliminary analysis on the 
DMS data. As the mass spectrometry data can be processed as and when it is produced it 
provides an opportunity to assess the data during the study rather than waiting until the 
end. 
6.2 Methods 
6.2.1 Sample and information collection 
Samples were collected on site at Royal Preston Hospital. The site was identified and set up 
in line with the process described and discussed in Chapter 5. Samples were collected from 
volunteer participants during their visit to a chest clinic run under the two week wait rule. 
To maintain age and sex matching only male participants over the age of sixty years old 
were used. Samples were categorised on the basis of the clinical description of the chest 
complaint the participants presented. Two broad categories were used; participants with a 
diagnosis of lung cancer were placed in a “Cancer” category and participants with a 
diagnosis that excluded lung cancer were placed in the “reference” group. The two week 
wait clinic is a fast-track clinical intervention that ensures that people with series signs and 
symptoms of respiratory disease are seen by a relevant specialist in the NHS within two 
weeks of their consultation with their general practitioner (GP)a; the full referral guidelines 
may be found on the National Institute for Clinical Excellence (NICE) website [168]. It is 
reasonable to assume that everyone attending such a clinic will have an underlying 
respiratory condition. 
                                                     
a
 While this is the current standard is should be noted that this may change depending on the political 
landscape 
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All samples were collected using the adaptive breath sampler described in chapter 2 
according to the protocol which was granted ethical approval by the Lancashire Hospital 
Trust Regional Ethics Board and the Royal Preston Hospital local ethics board. Each 
participant provided 2 samples, and another sample was taken sample from the medical air 
line. Medical air was supplied by the hospital air system at four bar pressure. After sampling 
the volunteer was asked to fill in a questionnaire (Appendix V) aimed to highlight any 
factors, both exogenous and endogenous, that may influence the analysis. 
6.2.2 Sample transport and storage 
Samples were transported in two different ways. When a researcher based in the laboratory 
was present the samples were couriered back by the researcher in a sealed container 
maintained at less than four degrees centigrade by re-freezable ice packs. When a 
researcher from the laboratory was not present during sampling, the samples were sent 
through a courier service for next day delivery in a sealed container maintained at less than 
four degrees centigrade by re-freezable ice packs. Once samples arrived at the laboratory 
they were stored at four degrees centigrade in a dedicated LEC LR207 spark-free laboratory 
fridge. 
6.2.3 Sample selection 
Although two samples were collected from each volunteer instrument faults sometimes 
interfered with the subsequent analysis. The current sample list, along with the relevant 
clinical data are summarised in Table 6-1. 
  
202 
 
Table 6-1 Sample list detailing the volunteer code, sample I.D.’s, date collected and the volunteers’ diagnosis. 
Volunteer 
code 
Sample I.D. Date collected Diagnosis 
CV-05 T270OC1 T580OC2 15/10/2009 Background emphysema, 
no evidence of malignancy 
CV-06 T129MF1 T128MF2 15/10/2009 No malignancy 
CV-07 T182FS1 T190FS2 21/10/2009 Currently unknown 
CV-08 T129BC1 T281BC2 04/11/2009 Appearances consistent 
with a primary pulmonary 
neoplasm with extensive 
nodal disease. StagingT4 
N2/3 M1/0. Squamous cell 
carcinoma 
CV-09 T288PS1 T287PS2 26/11/2009 Currently Unknown 
CV-10 T182CH1 N/A 26/11/2009 No malignancy 
CV-11 T572RW1 T141RW2 18/12/2009 Possible bronchiectasis, no 
malignancy 
CV-12 T067FH1 T065FH2 03/02/2010 No malignancy 
CV-13 T186MR1 N/A 3/02/2010 Provisional radiological 
diagnosis t4, n3, m1. Small 
cell lung cancer. 
CV-14 T184JL1 T282JL2 18/02/2010 Appearances of bronchial 
carcinoma if histologically 
proven then staging would 
be T4, N2, M0 
CV-15 T123PH1 N/A 18/02/2010 Benign TB a possibility, no 
malignancy 
CV-16 T487RA1 T283RA2 11/03/2010 Appearances are those of a 
primary pulmonary 
neoplasm at the right 
pulmonary hilum. 
Radiological staging= T4, 
N2, M0 
CV-17 T286KK1 T139KK2 11/03/2010 Appearances suggestive of 
a primary pulmonary 
neoplasm. Provisional 
stage= T4 N3 M0. Non-
small cell carcinoma 
 
At the time of writing a full set of samples had not been obtained. For this preliminary 
evaluation of the data and development of a work-flow only samples from participants who 
had been diagnosed with lung cancer were inspected. 
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6.2.4 Sample analysis 
Sample analysis was randomised for samples from volunteers taken on the same day. Due 
to the restriction placed on analysis that all samples should be run within forty eight hours 
of sampling and the fact that sampling occurred weekly, if only one volunteer was sampled, 
samples could not be randomised. 
The samples were analysed using the dual detector instrument described in Chapter 3. A 
system blank was run before and in between any sample analysis began to verify that the 
system was free from of contaminants and functioning. The instrument settings used were 
the same as previously described in chapter 3. The GC temperature program used is shown 
in Figure 6-1. 
 
Figure 6-1 GC temperature program used for the analysis of breath samples. 
This instrument produced two different sets of data, one from the mass spectrometer and 
one from the differential mobility spectrometer. Both sets of data were visually checked 
before any data processing was carried out. 
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6.2.5 Data processing 
Once the samples had been analysed the mass spectrometry data was analysed in three 
different stages, these are: 
1. Visualisation, 
2. Peak examination and, 
3. Identification and detected volatile table generation. 
6.2.5.1 Visualisation 
Each data set was selected in turn and visually inspected using Varian MS Workstation MS 
Data Review, Version 6.9 (Service Pack 1). Samples where the analysis had introduced 
artefacts or the instrument had not operated within specification were discarded. Samples 
that were contaminated with high levels of background volatiles were discarded. The 
sample was then inspected for resolved chromatographic peaks. Fully resolved peaks were 
identified visually and by examination of the underlying mass spectrum. Figure 6-2 shows an 
example of how peaks were visually distinguished as either resolved or unresolved. 
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Figure 6-2 Example chromatogram showing both resolved and unresolved peaks. The ‘shoulder’ that appears on the 
peaks, highlighted by the red dashed circles, are due to ions from different components that have not 
been fully separated while passing through the chromatography column. 
If a peak did not obviously fall into one or other groups, the underlying mass spectra were 
assessed to evaluate the peak homogeneity. This was done by examining the mass spectra 
at different points in the peak and assessing if the ions present changed, see Figure 6-3. 
Resolved peak
Unresolved peaks
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Figure 6-3 Example of how evaluation of the underlying mass spectrum was used to evaluate peak homogenietyis 
composed of a single or multiple components. A) shows a chromatogram with 2 points highlighted in a 
single peak. B) shows the mass spectrum at point 1 and C) shows the mass spectrum at point 2. While 
both spectrums B) and C) are from under the same chromatographic peak, the mass spectrum at both 
points is very different. 
Point 1
Point 2
A)
B)
M/Z = 119.5
M/Z = 73.2
M/Z = 227.0
C)
M/Z = 226.5
M/Z = 207.6
M/Z = 245.4
207 
 
A list of components was created from the resolved peaks by selecting the underlying 
spectrum of each resolved peak at its most intense point and searching it against the NIST 
library. If this returned a plausible assignment it was added. A plausible assignment is one 
where the observed mass spectra under the peak matches the mass spectra of a suggested 
identification given by a library search. Peaks that were due to analytes not present in the 
NIST library were still added without any compound identification. Where mass ions that 
were indicative of a specific compound class were observed the component was labelled as 
belonging to that class. The six most intense mass ions, not due to common background 
ions, were recorded for each component. The common background ions excluded from the 
mass ions recorded are listed in Table 6-2 and Table 6-3. 
Table 6-2 Observed ions, sources and possible compounds causing contamination peaks due to the analytical system. 
Observed ions (m/z) Source of contamination Possible compound(s) 
18, 28, 32, 44 Air leak H2O, N2, O2, CO2 
31, 51, 69, 100, 119, 131, 169, 
181, 214, 219, 264, 376, 414, 
426, 464, 502, 576, 614 
Leak on tuning compound 
vial 
Perfluorotributylamine 
(PFTBA) 
69 Foreline pump oil vapour Foreline pump oil 
 
Table 6-3 Observed ions, sources and possible compounds causing artefact peaks due to the analytical system. 
Observed ions (m/z) Source of artefact Possible compound(s) 
73, 147, 207, 221, 281, 295, 
355, 429 
Septum and column bleed Dimethylpolysiloxanes 
14, 16, 44 Out-gassing of ferrules N, O, CO2 
149 O-rings Plasticiser 
These component lists were then compared against each other to generate a single list of 
components found the collected breath samples and which samples they were found in. 
Peaks that were found to be composed of multiple components were processed further. 
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6.2.5.2 Peak examination and qualitative separation of chromatographically unresolved 
analytes. 
Unresolved peaks were manually analysed using Varian MS Workstation MS Data Review, 
Version 6.9 (Service Pack 1). This was done using a method based on the way unresolved 
peaks were determined in Figure 6-3. As previously shown in Figure 6-3, the mass ions 
under an unresolved peak change according to the concentration of the analytes eluting. By 
determining the correlations between ion intensities it is possible to extract individual 
component’s mass spectra from co-eluting peaks. Figure 6-4 shows co-eluting compounds 
and the intensities of their associated fragment ions. The ions with m/z 77, 131, and 106 
show a local maximum intensity at approximately 2.795 minutes while the ions with m/z 70, 
55 and 83 show two local maximum intensities at approximately 2.77 and 2.86. This 
indicates that there are three co-eluting peaks under the TIC, shown in black in Figure 6-4, 
that can be separated based on the local maxima observed at different retention times. By 
removing all of the ions except those that show a local maxima at the identified retention 
time a “cleaned” mass spectrum for each separate component can be created and searched 
against a mass spectral database (NIST for example). This can be repeated for each analyte 
underneath an unresolved chromatographic peak until all analytes under the peak have 
been distinguished. 
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Figure 6-4 Example of how unresolved peaks are distinguished based on their underlying spectra. The peak at 2.795 
minutes clearly contains different mass ions to the peak at 2.860 minutes. This example has been 
displayed using AMDIS for clarity. 
6.2.5.3 Identification and detected volatile table generation 
Once the chromatograms had been examined and the analytes separated under all of the 
unresolved chromatographic peaks, the cleaned mass spectrum of each analytes was 
searched for within the databases provided with the data processing package (Varian MS 
Workstation MS Data Review, Version 6.9 (Service Pack 1)  NIST 05 Main Library),It is helpful 
to note that similar compounds have a similar mass spectra, and this challenge is 
exacerbated at low concentrations, or with high background interferences or both. Figure 
6-5 shows the mass spectra of four methylated hydrocarbons, 2,2,3-trimethyl-pentane, 
2,2,4-trimethyl-pentane, hexane and 11-(2,2-dimethylpropyl)-heneicosane which have 
similar mass spectra. Although 2,2,3-trimethyl-pentane, 2,2,4-trimethyl-pentane and hexane 
would be expected to have similar mass spectra, with some differences based on the 
different fragments observed. 11-(2,2-dimethylpropyl)-heneicosane is a much larger 
molecule,  a larger molecule that has fragmented yielding the larger mass fragment-ions at a 
much lower intensity, if the background ions were particularly intense the larger fragments 
may not be seen and the compound may be incorrectly labelled as any of the other three. 
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Figure 6-5 Four different compounds that produce similar mass spectra. 2,2,3- and 2,2,4-trimethyl-pentane are very 
similar, as would be expected. Hexane is the next most similar, showing that there is a possibility of 
confusion. The most intense fragments of 11-(2,2-dimethylpropyl)-heneicosane are very similar to those 
of both the trimethylpentanes and hexane. If a large background was observed it is possible that the 
larger fragments would be masked and may not appear. 
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So, it is important to remember that spectral libraries are based on mass spectra collected 
for well resolved standards at a strong concentration. This means that interference from 
background ions can influence any library identification and cause misidentification and so it 
is likely to be difficult to distinguish between isomers. 
Consequently, each library hit was evaluated and the proposed assignments are attributed 
to those identities with high certainties, where several hits of similar molecules were 
observed that could not be distinguished a compound class was assigned instead of an 
identification. 
A compound list was generated from each breath sample that containing all of the resolved 
analytes along with an identification if applicable and a list of the six most intense mass ions 
observed for the analyte along with their intensities. This was done in an effort to 
standardise the reporting of compounds found in breath so it is easier to cross-reference 
with other research. As two samples were taken per volunteer the lists from the two 
samples were combined to give a full list of compounds observed for a single volunteer. The 
two lists from each volunteer were evaluated and merged to give a single list.  
Figure 6-6 shows a flow diagram which describes how the samples were processed after 
analysis. This was carried out for all of the samples collected from volunteers who were 
diagnosed with lung cancer. 
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Figure 6-6 The flow diagram for how the data sets were processed. 
6.3 Preliminary results from participants with lung cancer 
For these preliminary results only the volunteers diagnosed with lung cancer were 
investigated. Volunteer CV-13 was excluded as only one sample was successfully analysed. 
Volunteers CV-05, CV-06, CV-10, CV-11, CV-12 and CV-13 were excluded as their diagnosis 
excluded lung cancer. These samples along with any others from volunteers whose 
diagnosis excludes lung cancer will form the control group when the study is completed. CV-
07 and CV-09 could not be currently assigned to a group as a diagnosis of lung cancer has 
not been excluded or confirmed. 
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6.3.1 Preliminary data-processing 
All of the samples were analysed on the instrumentation described in chapter 2 and visually 
inspected in MS Data Review. Large contamination/artefact peaks were observed in several 
samples. These samples were still included in the analysis but areas of the chromatogram 
covered by the contaminant/artefact peaks were excluded. 
For each sample from a participant with a known malignancy a list of compounds was 
generated from the resolved and unresolved peaks using the methods described in Section 
6.2.5.2. These lists were then combined to generate a list of compounds observed in the 
breath of lung cancer sufferers. Where no hit was obtained for the mass spectrum of the 
component this was either recorded as no hit or a tentative assignment of compound class 
was provided based on the most intense observed ions. To begin building a database of 
breath compounds and the associated participant diagnosis/information meta-data was 
recorded for each volunteer including their diagnosis and their smoking status at the time 
the sample was collected. Other information was collected as per the questions outlined in 
the participant questionnaire sheet. 
6.3.2 Data processing 
The aim of this initial inspection of the data generated from the pilot study is to describe the 
nature of the data, its’ complexities and the best methods to address them. As well as 
differences between samples, there are other processes in the sample collection and 
analysis that may cause added complexity and these must be accounted for. The main 
challenges observed in the samples were: 
 Differing intensities between sample pairs, 
 Complex unresolved peaks, 
 Foreline pump contamination and siloxane contamination and, 
 Retention time shifting. 
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All samples were processed as described. To highlight the complexity of the samples the 
pairs have been plotted against each other and areas of complexity have been highlighted 
and discussed. 
6.3.2.1 Differing intensities in sample pairs 
From Figure 6-7 it can be seen that the intensity of peaks in the two samples collected from 
CV-08 are not consistent with each other. There are three reasons that this may be the case; 
the sampling was not as successful for the second sample, the analysis of the second sample 
using the instrumentation described in Chapter 3 was unsuccessful or the volatiles in the 
breath changed during collection of the second sample. While the volatiles observed in the 
breath are dynamic and may change from the collection of sample to sample it is unlikely 
they would undergo such a large change. The most likely case is that the adsorbent trap was 
improperly fitted to the mask. This could either cause a leak leading to less volatiles being 
drawn through the trap or it may have caused a block to the flow of air so that the pump 
was unable to draw the breath through the trap. 
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Figure 6-7 Showing the chromatograms produced by both samples collected from CV-08. 
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Figure 6-8 The first ten minutes of the analytical run for the two samples collected from volunteer CV-08. 
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Figure 6-8 shows the difference between the analysis of the first and the second samples 
collected from volunteer CV-08 for the first ten minutes of the analytical run. As can be seen 
the most intense peaks observed in the first sample (T129BC1) are repeated in the second 
sample (T281BC2). However, these are observed at approximately half to less than a quarter 
of the intensity of the same peaks in the first sample. These changes could be suggestive of 
either a problem during sampling or a problem during analysis. Figure 6-8 shows the 
problems that a loss of intensity can cause. Between six and ten minutes there are several 
peaks observed in the sample T129BC1 which are not observed in T281BC2. As the aim of 
this work is to search for unknown markers of disease, the apparent loss of peaks between 
two samples from the same participant taken consecutively is troubling. 
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Figure 6-9 Showing the chromatograms produced by both samples collected from CV-17. 
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Figure 6-9 shows the chromatograms produced during the analysis of the two samples 
collected from CV-17. Similar to the analysis of the samples from CV-08, T139KK2 shows a 
lower overall TIC intensity when compared to T286KK1, although this effect seems less 
pronounced between these samples, with an average decrease in intensity of approximately 
half at its most pronounced. This effect is highlighted in Figure 6-7, Figure 6-8 and Figure 
6-9. 
Figure 6-10 shows both samples collected from CV-14. For the most of the chromatograms 
the intensities of the peaks are very similar, showing that the collection and analysis of the 
samples has been constant. This is more easily observed in Figure 6-11. It shows that the 
analytes are approximately the same intensity across both samples with some variation that 
can be accounted for in the slight differences in sampling and analysis that will occur. From 
approximately 42 minutes onwards a marked difference can be seen between the two 
samples. The peaks observed in this region are generally associated with foreline pump 
contamination. It appears that the contamination is much higher in sample T184JL1 
compared to T282JL2. As the samples are sealed until analysis and kept at four degrees 
Celsius it is likely that this contamination occurred as a build up on the cold trap in the 
thermal desorption unit. This shows the importance of validating all samples manually 
before using automatic methods. 
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Figure 6-10 Showing the chromatograms produced by both samples collected from CV-14. 
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Figure 6-11 The first ten minutes of the analytical runs for the two samples collected from volunteer CV-14. 
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Figure 6-12 shows an increased intensity in the second sample collected from CV-16. This is 
opposite to the differences seen in Figure 6-7 and Figure 6-9. This indicates that it is more 
likely to be a sampler/instrumentation problem than a biological effect as the change is not 
consistent throughout the different sample sets. Again, the extent of the differences 
between the two samples can be more easily seen by examining the data more closely, as 
seen in Figure 6-13. This shows the extent of the differences between the two samples 
collected from the same participant and again highlights the need for manual inspection of 
the data, rather than a reliance on automated methods. 
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Figure 6-12 The chromatograms produced by both samples collected from CV-16. 
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Figure 6-13 The first twenty minutes of the analytical run for the two samples collected from volunteer CV-16. 
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6.3.2.2 Complex unresolved peaks 
Processing of complex unresolved peaks is the most challenging aspect of processing breath 
sample data. The method used to do this has been described in 6.2.5.2. Figure 6-14 shows 
the first four minutes of both samples collected from CV-17. This is a particularly complex 
region of the chromatogram, showing many unresolved peaks. This complex 
chromatography is seen in all of the sample pairs where the analysis was successful and 
made extraction of the single components difficult. To cope with this only components that 
could be satisfactorily determined based on the method previously described were 
considered. 
Figure 6-14 is typical of the chromatography that must be dealt with when examining breath 
sample data. This must be dealt with carefully to make sure that no miss-identifications are 
made. With this in mind it may be better to use a retention index system and mass 
spectrum cataloguing rather than relying on identification of the separate compounds. 
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Figure 6-14 The first four minutes of the TICs produced during the analysis of the samples collected from CV-17.. 
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6.3.2.3 Foreline pump contamination and siloxane artefacts and plasticisers 
Figure 6-15, Figure 6-16, Figure 6-17 and Figure 6-18 show examples typical of foreline 
pump oil contamination. This can be a problem as some of the volatile components of the 
pump oil may be similar to those observed in the breath. The larger compounds observed 
due to foreline pump oil contamination are more easily distinguished due to their later 
retention times and higher molecular weights. Due to the possibility that compounds from 
the foreline pump oil may be mistaken for endogenous breath samples any compounds that 
elute close to the foreline pump oil contamination were ignored. 
Differences in the intensity of the contamination peaks due to the foreline pump oil are 
observed for all of the sample pairs analysed. As this contamination occurs after sampling in 
the laboratory there are two possible ways the sample can be contaminated; 
1. The adsorbent trap can become contaminated or, 
2. The thermal desorber can become contaminated. 
The adsorbent traps are kept sealed before analysis and when placed in the thermal 
desorber they are contained in a sealed system. This means that it is unlikely that the 
absorbent trap will be contaminated. The thermal desorber is open to the atmosphere 
during stand-by time. This is a prime opportunity for contamination of the instrument. A 
possible solution would be to seal the thermal desorber with a conditioned trap during 
stand-by time and monitor the contamination due to the foreline pump oil to see if it is 
significantly reduced. 
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Figure 6-15 The twenty minute section of the analytical run from thirty minutes to fifty minutes. 
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Figure 6-16 Shows the difference in contamination levels due to the foreline pump. 
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Figure 6-17 TICs produced for the samples collected from CV-17. 
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Figure 6-18 The final twenty minutes of the analytical runs for the two samples collected from volunteer CV-16. 
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Siloxane artefacts are seen in all of the samples analysed. It is likely that the high water 
content of the samples is a contributing factor to the large siloxane peaks observed in the 
samples. Table 6-3 Observed ions, sources and possible compounds causing artefact peaks 
due to the analytical system. lists several mass ions that are associated with siloxanes, m/z 
207 being the most common. With experience it can be relatively easy to spot siloxane 
artefact peaks and these peaks may even be useful to help align data sets. Small resolved 
siloxane peaks do not present a problem and may even be beneficial but large, unresolved 
siloxane peaks can be a problem. Figure 6-19 is an example of a large siloxane peak 
observed in the samples from the participant CV-17. This peak may be co-eluting with other 
peaks that are masked due to its’ size and these peaks are dealt with in a similar way to 
foreline pump oil contamination peaks; unless and accurate identification can be given to a 
compound that co-elutes with a siloxane peak, the peak is ignored. 
Plasticiser peaks are caused by volatile compound bleed from septa, o-rings and other 
plastic parts within the instrument. As with siloxanes there are distinct mass ions associated 
with them, particularly m/z 149, and they are usually easy to spot with experience. These 
are treated in the same way as siloxane artefact peaks. 
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Figure 6-19 TICs from the two samples collected from CV-17. 
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6.3.2.4 Retention time shifting 
Retention time drifting caused problems with deciding if peaks were reproduced across all 
or some of the samples. Retention time drifting is when the same analyte appears at slightly 
different retention times in different samples. Figure 6-19 shows an artefact siloxane peak 
from a single sample from each volunteer. As previously seen in Figure 6-7, Figure 6-9, 
Figure 6-10 and Figure 6-12, retention times were reproducible over the pairs of samples. 
However, it can be seen in Figure 6-20 that retention times are not reproducible across the 
analysis of every sample. This means that compounds which could not be identified while 
creating the compound list for each set of samples may appear in several of the samples but 
cannot be positively identified as such due to retention time drift. 
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Figure 6-20 The chromatograms for one of the two samples from each pair of samples for participants diagnosed with lung cancer, including the only sample analysed for CV-13. The main 
peak shown is an artefact siloxane peak common to all of the samples to show the drift observed for the same compound in different samples analysed at different times. 
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Sample T283RA2 and T286KK1 show a very similar retention time for the observed peak and 
were collected on the same day and analysed in the same batch. Samples T282JL2 and 
T182MR1 also show a similar retention time and were within two weeks of each other. 
Samples T283RA2 and T286KK1 were collected one month after T282JL2 and show a small 
variation in retention time with the siloxane peak being less well retained in the later 
samples. Sample T129BC1 shows a larger retention time difference for the siloxane peak, 
with it being more retained. This shows a trend for a decrease in retention time over the 
course of the analysis, possibly due to deterioration of the column. 
For complex samples where many analytes are similar and unresolved retention time drift 
can be a large problem. As previously discussed in (CROSS REF SIMILAR MASS SPEC 
HEADING) many compounds have a similar mass spectrum, particularly at low 
concentrations and in samples with high background noise. As similar compounds will elute 
from the column at similar retention times, changes to this retention time could cause 
compounds to be confused for each other when comparing across samples. 
6.3.2.5 Addressing the complexities and identifying compounds found in the breath of 
volunteers diagnosed with lung cancer. 
All of the samples were analysed taking into account the complexities of the data outlined in 
the previous sections. For each sample a table of compounds was generated. This means 
two tables are generated for each participant, one for each sample. These two tables are 
then combined to create a single table for each participant. 
Once a table of compounds had been generated for each participant (Appendix VI Table 1 – 
Table 4) these were combined to create a table of all the compounds found in the breath of 
participants diagnosed with lung cancer. Where possible compounds that were observed in 
more than one participants samples were combined, such as benzene observed at 
approximately one point three five nine minutes, o-xylene and p-xylene observed at three 
point eight five three and four point zero three seven and the “no hits” compound observed 
in all of the samples at four point four five seven. Where peaks were not obviously the same 
across the samples they were included separately in the list. 
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The final list of compounds observed in the breath of participants with lung cancer can be 
seen in Appendix VI Table 5. The intensities of the observed mass ions are not included in 
this table for brevity. 
6.4 Discussion 
6.4.1 Compounds found in the breath of volunteers with lung cancer 
Appendix VI Table 5 contains a list of all of the compounds found in the breath of volunteers 
diagnosed with lung cancer. This will form the basis for a database of compounds found in 
human breath. The compound list contains a large number of compounds that could not be 
identified using the search tool for the NIST database. There are several reasons why this 
may be; 
 The compound is not listed in the NIST database and so no reasonable match can be 
found. 
 High background interference may be masking important mass ions and so hinder 
identification. 
 Changes in ionisation may not provide necessary mass spectrum for identification. 
 A large number of hits were given by the search with no obvious candidate. 
To deal with these possibilities several methods were used. When no identification is 
possible through the NIST program a tentative assignment of the compound class, such as 
hydrocarbon, benzene derivative et cetera, based on the most intense mass ions can be 
made. If this is not possible then the compound was still included but with no identification. 
When a large number of related hits were given, such as for the methylated hydrocarbons 
identified, only the compound class was given as it was felt that accurate identification of 
the compounds was not possible. Contamination/artefact peaks 
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There are several different stages where contamination of the samples is possible and it is 
also necessary to note the difference between contamination and artefact peaks. A 
contamination peak is a peak due to an exogenous compound entering the sample at some 
point in the process. This can occur at any point from when the sample tube is cleaned to 
when it is analysed. The compound class of the contaminant may make it easy to exclude, 
such as compounds containing chlorine in a biological sample. While hydrochloric acid is 
present in the stomach, this is a reasonable assumption as the reaction kinetics of 
chlorination of phenol, a compound likely to be chlorinated are unfavourable at pH 1-3 
[169] as observed in the stomach. However, certain contaminants, particularly 
hydrocarbons may be impossible to distinguish from the sample, particularly in a dynamic 
sample set such as breath samples. The best way to reduce the possibility of contamination 
is to minimise the points in the sampling and analysis protocols at which contamination is 
possible and to minimise the chance of contamination at these points. This is done by 
developing your sampling technique in a way to eliminate exogenous compounds, such as 
using a filtered medical air stream to feed a non-vented full face mask as laid out in the 
protocol for using the adaptive breath sampler [104]. Other methods include analysing 
samples in a timely fashion, in this study forty eight hours after collection was set as the 
maximum time a sample could be stored for prior to analysis, and using suitable transport 
and storage methods, such as maintaining the samples at a temperature equal to or below 
four degrees centigrade. Contamination sources in the analytical system include poor 
quality carrier gas, dirty carrier gas tubing, foreline pump oil vapour and leaks on the tuning 
compound vial or column connections. System maintenance and monitoring is the best way 
of controlling system contaminants. A list of common contaminants arising from the 
analytical system is shown in Table 6-2. 
Artefact peaks are peaks due to internal factors; in the case of this work they include bleed 
from degradable parts of the analytical system and, in particular, the degradation of Tenax 
to benzene. Some artefact peaks can be easily spotted based on the ions observed in their 
mass spectrum. A list of common artefact ions is included in Table 6-3. Artefact peaks are 
typically caused by column and septum bleed, out-gassing of ferrules and plastic parts such 
as o-rings. While factors such as the amount of water in the system and the highest 
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temperature that the column is raised to during the run determine the size of the artefact 
peaks, they tend to be present in all runs so are more easily distinguished compared to 
contamination peaks. 
As the pressure on the chromatography columns is higher than usual due to fact that both 
analytical columns need to be driven by a single flow it is possible that this is causing an 
increase in both contamination and artefact peaks observed during the analysis of the 
samples. There are two ways this can be dealt with: 
1. Post-processing to remove the peak 
This method would allow the system to operate as it currently is, however, with large 
contamination peaks observed it may cause analytes to be lost if they were to co-elute with 
these peaks. 
2. Split the samples between two analytical systems, one GC-MS and one GC-DMS. 
This method would solve the problem of having to use a very high pressure to drive two 
analytical columns simultaneously, but would cause a loss in sensitivity. This method is 
probably the best compromise and should be explored. 
6.4.2 Normalisation of data sets 
One of the main problems with breath data is the sample to sample variability. When purely 
looking to identify compounds and possible differences between two groups this may not 
present a large problem but if this data is to be used for any statistical analysis this needs to 
be addressed. Normalising the final data sets is imperative and identifying what to 
normalise against will be important. The options available are: 
 Normalise against the largest peak in all the data sets. This may cause some smaller 
peaks to be lost, particularly if the average intensity of some of the data sets is 
significantly lower than the most intense, as has been shown in this work. 
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 Normalise against the same peak in every data set. This would restrict normalisation 
to within each data set and so smaller peaks will not be affected by normalising 
against an external peak, however, identifying a peak which is consistent throughout 
all of the data sets is difficult. 
 Normalise against the largest peak in the data set. This would be the most likely 
option as it restricts normalisation to within each data set while varying which peak 
is used to normalise against keeping it constant. 
Of these options the most plausible would be to normalise against the largest peak within 
each data set. This would remove the influence of large intensity differences between data 
sets caused by the instrumentation or sampling equipment and would also mean that there 
was no need to identify a consistent analytical peak. 
6.4.3 Manual versus automated deconvolution methods 
There are both manual and automated deconvolution methods that can be used for 
deconvoluting complex GC-MS mass spectrometry data. There are advantages and 
disadvantages to both manual and automated methods. Manual methods allow the person 
processing the data to decide if a peak is composed of one or more components and which 
ions belong to which component. This can be a long and difficult task depending on the data 
set being processed and there is the chance that bias can be added to the separation of the 
peaks. However, as the researcher is able to use their knowledge to decide which ions 
belong to which component of the peak, it can be a much more accurate method than 
automated processing. 
The main advantage of automated methods is the speed at which they can process the data 
and for complex data sets this can be extremely useful. However, the deconvolution relies 
on the algorithms within the software package, of which little or nothing may be known. 
Automated scanning of a manually produced list can provide a compromise between the 
two, identifying peaks already found in previous samples. Once this has been carried out 
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manual deconvolution of the remaining peaks and addition of identified components to the 
list used to search the samples will reduce the manual portion of the processing over time 
as the size of the list increases. This method would rely on two things; that the same peaks 
appear at the same retention time, within the set retention time window of the processing 
package, and that the mass spectrum for each peak is reproducible between samples. Drift 
in retention time can be due to several factors and can be monitored using a standard mix 
to assess the reproducibility of the system. This standard mix can also be used to create a 
set of retention indices [170] to correct for any retention time drift in identified peaks. 
Maintaining reproducible mass spectra can be difficult in a sample as dynamic as breath, as 
interference from co-eluting compounds can cause the observed spectrum at a specific time 
to be different. Only manual deconvolution can guarantee that all peaks are inspected and 
deconvolved. 
6.4.4 Breath compound database 
The compounds and their associated meta-data can form the basis of a human breath 
volatile database. Before setting up a database it is important to outline and define a 
structure for each entry. They must contain all the relevant information in a manner that 
allows the users to search for it and be presented with the required information. When 
building a database of VOCs found in human breath this must be taken into account. For 
example; if someone wishes to compare their list of VOCs for a specific disease to the 
database they must be able to search by disease. This search should then present them with 
a list of compounds found in volunteers with the particular disease and allow them to easily 
cross-reference their own list against the compounds contained in the database. 
Allowing for searching based on the mass spectrum is important as not every compound can 
be identified. This means that compounds that cannot currently be identified can still be 
included in the database. 
  
242 
 
6.5 Conclusions 
This work has shown that the described methods can be used to analyse breath samples and 
identify the individual compounds present. The data presented in this preliminary study 
show that human breath is both variable and dynamic. The current methods used to identify 
the compounds observed need improvement mass spectral libraries should be used with 
caution. Classifying compounds based purely on their mass can cause problems when 
comparing results from different centres. There are two ways to improve this situation 
1. Record the compound in terms of mass and retention index. 
By using two different physiochemical properties to classify the compounds cross-
comparisons of results will be made easier. It will also be easier to identify compounds 
which are recurring in different sample sets. The use of retention index instead of retention 
time means that changes to the retention time caused by changes to the column due to 
damage or aging will not affect the classification of compounds. Identifying a set of 
compounds that can be used to create a retention index ladder, such as straight chain 
hydrocarbons, is important. The move to using retention indices instead of retention time 
should be the aim for breath research as this would allow cross comparison much easier. 
2. Record the mass spectra of the analytes from each sample for comparison. 
Electron ionisation (EI) mass spectrometry can cause problems. The fragmentation patterns 
can cause misidentifications of compounds and a reliance on automated deconvolution and 
automated searching is not sufficient for this type of data. Recording the mass spectrum of 
each analyte means that these can be compared to the mass spectra of future samples, thus 
not relying on general database identifications. As a move in this direction the top six mass 
ions and their intensities were recorded in this work. These can be compared to future 
samples to more accurately identify if a compound is recurring in different samples. 
Chemical ionisation (CI) mass spectrometry is a softer ionisation method that may be 
beneficial in breath analysis. While CI is selective, based on whether a molecule will react 
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with the ions introduced by chemical ionisation, it will produce molecular ions, making 
identification of analytes easier. 
The mass analyser used in this work was a quadrupole ion trap. The benefit of using a 
quadrupole ion trap is that it can perform multiple fragmentations on a selected ion to 
accurately identify the compounds of interest. The problems with using a quadrupole mass 
analyser are the effect of space charging in the trap where a high number of ions are 
present and the poor mass accuracy compared to other instruments. A time-of-flight (TOF) 
mass analyser could provide greater mass accuracy. Combined with a softer ionisation 
source this would allow for more accurate identification of the analytes. Recent work in the 
use of thermal desorption - electrospray ionisation – time of flight mass spectrometry show 
[89] that this is possible and should be developed to target the compounds expected to 
appear in breath samples. 
The development of a database of compounds seen in breath would allow researchers to 
easily cross-reference possible biomarkers with other centres samples. This will do two 
things, it will allow researchers to easier check their compound lists against compounds 
already described in breath and it will have the effect of building a large knowledge base of 
samples and what diseases they are present in. By recording what compounds are present 
in certain diseases this can be used to check any possible biomarkers of a specific disease 
against the samples associated metadata to see if it could be caused by any other disease 
that the sample giver was suffering from. 
Overall the methods used have allowed for the identification of the compounds found in the 
breath samples of lung cancer sufferers. The continuation of this study will allow for a 
preliminary investigation into possible biomarkers of lung cancer. This work can then be 
extended using the data collected with the differential mobility spectrometer with an aim to 
develop a point of care device for the detection of lung cancer. 
  
244 
 
7 Overall discussion, conclusions and future work 
7.1 Overall discussion 
This research sought to establish the systems and work-flow for prospecting for volatile 
organic compound markers in the breath of individuals with lung disease. There were four 
principal objectives: 
 To design and commission a Thermal desorption CG-DMS/MS dual detector 
instrument to increase the amount of data collected from a single sample. 
 To develop a method for preparing three dimensional DMS for chemometric analysis 
while maintaining the full complexity of the data set. 
 To set up and implement a collaborative breath sampling clinical campaign within 
the National Health Service (NHS) 
 To evaluate and assess the initial findings from the collaborative breath sampling 
study. 
The implementation of a dual detector instrument was key to this work. Breath samples 
obtained from people with lung cancer are extremely hard to obtain, and rightly so due to 
strict ethical governance of who can interact with them in a clinical setting. Only a limited 
number of samples may be collected from a volunteer and this means that extracting the 
maximum amount of information possible from every sample is important. The use of two 
different detectors, an MS and DMS to analyse each sample increased the amount of data 
gained from each sample. This approach enabled a fieldable system (DMS) to be tested and 
characterised for use in an in-clinic operation alongside “gold-standard” mass spectrometric 
detection. The mass spectrometric data were intended to complement and validate the 
DMS data. 
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There were some problems with the system: 
 The differences in the two chromatographic columns meant that the retention times 
of the same components were different for each detector. This means that future 
data processing will need to establish robust approaches to alignment of data for the 
two channels. 
 High levels of water in the breath samples led to an increased column bleed and as 
such a higher background noise signal. 
Differences in retention time may be accounted for by moving to a retention indices method 
for both detectors. This would also correct for any retention time differences between data 
sets from the same detector which is a major problem in data processing. Despite the issues 
highlighted this system still has the major benefit of providing two data sets per sample and 
at this initial stage of the research this is a major benefit. 
With large, complex data-sets such as those produced from breath samples the data 
processing methods must be capable of analysing all of the data in a reliable way. 
Multivariate techniques are seeing an increased use in similar research areas such as 
metabolomics. The main problem with processing DMS data in this way is that multivariate 
methods such as PCA or PC-DFA cannot be applied to three dimensional data. The current 
methods or reducing the dimensionality of the data, such as summing across the 
compensation voltage axis, do not maintain the full information contained within the data. 
The Euclidian-based transformation method described can maintain all the information 
contained within the data set while converting it into a suitable form for application of 
multivariate techniques. 
This method was tested extensively to show that it was capable of distinguishing between 
the smallest changes expected in a real data set. This method was successful in all of the 
tests applied, showing a significant improvement over the most recently published method. 
The testing of the method also highlighted the main issue that needs to be addressed, 
namely alignment of the data sets. Small changes in an analytes position in the retention 
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time or compensation voltage axis can cause the problems with the data processing and this 
needs to be addressed if this method is to be utilised to its’ fullest. At the moment the 
follow up research is exploiting the ubiquitous presence of siloxanes in the negative mode 
to enable alignment on retention indexing. 
This method seeks to bring into line the data-processing techniques, which are currently 
lagging behind, with the analytical techniques. Allowing for processing of the full data set 
rather than a reduced set makes full use of the data produced and allows researchers to 
easily utilise the full data set that a DMS can produce for multivariate processing, something 
that is currently lacking. 
For researchers not based in a clinical environment being able to establish a collaboration 
within a clinical environment is key. A clinical environment provides access to diseased 
participants in a controlled location, it provides access to experts who can provide meta-
data such as tumour staging and information on the participants medical records. It also 
provides a familiar location that feels safe for the participants to set them at ease. To 
establish a collaboration within the National Health Service there are several steps that 
must be completed. Knowing these steps and planning accordingly is vital as the research 
cannot progress until they have been completed. External researchers require a Research 
Passport to work within the NHS, all research involving NHS patients as participants requires 
ethics approval at both the regional and local level and successfully carrying out the 
sampling campaign requires careful management as it will require interacting with NHS 
staff. 
This work has described what needs to be done implement a successful collaboration within 
the NHS. To guide the implementation of a collaboration a flow chart and a Gantt chart are 
provided detailing the steps taken and the time each step is expected to take. These tools 
are helpful to managing a successful project helping the project manager to track all of the 
different requirements and keep the research going. While research is ever changing and a 
project must change to meet the requirements, managing the aspects that must be 
completed well will increase the productivity of the work. 
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The preliminary findings from the described pilot study highlight some key points that must 
be considered as this research progresses. 
7.2 Conclusions 
 A dual detector instrument was implemented to increase the amount of data 
produced for each sample. This set-up will also allow for testing of the utility of a 
DMS as a detection technology for breath analysis 
 A new Euclidian based approach to transforming a DMS data surface while 
maintaining the full structure of the data set has been developed. This method was 
shown to maintain all of the information contained within a data set and showed a 
marked improvement over the current method it was compared with 
 The limits of the Euclidian based approach were tested and it was shown to be 
capable of providing data sets that could be distinguished using multivariate 
techniques based on differences in the data sets that were similar to those expected 
in breath samples 
 A work flow for a collaboration within the NHS was described along with suggested 
project management tools, namely a Gantt chart and a work flow diagram detailing 
steps that must be taken to successfully implement the study. 
 A description of the documentation required for external researchers to conduct 
research within the NHS are detailed and included in the workflow and Gantt charts 
to highlight that these must be completed in a timely fashion so the research is not 
held up. 
 The initial results from the clinical campaign involving patients referred to the two 
week wait clinic are discussed. The need for a more rigorous method for both 
assigning and cataloguing the VOCs found in human breath and the associated meta-
data. 
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 The current method of using the highest hit in a database to assign a compound 
found in breath samples needs addressing as this is not always accurate. Recording 
mass spectra along with the identification would allow for better cross-referencing 
of samples to confirm markers. 
7.3 Future work 
This research has highlighted several key areas that require further work, these are 
discussed here. 
While EI ionisation methods are standard practice for GC-MS this may not be the most 
appropriate ionisation method. Chemical ionisation methods which are more likely to 
provide monoisotopic ions would make identification of VOCs easier, particularly for VOCs 
that are very similar and produce very similar fragmentation patterns. 
Direct analysis of the breath samples or real-time breath analysis would be beneficial as this 
would shorten the analytical time considerably. The first step towards this has been 
completed by combining a thermal desorption unit with an electrospray ion mobility mass 
spectrometry instrument [89]. This dramatically reduced the analytical time required per 
sample. Fine tuning of the ionisation method may be required depending on the likely 
biomarkers, but this is a step in the right direction. 
The alignment of the MS and DMS data needs to be tackled both individually and jointly. 
Moving to a retention index method would aid alignment for the mass spectrometry data. 
This method may also aid alignment of the DMS data with the MS data. The alignment of 
the DMS data was shown to have the largest negative effect on the data analysis and this 
needs to be addressed. Methods similar to those used in protein analysis could be 
considered, but any method used must be carefully controlled so as not to add bias to the 
data set. 
Further development of the DMS technology to provide cheap instruments would be 
beneficial as this would reduce the costs of any point of care device. Development of 
injection and ionisation techniques more applicable to the samples would also be beneficial. 
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Appendix I 
Table 1 Peak parameters for set A used in Test 1. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 89 0.2 0.9 
2 -0.87 0.2 144 0.2 0.9 
3 -3 0.2 210 0.2 0.7 
4 2 0.2 210 0.2 0.78 
5 0 0.2 180 0.2 0.8 
6 6 0.2 153 0.2 0.8 
7 -1.5 0.2 220 0.2 0.44 
8 -2.3 0.2 234 0.2 0.64 
9 0.36 0.2 260 0.2 0.58 
10 0.99 0.2 92 0.2 0.82 
 
Table 2 Peak parameters for set B used in test 1. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 89 0.2 0.9 
2 -0.87 0.2 144 0.2 0.9 
3 -3 0.2 210 0.2 0.7 
4 2 0.2 210 0.2 0.78 
5 0 0.2 180 0.2 0.8 
6 -2.4 0.2 170 0.2 0.65 
7 0.97 0.2 200 0.2 0.43 
8 0.34 0.2 100 0.2 0.84 
9 4.12 0.2 270 0.2 0.32 
10 0.99 0.2 165 0.2 0.66 
 
Table 3 Peak parameters for set A used in Test 2. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 88.969 0.2 0.45 
2 -1.4 0.2 144.578 0.2 0.3 
3 -3.16 0.2 210.313 0.2 0.25 
4 2.11 0.2 210.313 0.2 0.4 
5 0.35 0.2 179.969 0.2 0.31 
6 -2.58 0.2 169.86 0.2 0.28 
7 0.94 0.2 200.188 0.2 0.17 
8 0.35 0.2 100.094 0.2 0.2 
9 -4.33 0.2 270.969 0.2 0.23 
10 0.94 0.2 164.813 0.2 0.38 
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Table 4 Peak parameters for set B used in Test 2. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 88.969 0.2 0.45 
2 -1.4 0.2 144.578 0.2 0.3 
3 -3.16 0.2 210.313 0.2 0.25 
4 2.11 0.2 210.313 0.2 0.4 
5 0.35 0.2 179.969 0.2 0.31 
6 -2.58 0.2 170.875 0.2 0.28 
7 0.94 0.2 200.188 0.2 0.17 
8 0.35 0.2 100.094 0.2 0.2 
9 4.45 0.2 270.969 0.2 0.23 
10 1.53 0.2 164.813 0.2 0.38 
 
Table 5 Peak parameters for set A used in Test 3. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 88.969 0.2 0.21 
2 -1.4 0.2 144.578 0.2 0.16 
3 -3.16 0.2 210.313 0.2 0.09 
4 2.11 0.2 210.313 0.2 0.05 
5 0.35 0.2 179.969 0.2 0.12 
6 -2.58 0.2 169.86 0.2 0.1 
7 0.94 0.2 200.188 0.2 0.2 
8 0.35 0.2 100.094 0.2 0.13 
9 -4.33 0.2 270.969 0.2 0.19 
10 0.94 0.2 164.813 0.2 0.20 
 
Table 6 Peak parameter for set B used in Test 3. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 -0.82 0.2 88.969 0.2 0.21 
2 -1.4 0.2 144.578 0.2 0.16 
3 -3.16 0.2 210.313 0.2 0.09 
4 2.11 0.2 210.313 0.2 0.05 
5 0.35 0.2 179.969 0.2 0.12 
6 -2.58 0.2 170.875 0.2 0.1 
7 0.94 0.2 200.188 0.2 0.2 
8 0.35 0.2 100.094 0.2 0.13 
9 4.45 0.2 270.969 0.2 0.19 
10 1.53 0.2 164.813 0.2 0.20 
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Table 7 Peak parameters for set C used in Test 3. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 -2.58 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.14 
8 3.87 0.2 146.61 0.2 0.21 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
 
Table 8 Peak parameters for set A used in Test 4. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 -2.58 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.21 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
 
Table 9 Peak parameters for set B used in Test 4. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 -2.58 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.01 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
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Table 10 Peak parameters for set A used in Test 5. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 2.11 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.21 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
 
Table 11 Peak parameters for set B used in Test 5. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 2.7 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.21 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
 
Table 12 Peak parameters for set A used in Test 6. Peak 8 included as a reference only as this peak drifts in the data files. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 -2.58 0.2 214.344 0.2 0.01 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.21 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
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Table 13 Parameters for peak 8 in each data file of set A used in Test 6. 
Sample No. Cv location Cv spread Time base location Time base spread Intensity 
A1 3.87 0.2 146.61 0.2 0.21 
A2 3.28 0.2 147.625 0.2 0.21 
A3 3.87 0.2 145.594 0.2 0.21 
A4 4.45 0.2 147.625 0.2 0.21 
A5 3.28 0.2 146.61 0.2 0.21 
A6 4.45 0.2 145.594 0.2 0.21 
A7 3.87 0.2 144.578 0.2 0.21 
A8 3.87 0.2 146.61 0.2 0.21 
A9 3.28 0.2 144.578 0.2 0.21 
A10 3.28 0.2 148.625 0.2 0.21 
A11 3.87 0.2 146.61 0.2 0.21 
A12 4.45 0.2 146.61 0.2 0.21 
A13 3.28 0.2 145.594 0.2 0.21 
A14 4.45 0.2 146.61 0.2 0.21 
A15 3.87 0.2 145.594 0.2 0.21 
A16 3.87 0.2 144.578 0.2 0.21 
A17 3.28 0.2 146.61 0.2 0.21 
A18 3.87 0.2 148.625 0.2 0.21 
A19 4.45 0.2 144.578 0.2 0.21 
A20 3.87 0.2 146.61 0.2 0.21 
 
Table 14 Peak parameters for set B used in Test 6. Peak 3 included as a reference only as this peak drifts in the data files. 
Peak no. Cv location Cv spread Time base location Time base spread Intensity 
1 3.28 0.2 88.985 0.2 0.15 
2 0.35 0.2 115.266 0.2 0.2 
3 -2.58 0.2 214.344 0.2 0.19 
4 1.53 0.2 214.344 0.2 0.15 
5 0.94 0.2 159.75 0.2 0.08 
6 2.7 0.2 167.844 0.2 0.06 
7 -4.92 0.2 101.11 0.2 0.18 
8 3.87 0.2 146.61 0.2 0.01 
9 -1.99 0.2 177.953 0.2 0.1 
10 -0.82 0.2 251.766 0.2 0.18 
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Table 15 Parameters for peak 3 in each data file of set B used in Test 6 
Sample No. Cv location Cv spread Time base location Time base spread Intensity 
B1 -2.58 0.2 214.344 0.2 0.19 
B2 -2.58 0.2 213.344 0.2 0.19 
B3 -3.16 0.2 214.344 0.2 0.19 
B4 -2.58 0.2 212.328 0.2 0.19 
B5 -2.58 0.2 214.344 0.2 0.19 
B6 -3.16 0.2 214.344 0.2 0.19 
B7 -3.16 0.2 215.36 0.2 0.19 
B8 -1.99 0.2 216.375 0.2 0.19 
B9 -1.99 0.2 215.36 0.2 0.19 
B10 -2.58 0.2 214.344 0.2 0.19 
B11 -2.58 0.2 212.328 0.2 0.19 
B12 -1.99 0.2 214.344 0.2 0.19 
B13 -3.16 0.2 212.328 0.2 0.19 
B14 -1.99 0.2 212.328 0.2 0.19 
B15 -1.99 0.2 215.36 0.2 0.19 
B16 -2.58 0.2 214.344 0.2 0.19 
B17 -3.16 0.2 213.344 0.2 0.19 
B18 -3.16 0.2 212.328 0.2 0.19 
B19 -2.58 0.2 214.344 0.2 0.19 
B20 -2.58 0.2 215.36 0.2 0.19 
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Appendix II 
Code for Euclidian transform programme 
Option Strict Off 
Option Explicit On 
Friend Class Form1 
 Inherits System.Windows.Forms.Form 
 ' Written by: Sultan Shair 
 ' Department of Chemistry 
 ' Loughborough University 
 ' LE11 3TU 
  
 Public Sub Form1_Load(ByVal eventSender As System.Object, ByVal eventArgs As 
System.EventArgs) Handles MyBase.Load 
   
  Me.Show() 
   
 End Sub 
  
 Private Sub Dir1_SelectedIndexChanged(ByVal eventSender As System.Object, ByVal 
eventArgs As System.EventArgs) Handles Dir1.SelectedIndexChanged 
  Label1.Visible = False 
 End Sub 
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 Private Sub Drive1_click() 
  Label1.Visible = False 
 End Sub 
 Private Sub File1_SelectedIndexChanged(ByVal eventSender As System.Object, ByVal 
eventArgs As System.EventArgs) Handles File1.SelectedIndexChanged 
  Label1.Visible = False 
 End Sub 
  
 Private Sub Dir1_Change(ByVal eventSender As System.Object, ByVal eventArgs As 
System.EventArgs) Handles Dir1.Change 
  File1.Path = Dir1.Path 
 End Sub 
  
 Private Sub Drive1_SelectedIndexChanged(ByVal eventSender As System.Object, 
ByVal eventArgs As System.EventArgs) Handles Drive1.SelectedIndexChanged 
  Dir1.Path = Drive1.Drive 
 End Sub 
  
 Public Sub File1_DoubleClick(ByVal eventSender As System.Object, ByVal eventArgs 
As System.EventArgs) Handles File1.DoubleClick 
  Dim sFilename As Object 
  Dim l, i, g, c, j, ma As Object 
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  Dim Data(3000, 3000) As Double 
  Dim RowSize As Double 
  Dim ColSize As Double 
  Dim RowCount As Double 
  Dim ColCount As Double 
  Dim ex(500000) As Object 
  Dim m(500000) As Object 
   
  Dim ApExcel As Microsoft.Office.Interop.Excel.Application 
  ApExcel = New Microsoft.Office.Interop.Excel.Application 
 
  sFilename = Dir1.Path & "\" & File1.FileName 
   
  ApExcel.Workbooks.Open(sFilename) 
   
   
  For g = 1 To 3000 
    
    
   RowCount = ApExcel.Cells._Default(g, 1) 
   If RowCount = 0 Then 
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    RowCount = g 
     
    RowCount = g - 1 
    GoTo Step1 
   End If 
    
   System.Windows.Forms.Application.DoEvents() 
    
  Next g 
   
Step1:  
  For c = 1 To 3000 
   ColCount = ApExcel.Cells._Default(1, c) 
   If ColCount = 0 Then 
     
    ColCount = c 
    ColCount = c - 1 
    GoTo Step2 
   End If 
   System.Windows.Forms.Application.DoEvents() 
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  Next c 
  
   
Step2: 
  For j = 1 To ColCount 
   For i = 1 To RowCount 
    Data(i, j) = ApExcel.Cells._Default(i, j) 
    System.Windows.Forms.Application.DoEvents() 
   Next i 
   System.Windows.Forms.Application.DoEvents() 
  Next j 
   
  
  'mat = RowCount * ColCount 
  For i = 1 To RowCount 
   For j = 1 To ColCount 
    ex(l) = ((i ^ 2) + (j ^ 2)) ^ (1 / 2) 
    m(l) = Data(i, j) 
    l = l + 1 ' counter 
    System.Windows.Forms.Application.DoEvents() 
   Next j 
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   System.Windows.Forms.Application.DoEvents() 
  Next i 
   
  For ma = 1 To l 
   FileOpen(2, Dir1.Path & "\" & " Corrected " & File1.FileName, 
OpenMode.Append) 
    
   PrintLine(2, ma & "," & m(ma) & "," & ex(ma)) 
   FileClose(2) 
   System.Windows.Forms.Application.DoEvents() 
  Next ma 
  MsgBox("your data is now fixed") 
 End Sub 
End Class 
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Appendix III 
Detection of Volatile Organic Compounds in the exhaled Breath of Patients 
referred urgently to the chest clinic: a Pilot Study 
Investigators: 
 Gavin Blackburn, Ph.D. Research Student, University of Loughborough 
 Professor Paul Thomas, Professor of Analytical Science University of Loughborough 
 Dr Stephen Fowler, Lecturer and Honorary Consultant, University of Manchester and 
Lancashire Teaching Hospitals NHS Trust 
 Professor Roy Goodacre, Professor of Biological Chemistry, University of Manchester 
 Professor Ian Wilson, Principal Scientist AstraZeneca, Alderley Park, Cheshire UK.  
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Background 
Respiratory disease can range from simple chest infections to more serious illness. Emphysema, 
bronchitis, chronic obstructionary pulmonary disease (COPD) and lung cancer can all have very 
similar initial symptoms. In people with a high risk of serious illness, such as lung cancer, it is 
important that the disease is detected as early as possible so appropriate treatment can be given. 
Lung cancer is the most common cause of death from cancer for both men and women. In the UK 
24% of all male cancer deaths and 18% of all female cancer deaths are due to this disease[171, 172]. 
Figure 1, (Reproduced from Reference 1) summarises the distribution of this disease by age and 
gender within the UK. It is also important to note that lung cancer has one of the lowest survival 
outcomes of any cancer. Only 25% of patients in England and Wales are alive one year after 
diagnosis, and only 7% of patients survive for 5 years from the date of diagnosis[173]. For most 
cases, the only chance of cure comes from surgery, and this is only possible when the cancer is 
diagnosed before it has spread beyond the primary site. Lung cancer may be diagnosed incidentally 
when a chest x-ray has been performed for another purpose, for example during a health screen. 
However in the majority of cases the suspicion is raised by the patient bringing symptoms (for 
example haemoptysis, chest wall pain, or weight loss) to their GPs’ attention. Unfortunately such 
symptoms often develop after the disease has progressed beyond the point when surgery would be 
an appropriate treatment. 
 
Figure 1 Number of deaths and age-specific mortality rates, lung cancer, by gender, UK, 2005 [172] 
In contrast to breast and cervical cancer, there is no agreed screening strategy for lung cancer in the 
UK. The eventual goal of our research is the delivery of a detection system potentially suitable for 
use in a screening programme for a range of diseases, including lung cancer. Our hypothesis is that a 
sensitive non-invasive test that can detect the volatile compounds associated with disease-specific 
symptoms, such as lung-tumour growth, and metabolism in the exhaled breath of patients will 
differentiate them from those without disease. The ultimate benefits are clear: sensitive detection of 
different respiratory diseases before the disease spreads from the primary site enables early 
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treatment, and increased survival rates for serious illness. Further, more detailed knowledge of how 
these diseases alter the profile of volatile organic compounds in patients’ breath provides new 
insights into the progression and mechanism of disease. The discovery of volatile markers that are 
related to therapy and drug regimes will enable objective assessments of the disease state and pave 
the way for personalised medicine and care programmes to be effectively implemented. 
Current diagnostic and screening methods for patients suspected to have lung cancer are expensive, 
and a typical patient will undergo a minimum of chest radiography (CXR), computer tomography (CT) 
scanning, and bronchoscopy before a diagnosis is confirmed or excluded.  
Modern state-of-the-art chemical detection systems have the theoretical capacity to detect volatile 
compounds associated with lung cancer, and one such technology , ion mobility spectrometry, and 
specifically differential mobility spectrometry (DMS) also has the capacity to be miniaturised and 
used in point-of-care applications. 
Previous research in breath analysis using mass spectrometry, reported by Phillips et. al.[36], 
demonstrated the feasibility of differentiating between participants with lung cancer and 
asymptomatic controls. Further, it was possible to identify the compounds that caused the observed 
differences. Baumbach and co-workers [30] have reported success in detecting lung cancer from 
breath samples analysed with ion mobility spectrometry (IMS). Our use of ion mobility technology 
will improve on this work by using DMS in combination with mass spectrometry (MS) to deliver 
higher resolution data and enable miniaturised point-of-care systems targeted towards marker 
compounds for lung cancer to be developed. 
Our consortium has conducted an investigation into the detection of Chronic Obstructive Pulmonary 
Disease (COPD). We have differentiated between healthy non-smoking, healthy smoking and 
diseased volunteer participants (manuscript in preparation), and we have developed the research 
protocols to enable us to run a pilot study of patients referred urgently to the chest clinic. 
Hypothesis and aims 
The research hypothesis is that there is a detectable difference between the volatile organic 
compounds present in the breath of diseased and healthy participants. The chemical differences can 
be identified as candidate biomarkers for diagnosed diseases, such as lung cancer, and allow the 
development of point-of-care systems to specifically monitor these compounds with very high 
sensitivity. 
This study will collect breath samples and chemically analyse them. Using advanced statistical 
approaches the intent is to establish if it is possible to distinguish between the exhaled breath of 
participants with diagnosed disease and the exhaled breath of phenotypically matched controls. 
Further the intention is to determine the chemical identity of any candidate markers that are 
discovered in this study. 
The sampling method is a relatively simple, non-invasive process that has been designed to make 
sure the participant is comfortable. It has been tested previously with participants suffering from 
COPD and healthy controls [104], and the results of the early COPD trial are encouraging with some 
indication that it is possible to differentiate between the breath samples of asymptomatic controls 
and participants with COPD. 
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Methods 
Setting 
A quiet room in Royal Preston Hospital with a medical air supply, a table for breath sampling 
equipment, three power points, a seat/bed for volunteer participants and a seat for the operator. 
Volunteer participants: diseased, healthy. 
Volunteers will be recruited from individuals who have been referred by their general practitioner to 
the chest clinic under the urgent “two-week wait” category that is reserved for patients with 
possible lung cancer. For example they may have had a suspicious CXR, or symptoms of 
haemoptysis, or weight loss, and they almost always have a significant smoking history. These 
patients are investigated using a computerised tomography (CT) scan of their chest and fibre-optic 
bronchoscopy to further clarify the diagnosis. Where these tests do not exclude lung cancer, further 
tests such as surgical biopsy and positron emission tomography-CT (PET-CT) may be necessary.  
Following diagnosis a treatment strategy is formulated at the weekly lung cancer multi-disciplinary 
team meeting and may include any combination of surgery, chemotherapy and radiotherapy, with 
the aim of cure or palliation of symptoms. Where lung cancer is excluded, patient follow up depends 
on individual circumstances. 
Volunteer participants will be recruited upon referral to the “two-week wait” chest clinic. They will 
be asked to take part in the study during one of their visits to the chest clinic before diagnosis. 
Prospective participants will be provided with information about this study by either their 
consultant, lung cancer nurse specialist or a research nurse, and where they are able and willing 
informed consent to participate in the study will be obtained. Subjects will have at least 24 hours to 
decide whether to participate in the study. If possible the breath sample appointment will be made 
to coincide with their next hospital appointment for consultation or treatment. It is important to 
note that breath samples must be obtained before any treatment or test has been carried out. All 
participants will receive the same information regarding the study. All participants will be informed 
that their final diagnosis will be made available to the researchers by sample codes only, no names 
or addresses will be used. 
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Figure 2 Recruitment pathway for volunteer participants in the proposed study and sample separation 
Inclusion criteria 
Subjects referred to the chest clinic with possible lung cancer. 
Cases: lung disease confirmed 
Controls: lung disease excluded 
Age > 18yrs 
Inclusion criteria may be tailored at the predetermined "halfway" point in the study (after 10 cases 
and controls have been recruited) to correct for any between-group inequalities in gender or COPD.  
We know that both these factors may affect the exhaled breath VOC profile from our pilot work in 
COPD.  It is important therefore that the male: female ratio and mean / range of lung function is 
similar in each group.  We plan therefore to review demographics after 10 cases and controls have 
been recruited, and if there is any gender or lung-function bias, then select participants as 
appropriate of the basis of gender or lung function for the second half of the study in order to 
balance numbers. 
“2 week wait” referral 
to chest clinic 
Lung cancer excluded 
samples 
Lung cancer diagnosed 
samples 
Samples separated 
First outpatient 
consultation 
Recruitment: 
Consent and sample 
Diagnostic 
investigations 
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Exclusion criteria 
Co-morbidities that are likely to significantly affect metabolic status.  i.e. Diabetes mellitus, chronic 
renal failure, chronic liver failure 
Other active malignancy 
Breath collection 
An adaptive breath sampler will be used to collect 5 samples of breath from each volunteer. The 
sampler consists of a full-face mask to which a t-piece, adsorbent tube assembly and a tube attached 
to a pressure sensor are connected. The t-piece allows for connection of a medical-air line (which is 
filtered up-line) and a one-way valve. This means that only the filtered medical air will be breathed 
by the volunteer participant and will effectively eliminate the presence of exogenous compounds 
due to room air.  
The adsorbent tube assembly consists of a capillary held in a reducing ferrule in a SwagelokTM 
reducing union. This is connected to the mask via a PTFE connection that holds the assembly in 
place. The absorbent tube is connected to the other side of the union using a bolt and a PTFE ferrule 
which creates an air-tight connection. The other end of the tube is then connected to the sampling 
controller that is linked to a computer programme that allows a selected part of the breath profile to 
be selectively sampled. Figure 3 is a simplified schematic of the sampler, for a more detailed 
discussion see ref 6. 
 
Figure 3 Schematic of breath sampler.  A: purified air supply, B: pressure regulator, C: pressure relief valve, D: breathing 
mask, E: mask air supply assembly, F: adsorbent sampler assembly, G: balanced and matched micro-
control valves, H: pressure transducer connected to the mask, I: precision air sampling pump, J: laptop 
computer 
Sampling requires the volunteer participant to sit quietly for about 30 minutes while wearing a full-
face mask and breathing filtered air. The sampled portions of breath are collected in tubes 
containing adsorbents which are attached to the mask and changed periodically (after 2.5 l exhaled 
air has been sampled). The sampling of the breath is controlled from a laptop running a programme 
which measures the pressure change within a tube connected to the mask. This allows the system to 
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detect what portion of the breath that is sampled and allows us to target air from early or late 
expiration (approximating to the proximal or distal airways) as required. There are several factors 
that can add bias to the study and these will need to be taken into account. For example, diet, 
smoking and medication could affect the results. To help us control for this, participants will be 
asked to refrain from smoking and eating/drinking for 2 hours before the procedure is carried out 
(unflavoured water will be allowed). 
Urine Samples 
Urine samples will also be obtained from the participants just before or after a breath sample is 
taken. These samples will be shipped to AstraZeneca’s Alderley Park Research Laboratory where 
they will be stored, processed and analysed. The complementary data available from urine will be 
particularly helpful in establishing whether responses seen in breath are due to systemic or local 
(lung) effects. Note that the AstraZeneca research facility at Alderley Park is covered under the 
Human Tissue Act and all samples will be stored in a secure freezer on an anonymous basis with 
access limited to only those people who are directly related with the study.  
Sample processing 
The breath samples will be analysed using a thermal desorption – gas chromatograph – mass 
spectrometer/differential mobility spectrometer (TD-GC-MS/DMS). The basic operation of this 
system is to allow us to detect all the different volatile chemicals in a breath sample. The MS allows 
us to identify single components and look for differences in peoples’ breath. It is an extremely 
powerful and useful tool and will aid us in identifying potential biomarkers. The data it generates is 
displayed in two forms; a chromatogram and a mass spectrum. An example chromatogram is 
displayed below in Figure 4. 
 
Figure 4 Example of chromatographic data. 
The chromatogram above, in Figure 4 allows the relative concentrations of the different volatile 
components of exhaled breath to be estimated. Each point on the chromatogram is built up from 
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integrated mass spectra, which may be used to identify the compound. An example is given in Figure 
5, a mass spectrum of decane. The x-axis is the mass-to-charge ratio (m/z) and the y-axis shows the 
relative abundance of the ion fragments yielded by decane to the ionisation source of the mass 
spectrometer. 
The differential mobility spectrometer generates a three-dimensional matrix that can be used like a 
fingerprint for a disease (see title page for an example of DMS output). The data from this 
instrument will be used in the statistical analysis to investigate differences between the healthy and 
diseased groups.  DMS has several important benefits giving it the potential to be developed into a 
desktop detection device for point-of-care applications: it is smaller and easier to maintain than a 
mass spectrometer, and can also be optimised to detect specific compounds enabling specific 
markers to be detected with very high sensitivity and selectivity. 
Data analysis 
All data will be treated as confidential and rendered anonymous at the point of sampling.   Data 
analysis will be carried out under the supervision of Prof Roy Goodacre. 
The data flow that we shall use for the analysis of the VOC profiles is detailed in Figure 5, and follows 
the accepted practices laid out by the Metabolomics Standards Initiative [174]. 
 
Figure 5 Data processing / analysis flow chart. 
Briefly 
(1) Data deconvolution and pre-processing will be performed following data collection. 
Deconvolution will be performed using the instrument manufacturer’s software so that VOC 
peak lists are generated. Pre-processing will depend on the data structure and so will not be 
explicitly detailed here. 
Experimental design
Data collection
Data deconvolution
Data pre-processing
Data interpretation
Unsupervised
learning
Discriminant
analysis
Exploratory
analysis
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(2) VOC profile reproducibility will be tested using (a) rank testing based on pair-wise 
comparison of the profiles generated from the same individual and those between different 
individuals, and (b) principal components-canonical variates analysis (PC-CVA) calibrated 
with a priori information on the A-C profiles from each individual, 90% chi-sqrd tolerance 
regions will be constructed and the D profile projected into this PC-CVA space  
(3) Unsupervised learning of principal components analysis (PCA) and hierarchical cluster 
analysis (HCA) will be used to uncover any natural relationship within the samples, this may 
show groups that are related to disease phenotype or any of the clinical metadata, and is 
also useful for detecting any outliers (both biological and analytical). 
(4) Discriminant analysis using partial least squares with bootstrap methodology will be used 
to test the hypothesis that VOC profiles can stratify patients according to: 
a. VOC profiles of lung cancer versus non-lung cancer controls 
b. VOC profiles of small cell versus non-small cell lung cancer 
c. VOC profiles of lung cancer versus different lung disease 
(5) Individual datapoints from the chromatogram will be compared between groups using 
ANOVA and ROC analysis, to identify potentially discriminating compounds 
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Figure 6 PC-DFA analysis example. HNS = healthy non-smoker, HS = healthy smoker, DNS = diseased non-smoker. 
Summary 
The breath sampling, analytical approaches and data processing strategies summarised in this 
application have been awarded a diploma by the International Association of Breath Research for 
research in breath sampling and analysis, (Prague September 2006). Preliminary data and results 
from pilot studies with COPD indicate that this is a sensitive approach capable of identifying volatile 
markers in breath that may be able to discriminate the presence of lung cancer. The proposed study 
is intended to establish the feasibility of using point-of-care volatile organic compound analysis and 
detection system to reliably screen breath samples for presumptive testing of lung cancer. If 
successful this will pave the way for earlier diagnosis with the potential of ultimately increasing 
survival rates. 
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Appendix IV 
Participant information sheet 
Part 1 
Invitation to participate 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
This part (part 1) tells you the purpose of this study and what will happen to you if you take 
part. Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part. 
What is the purpose of this study? 
We are testing a new way of detecting changes in the lungs, through measurement of tiny 
amounts of chemical substances in the breath.  These substances arise from all the 
processes and reactions that occur in the body.  We think that analysis of these compounds 
may be able to give us information about diseases such as lung cancer, and this may lead to 
a test that can detect the disease early in the future. 
Why have I been invited? 
You will have been invited because you have been urgently referred to the chest clinic and 
this makes you part of the group of people we are particularly interested in seeing. 
Whatever the outcome of your general diagnosis is from the chest clinic, any data collected 
by us is still useable. 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, 
which we will then give to you. We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any time, giving a reason. This would 
not affect the standard of care you receive. 
What will happen to me if I take part? 
If you agree to take part we will arrange a single visit lasting about 45 minutes.  If possible 
we will arrange this for a time when you are coming to the hospital for another reason, for 
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example for a further clinic visit.  At this visit we will first ask you a series of questions 
relating to factors that can influence the chemical substances in the breath.  These will 
include questions about food, drink and medications recently consumed, smoking, other 
medical conditions.  For the same reasons, you will be asked to refrain from eating, drinking 
(other than unflavoured water) and smoking for two hours prior to the study visit. 
After we have collected this information, we will collect a breath sample. This involves 
wearing a face mask that is connected to an air supply.  You will be asked to breathe 
normally throughout the test, whilst resting in either a chair or bed.  A sampling tube is 
connected to the mask on which we will collect the sample. 5 samples will be collected in 
total and the process will take about half an hour. 
You will also be asked to provide a urine sample during the study visit.  We will analyse this 
in a similar way to the breath samples, as it may be possible that similar chemical changes 
can be detected in the urine as well. 
None of your usual medication or any proposed treatment will be changed or delayed if you 
participate in this trial. 
What will I have to do? 
As mentioned above we need you to not smoke, eat or drink (although you are permitted to 
drink unflavoured water) for two hours prior to the study visit.  In addition we ask you not 
to use perfumed products (which include not only perfume, but also deodorants, after-
shaves), or any facial products (such as make-up or creams (scented or un-scented)) on the 
day of the study visit. 
What are the possible disadvantages and risks of taking part? 
We do not anticipate any risk from taking part in this study.  Some participants may 
experience slight initial discomfort wearing the mask, although we have tested this 
previously in patients with chronic bronchitis and emphysema without any difficulties. Some 
patients experienced slight claustrophobia when first wearing the mask but this was in very 
few cases and was not enough to cause anxiety. 
What are the possible benefits of taking part? 
There will be no direct benefits to you from taking part in this research, The aim is to hopefully 
develop a test that may be used in future to detect lung cancer and other respiratory diseases in 
patients with these conditions. 
What if there is a problem? 
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Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. You may withdraw from the study at any time; either before or 
during. The detailed information on this is given in Part 2. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision.  
 
Part 2 
What will happen if I don’t want to carry on with the study? 
If you decide to withdraw from the study before or during the study visit this will not affect 
your clinical treatment at all.  You may elect to withdraw from the whole study, or to 
contribute only to a part of the study (for example if you wish to give a breath sample, but 
not a urine sample, or vice versa), in which case we will use only the sample(s) you have 
agreed to provide. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number 01772 
523237). You may ask a researcher to clarify anything about the study at any time, both 
before and during sampling. If you remain unhappy and wish to complain formally, you can 
do this through the NHS Complaints Procedure. Details can be obtained from the hospital. 
In the event that something does go wrong and you are harmed during the research due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against Lancashire Teaching Hospitals NHS Trust but you may have to pay your legal costs. 
The normal National Health Service complaints mechanisms will still be available to you (if 
appropriate). 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised. 
Involvement of the General Practitioner 
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With your consent, your General Practitioner will be informed of your participation in this 
study. 
What will happen to the samples I give? 
The breath samples are collected in small tubes that will be sent to the Department of 
Chemistry at Loughborough University for processing.  Your name will be removed, and the 
samples identified only with a code number and initials. The urine sample will be processed 
here at Preston Hospital and sent for analysis to AstraZeneca laboratories at Alderley Edge.  
Your name will also be removed from these samples which will be identified by code 
number and initials only.  No genetic testing will be performed on any of your samples. 
What will happen to the results of the research study? 
It is intended to publish the results of this study in a scientific journal. Data generated will be 
kept at both Astra Zeneca laboratories at Alderly Edge and the Department of Chemistry at 
Loughborough University. Your name and address will not be kept at either of these 
locations and the data will only be made available to people who are directly involved with 
the study. 
Who is organising and funding the research? 
This study is a collaboration between Lancashire Teaching Hospitals, the Universities of 
Manchester and Loughborough, and AstraZeneca, and has been planned and funded jointly 
by these institutions. 
Who has reviewed the study? 
This study has been reviewed and given favourable opinion by the regional Research Ethic 
Committee to protect your safety, rights, wellbeing and dignity. 
Who should I contact for further information? 
Dr Stephen Fowler 
Lecturer and Honorary Consultant in Respiratory Medicine 
Lancashire Teaching Hospitals NHS Trust 
Royal Preston Hospital 
Fulwood 
Preston 
PR2 8BP 
Tel: 01772 523237 
Thank you for taking time to read this information sheet and considering helping us with 
our research.  Please retain a copy for your reference. 
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Appendix V 
Volunteer Questionnaire 
Detection of volatile organic compounds in the exhaled breath of 
patients referred to the chest clinic at (state location): a pilot study 
We will be measuring the chemicals in your breath. Some of these will have come from your 
diet, lifestyle it helps us a lot if you are able to go through the questions below and provide 
us with as much information as you can about: make-up, diet and activity All answers will be 
treated in confidence, with none of your answers being released outside of the research 
team and no-one other than the principal investigators will be able to link your name to 
your answers. 
Volunteer Questionnaire: 
Date: 
Patient details 
Name  
Patient Reference  
Age  
Sex  
Ex/current Smoker?  
Pack Years  
Average Calories per day  
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Today 
Are you wearing any make-up? 
Have you used any facial 
products? 
 
Are you wearing any perfume?  
Have you used any 
toothpastes/ mouthwash? 
 
Have you eaten at all prior to 
procedure? If yes, what have 
you eaten? 
 
Have you drunk anything other 
than plain water? If yes, what? 
 
Last bowel movement? 0-2 hours              2-6 hours              6+hours 
  
 
Exposure within the last 72 hours? Place of exposure 
Petrol  
Dry cleaning  
Alcohol  
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Cigarette Smoke  
Freshly painted surfaces  
 
This week 
Average alcohol 
intake (units): 
 
Portions of: Fish Cheese Fruit 
Caffeinated 
drinks(cups/cans): 
Tea Coffee Soft drinks 
 
Researcher use only: 
Sampling equipment: 
Tube 1: Tube 2: Tube 3: Tube 4: Tube 5: 
Mask No.:  
Capillary 
Number: 
 
 
Notes: 
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Appendix VI 
Designing and implementing a collaborative breath sampling 
clinical campaign within the National Health Service (NHS) 
Introduction 
Breath sampling research can take place in many different locations depending on its aim. 
Where the subjects are healthy volunteers they can normally be recruited through the 
research institute where the sample collection and analysis can be performed in the same 
place. While healthy volunteers and others with less debilitating symptoms can reasonably 
be asked to attend a laboratory for sampling, people with serious conditions and perhaps 
with much reduced life expectancy cannot be asked.  
Ethical approval for studies that seek to ask participants with extremely serious clinical 
conditions to travel to a research facility will not, nor should it, be granted ethics This means 
that for volunteers in this group the recruitment and sampling must take place at a location 
convenient to them, and in such a manner that does not put under any undue stress on 
them. The best approach is to locate the research facility into the hospital or clinical 
infrastructure. Researchers in these locations have access to clinics for volunteer 
recruitment and the necessary analytical instrumentation to process the samples rapidly. 
However breath profiling is not a mainstream clinical approach and at the moment 
researchers do not have access to both volunteers and the analytical instrumentation. 
Multiple site collaboration allows such studies to proceed. Within the UK research, 
collaboration between an NHS facility and a research team enables techniques of potential 
benefit to clinicians in the future to be developed without the expense and risk of disruption 
the clinical operation to a significant extent. There are, however, many steps and processes 
that must be accomplished to establish the research concepts, infrastructure and access to 
the clinics to meet with volunteer participants to take samples. All of this activity needs to 
be planned and managed from the outset of the proposed research collaboration. 
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This chapter describes the activity and preparation needed to ensure a clinical study can 
take place. An important element in this is the documentation that must be generated to 
accompany such activities. The project management aspects are also discussed along with a 
timeline, in the form of a Gantt chart. 
Initial discussion with clinical lead 
The clinical lead should be a senior and experience member of the clinical staff where the 
proposed research is envisaged to occur. Initial discussions with the clinical lead address the 
proposed research and enable the clinical expert to assess the proposed sampling campaign. 
After which the clinical lead will also lead the external researchers through the: 
 Recruitment of volunteer participants; 
 Location for sampling within the NHS site; 
 Possibility of NHS staff assisting during the campaign and; 
 The amount of access the external researchers will be granted to the volunteers.  
During these initial discussions the researchers should develop a plan that describes and 
justifies: 
 How many samples are needed from each volunteer participant; 
 How many volunteer participants are needed; 
 How the samples are to be analysed: 
 How the data are to be processed and; 
 What, if any, metadata from the participant’s medical records will be required. 
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Study plan 
It is essential to develop a detailed plan of the whole study, from initial recruitment through 
sampling, analysis and data processing. This study plan will form the basis of any research 
protocol that will be prepared. Most aspects of the study plan should have been discussed 
at the initial meetings with the clinical lead. There are several important questions that this 
plan should seek to address, these are: 
 How will volunteers be recruited and where will they be recruited from? 
 Who will take the volunteers consent? 
 Where will samples be taken? 
 How many samples will be taken and how long will a volunteers visit last? 
 What are the logistics for transporting/delivering the samples to the laboratory? 
 How will the samples be analysed? 
 How will the data be processed? 
 Who will have access to sensitive volunteer information? 
By answering all these questions the major points for the research protocol will be covered. 
There may not be answers to some of these questions, such as where sampling will occur, 
but the answers should seek to provide specifications so identification of suitable sites and 
procedures at a later stage is straightforward. In this work for example the sampling site was 
specified as: 
“A quiet room with space for a researcher and a volunteer, with a medical air line to 
supply the breath sampler and three 13 A 3-pin sockets for the sampling equipment. A 
comfortable chair/bed for the volunteer to use during sampling and a table to set up 
the sampling equipment is also needed.” 
Once such a specification has been established in the study plan identifying possible sites 
becomes more straightforward. Later on in the study it became clear that most volunteer 
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participants had at least one person accompanying them, and so their comfort and welfare 
also needed to be taken account of. 
Obviously the study plans evolve and develop and specification may change. For example in 
this project the recruitment procedure was modified to allow the participant to waive the 
24 hour period of reflection if the participant was happy to do this; collecting samples on 
their initial clinical visit was found to be more convenient for them than planning a follow-
up visit. This was because the volunteers attended the chest clinic in the morning, 
underwent diagnostic tests from mid morning to early afternoon and then saw their 
consultant for a follow up later on in the afternoon. This meant that the volunteers had a 
large period of time where they were at the clinic and could give samples. While this was 
mentioned in the ethics application forms, it was submitted as a change as this became the 
norm and it was felt by the researchers that the ethics board should be informed of this. 
Changes like this are to be expected and the plan should evolve with the study, but having 
an initial plan can help highlight these problems early on. 
In summary all activities should be fully planned and understood along with the expected 
research outcomes. Once a study plan has been discussed and finalised it is time to write 
the research protocol. 
Ethics 
When a study requires interaction with volunteers from a clinical setting, an ethics 
application must be made to the relevant NHS regional ethics board. Making an ethics 
application means submitting a proposal to a NHS regional ethics board, who will then 
review and make a decision as to whether the research is worthwhile. The members of the 
ethics board will take into account potential benefits and risks, and whether all the expected 
ethical standards have been met. 
There are two documents that are required for an ethics application, the research protocol 
and the online ethics application form. Supplementary material such as participant 
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questionnaires should be included in the research protocol. This section describes these and 
reviews the online ethics forms that must be completed so the application can be made. 
Research protocol 
The protocol must make the case for the research; discuss the relevance of, and the need 
for, the study. This is the document on which the research will be judged, and a decision will 
be made as to whether the research meets the required standards. There are many factors 
that will be considered when deciding if the research reaches the standard required for 
ethical approval including the following five general areas; 
It will take into account the volunteers who will be asked to participate and they must not 
be put under any unnecessary stress, 
Any potential benefits from the study must be outlined, 
What access, if any, to volunteers medical records must be outlined, along with who will 
have access to the information and what will be done to keep volunteer involvement 
confidential, 
What the data will be used for, what processing it will undergo and what output is expected, 
What, if any, analysis of samples containing volunteer DNA will be undertaken, where any 
such samples will be stored and what the data will be used for. 
The ethics committee will often provide the researchers with constructive feedback to assist 
them in undertaking better designed and more skilfully executed work to higher ethical 
standard. For example: 
During the writing of the protocol for the study in two week wait patients the aim of 
the study was altered from investigating volunteers with lung cancer to investigating 
volunteers urgently referred to the two week wait clinic. This change was because the 
point of sampling could occur before the volunteer had received a diagnosis from a 
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clinician and any mention of lung cancer in the study documents would cause undue 
stress. This is an example of where a study needs to be changed so it can be ethically 
conducted. Volunteers with lung cancer would still be included in the study, as 
volunteers could be selectively recruited based on the clinicians’ prior knowledge, but 
no undue or unnecessary stress would be caused in any volunteers. Submitted with 
the research protocol should be any patient information forms (Appendix IV) and 
questionnaires (Appendix V) and any other forms that are required. The Research 
Protocol for this work is included in Appendix III. 
Online ethics forms 
Once a research protocol has been finished, the online ethics application forms must be 
completed and submitted, along with the research protocol, for ethical approval. These can 
be found at www.myresearchproject.org.uk. Much of the information required for these 
forms can be extracted from the research protocol. The bulk of the forms can be completed 
by the external researcher, with the clinical lead completing any questions relating to the 
NHS location and clinical aspects of the trial. 
Ethics approval meeting 
Once the Ethics documentation has been submitted, a meeting will be scheduled by the 
regional ethics board where the research will be discussed between the members of the 
board, and any recommendations can be made. The researchers are invited to the meeting 
so they can answer any questions the panel may have regarding the study. Once this 
meeting has taken place the board will make their decision and pass their recommendations 
on the researchers. The board may grant the study approval after the first meeting or the 
recommendations may require changes to be made to the protocol. If changes are required 
the ethics application may need to be re-submitted and reconsidered. Sometimes the 
changes are minor and the board requires written notification that they have been made 
before they grant approval. 
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Once approval has been granted by the regional board, the documentation can be passed 
on to the location ethics board. 
Local ethics approval meeting 
Once the regional NHS trust ethics board has granted the study ethical approval, the 
documentation must be past to the NHS locations local ethics board for approval. The local 
ethics board will review the applications and make recommendations for any changes they 
feel are necessary to the protocol. With these changes made the ethical approval process is 
completed. 
Researcher documentation 
There are several pieces of documentation required for different stages of the study. The 
bulk of this documentation is required for any researcher who wishes to obtain an honorary 
contract with an NHS location. An honorary contract is required for researchers who wish to 
participate in taking samples from volunteers. 
Curricula Vitae 
The chief investigator, research student supervisor and research student must all submit 
curriculum vitae along with the ethics application documents. 
NHS research passport 
Outside researchers are required to hold a research passport if they wish to work within an 
NHS location and they fall within the pre-defined groups set out in the literature. 
Documentation is available from the National Institute for Health Research on who requires 
a research passport and how to apply for one [158]. The research passport allows 
researchers to obtain an honorary contract to allow them to carry out research within NHS 
locations. It was implemented so that external researchers could move from one NHS site to 
another and obtain an honorary contract without having to fill out the same paperwork at 
each location. 
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Research passport documents 
There is a standard form to be filled out and a set of checks that are carried out on every 
researcher who applies for a research passport. This means that a researcher can move 
between locations and start new studies without the need for the same checks being carried 
out each time. As well as the forms that must be submitted there are two independent 
checks that may be required depending on the work being carried out. These are an 
occupational health check and a criminal records bureau check. 
Occupational health 
An occupational health check is required in some circumstances, depending on what 
research is being carried out. This check is undergone at the researchers’ place of 
employment, not within the NHS. The occupational health check will make sure the 
researcher is capable of carrying out the work within the hospital. It will also make sure that 
the researchers’ immunizations and vaccinations are up to date so they are not a risk to the 
volunteers they must interact with. This protects both the researcher and the NHS location 
where they will be working as it provides evidence that they are fit to work. The 
occupational health department will require the research protocol so they can assess what 
work will be undertaken within the NHS and what checks must be made. If any amendments 
are made to the protocol that may require additional checks, the researcher should inform 
the occupational health department. Once the checks have been carried out and the 
researcher has been cleared to work, the forms must be signed and passed back to the 
department coordinating the application for the research passport. 
Criminal records bureau (CRB) check 
The criminal records bureau is “…an executive agency of the Home Office set-up to help 
organisations make safer recruitment decisions [159]”. A full and detailed description of the 
checks that can be carried out, a list of the data sources they use and their code of practice 
can be found on their website [160]. The CRB check is carried out to make sure the 
researcher is suitable to carry out certain aspects of the study. This may include interacting 
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with vulnerable patients such as children or vulnerable adults, having access to patient 
medical records or operating within patient areas of an NHS hospital. The CRB check must 
be sponsored by the researchers’ employer. The forms that are required will be issued to 
the researcher, who must fill them out and return them to be processed and sent to the 
CRB. Notification of the result of the check will be sent to the researchers’ address, this may 
take 2-3 months and this time should be allowed when planning the clinical study. Once the 
check results have been received a copy of them should be sent to the department who are 
coordinating the application for the research passport. 
Honorary contract 
Once the research passport has been completed and signed off, the researcher can apply for 
an honorary contract with the NHS location where the research will be carried out. While 
the research passport is required for the researcher to apply for an honorary contract, the 
honorary contract is required if the researcher wishes to work within the NHS. Once an 
honorary contract has been granted, the researcher is allowed to interact with volunteers 
without direct supervision from the clinical staff. This means that the researcher can 
operate within the hospital without interrupting the clinical staff when they are working. 
Clinical location set up 
Identification of sampling site 
The identification of a suitable sampling site is discussed during the initial research meetings 
with the clinical lead. The description of a suitable location and the required elements will 
have been set out in the study plan to specify an appropriate site. It is helpful to note that 
there are several things that need to be taken into account when locating a site within a 
large organisation such as an NHS hospital. As many of the possible locations could be in 
different departments, discussion with the relevant staff about availability of sites will help 
eliminate anything unsuitable. Depending on the demographic of the volunteers, it may be 
necessary to limit the site to a specific area of the hospital. Also, the required services, 
particularly the medical air line, are likely to be in very specific, and possibly limited, places. 
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The clinical lead should be able to identify any suitable possibilities and once this has been 
done an inspection of each site and discussion between the clinical lead and the external 
researchers should limit the sites down to one or two. These sites can then be discussed to 
confirm availability and a specific site can be chosen. 
Installation and testing of sampling equipment at site 
Once a site has been chosen it is then necessary to install and test the sampling equipment. 
In this study all the sampling equipment could be transported to and from the sampling 
location, meaning that secure storage of the equipment was not an organisational factor 
problem. Tests were conducted on-site to ensure that all the equipment functioned 
properly and the site was comfortable for the volunteers and the researchers. On site 
testing allowed any mechanical faults with the sampling equipment caused by transport 
from the laboratory to be identified and fixed. A major element of the breath sampling 
equipment is the medical air supply pressure required to pressurise the external air filters. 
Medical air is supplied via a generator within NHS hospitals and it must be regulated to a 
maximum pressure of four bars when being used to supply air to a face mask. This is an 
important and small detail that reflects the need for careful and detailed assessment of the 
site. 
Volunteer recruitment 
The process of volunteer recruitment will have been set out in the ethics protocol. This will 
have been reviewed by the ethics board and approval given. This process should be 
discussed with the relevant clinical staff. In the case of this research, the clinicians who ran 
the two week wait clinic and a research nurse recruited the volunteers. The role of research 
nurses in this aspect is very important as they generally are able to achieve effective rapport 
with the population of potential volunteers and answer questions in a straight forward and 
empathetic way. Clearly, it is important to provide the clinical staff with straightforward 
briefings about the research and effective summaries of the participant information sheets. 
Researchers should ensure that they are available to discuss the ethics and associated 
protocol, the volunteer information sheet (Appendix IV) and to answer any questions with 
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the clinical team. The researchers need to ensure that everyone involved in the study knows 
what the aims are and what is required for it to be successful. Staff changes are normal in 
many clinical settings so the researchers should plan to do this regularly. 
Infection control 
Different clinical settings have different local rules regarding infection control. It is essential 
that the research team inform themselves of the local rules and abide them. The 
preparation of the sampling equipment necessarily involves cleaning and disinfection of the 
components that are reused. Appropriate training, supervision and audit are required to 
ensure that this essential element is correctly followed. 
Breath sampling 
Before the study can start, the breath sampling procedure needs to be thoroughly tested. 
This will highlight logistical requirements as well as test the sampling equipment again. The 
whole process should be tested from sample transport, sample acquisition to sample 
recovery and analysis. (This means that if it is planned to post the samples from the clinical 
location to the laboratory this should be done, even if the researcher is currently travelling 
between locations during the set-up.) These tests also allow clinical staff to observe the 
process, provide suggestions and observations and ask further questions that occur to them. 
It may be that clinical staff will take over the sampling and so the initial sampling run 
through provides a good starting point for training. Once the run through has been 
completed and the process and logistics have been tested and are satisfactory, the study 
can be begun. 
Sample analysis 
The analytical protocol must be validated before the study starts, normally before the study 
is discussed with the lead clinician, although further development of the analysis method 
can continue until the samples have started to be collected. The samples must be 
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catalogued so that they can be traced back to the volunteer who gave them, but should not 
include any personal information. 
Sample storage and transport should be considered. For this work, as no storage study of 
adsorbent trap breath samples has been carried out, the samples were transported in 
“freezer packs” and stored at 4 degrees Celsius. All samples were analysed within 72 hours 
of sampling. 
All the samples should be analysed using the same method of analysis so that they are 
directly comparable. This means that the instrumentation must be established in the 
laboratory and maintained to a high standard during the period of the study. In this work all 
of the samples were analysed on a thermal desorption gas chromatography mass 
spectrometry/differential mobility spectrometry platform. This provided two different sets 
of data for each sample, so gaining the maximum amount of information for each sample 
collected. 
Flow diagram and Gantt chart 
Using a flow diagram illustrates the relationships between the steps that are needed to set 
up the clinical study. It gives researchers an easy reference to check where they stand in 
each individual task, and what needs to be done to complete them. As a quick reference 
tool it can keep the work focused on the required tasks and make sure everyone in the team 
knows what is required. As a tool it gives a project manager a quick guide as to what is 
required of each team member at each stage of the project and means that the next steps 
can easily be moved on to. 
A useful tool for planning a study is a Gantt chart. A Gantt chart allows a team to see what 
steps need to be taken and when along a project timeline. It allows them to see what should 
be being worked on at any point and what goals need to be achieved at certain times. It 
shows what tasks need to be completed before other tasks can be started and assigns the 
workload for each person working on the project. Like the flow diagram it shows any 
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dependencies for each task and can also show the percentage complete of each task during 
the process. 
Figure 5-1 and Figure 5-2 show a flow diagram and an “idealised” Gantt chart for setting up 
a collaborative breath sampling study within the NHS. 
  
291 
 
Appendix VII 
Table 1 Compounds found in the breath of participant CV-08 
 Compound M/Z observed in 
1.438 Benzene 77.9 76.9 49.9 50.9 51.9 73.9 BC1, BC2 
Intensity 155152 29752 28566 27522 22896 11755 BC1, BC2 
1.608 No Hits 72.8 73.8 54.7 56.7 55.6 74.7 BC2 
Intensity 39300 32743 10867 10048 6293 5767 BC2 
1.683 No Hits 76.9 44.9 72.8 77.8 69.3 56.5 BC2 
Intensity 24844 8086 7464 3573 3045 2870 BC2 
1.739 No Hits 93.9 92.3 44.9 96.4 91.2 94.9 BC1 
Intensity  39459 10395 9632 8603 6920 5143 BC1 
1.926 No Hits 82.4 54.6 80.8 66.9 93.7 79.7 BC1 
Intensity  18576 17821 8639 5366 4854 4566 BC1 
2.395 Toluene 90.9 91.8 62.9 64.8 92.9 88.9 BC1 
Intensity  503719 291569 59234 33341 26039 24945 BC1 
2.75 No Hits 93.9 175 176.9 176 93 91.8 BC1 
Intensity  28518 17163 13894 8977 8348 8308 BC1 
3.003 No Hits 94.4 96.7 44.9 95.6 92.6 76.8 BC1 
Intensity  45503 11153 9445 6064 4480 4016 BC1 
3.434 No Hits 94.4 72.8 73.7 44.9 54.8 96.7 BC1 
Intensity  19075 14738 11432 7432 5287 5201 BC1 
4.046 p-xylene 91 105.8 94.9 91.9 77.9 105.1 BC1, BC2 
Intensity  113272 24225 10539 9314 8927 8754 BC1, BC2 
4.253 o-xylene 91 105.9 105.1 94.9 79 92 BC1 
Intensity  104722 50672 16470 13687 10854 8840 BC1 
4.422 No Hits 102 75.9 73.9 49.9 63 74.9 BC1 
Intensity  19659 4622 3885 3807 3459 3310 BC1 
4.792 styrene 104 78 91 103 105.9 50.9 BC1, BC2 
Intensity  91752 54005 50443 46519 28467 18711 BC1, BC2 
4.851 No Hits 72.9 55.7 54.8 69.7 68.8 96.5 BC2 
Intensity 4283 4259 3566 3531 3466 2158 BC2 
5.076 No Hits 56.7 55.8 84.5 54.8 73 69.8 BC1 
Intensity  11594 4363 4236 3313 2689 2598 BC1 
5.962 No Hits 92.9 91 91.9 78.9 151 77 BC1 
Intensity  26880 15800 13047 8785 6877 6144 BC1 
6.608 No Hits 90.9 149 72.9 91.9 151 119.6 BC1 
Intensity  16198 3610 3373 3264 3213 2999 BC1 
6.9 2-chloro-acetophenone 104.9 76.9 50.9 94.9 49.9 105.7 BC1, BC2 
Intensity  218848 83585 58736 45837 42413 26801 BC1, BC2 
7.143 No Hits 94 105 120 66 95 63 BC1 
Intensity  11806 10752 5766 5317 4404 4141 BC1 
7.378 Phenol 94 66 92.9 64.9 91 63 BC1 
Intensity  24405 11671 10418 5520 5493 5034 BC1 
7.416 No Hits 94 66 105 92.9 64.9 91 BC1 
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Intensity  23688 15470 13462 7934 5520 5141 BC1 
7.597 Phenol 93.9 66 64.9 62.9 61.9 94.9 BC2 
Intensity 99002 43159 17651 9186 6317 6264 BC2 
7.668 Benzonitrile 103 75.9 66 93.9 50 75 BC1 
Intensity  99088 28782 21178 16121 15349 14613 BC1 
9.249 No Hits 56.7 55.7 69.8 54.8 82.7 57.7 BC1, BC2 
Intensity  222443 29467 24761 15865 12230 8761 BC1, BC2 
9.332 Limonene 92.9 79 67 93.8 67.8 90.9 BC1, BC2 
Intensity  34674 27240 27177 22600 16346 15377 BC1, BC2 
9.509 Hydrocarbon 56.7 69.8 70.6 55.7 54.8 82.7 BC1, BC2 
Intensity  80687 42328 33793 27793 25507 20663 BC1, BC2 
9.646 Benzyl Alcohol 78.9 76.9 106.9 107.9 72.8 50.9 BC2 
Intensity 16654 5389 4916 4644 3751 3738 BC2 
10.075 No Hits 56.8 69.8 70.6 55.8 54.8 82.7 BC1 
Intensity  51298 28256 18031 17706 10741 7989 BC1 
10.746 2-chloro-acetophenone 104.9 76.9 50.9 94.9 49.9 105.9 BC1, BC2 
Intensity  81905 32830 24083 16134 8891 5349 BC1, BC2 
12.52 No Hits 81.1 66.9 69.7 95 55.7 56.8 BC1, BC2 
Intensity  21390 17263 16023 15415 15236 13817 BC1, BC2 
16.813 methylated alkane 80.9 67 67.9 54.7 82.8 81.8 BC1, BC2 
Intensity 14768 12693 8715 8025 7997 7841 BC1, BC2 
16.79 No Hits 80.9 67 67.9 82.8 54.8 81.9 BC1 
Intensity  28517 23597 17643 17127 15827 14212 BC1 
20.296 No Hits 117.1 90 141.1 142.1 88.9 62.9 BC1 
Intensity  33308 15631 14894 14641 12439 7540 BC1 
23.958 No Hits 91 119 105 92.9 72.9 93.9 BC1 
Intensity  10628 9673 7094 6901 6703 6370 BC1 
28.027 No Hits 107 93 69 79 151 91 BC1 
Intensity  17248 11602 10275 7018 6169 5504 BC1 
 
Table 2 Compounds found in the breath of participant CV-14 
 Compound M/Z Observed 
in 
1.403 Benzene 78.1 50 51 77 55.8 52 JL1, JL2 
Intensity  487927 118291 92466 82742 62504 62173 JL1, JL2 
1.548 No Hits 40.9 43 73 74 54.9 69.7 JL2 
Intensity  59973 48989 44245 38604 35878 35253 JL2 
1.611 No Hits 40.8 42.9 77.1 39.9 69.7 70.5 JL2 
Intensity  52226 46437 46075 20341 19718 18744 JL2 
1.728 No Hits 44.9 43 88.7 40.8 42 60.9 JL2 
Intensity  115876 94660 40881 23842 17396 15064 JL2 
1.837 No Hits 82.7 54.9 40.9 42.9 55.8 41.8 JL2 
Intensity  93209 65141 46832 29850 27771 22963 JL2 
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1.927 No Hits 45 39.9 40.9 87.9 43 73 JL2 
Intensity  23216 18830 17718 16017 15876 10046 JL2 
1.982 No Hits 79.1 40.9 42.9 95 39.9 77.1 JL2 
Intensity  29255 18115 17467 15365 14174 13774 JL2 
2.272 Toluene 91.1 92.1 63.1 65 50.1 51.1 JL1, JL2 
Intensity  1009669 700375 168262 83594 75943 75217 JL1, JL2 
2.434 No Hits 96.6 40.9 54.8 40 68.9 91.2 JL1, JL2 
Intensity  87986 35749 34370 20063 18598 17817 JL1, JL2 
2.706 No Hits 40.8 42.6 96.7 84.2 55 41.8 JL1, JL2 
Intensity  67152 45187 41058 30729 26549 25294 JL1, JL2 
2.742 Hexanal 40.8 55.8 42.9 43.9 71.6 54.8 JL1, JL2 
Intensity  84767 75661 48478 47649 32883 26555 JL1, JL2 
2.824 1,1-dimethyl-
cyclohexane 
96.6 40.8 54.9 39.9 43 55.7 JL2 
Intensity  65551 28365 26163 14654 12145 10897 JL2 
2.841 No Hits 96.1 42.9 95.1 54.9 40.9 91.1 JL1 
Intensity  34613 29048 26442 24533 17384 9672 JL1 
2.877 No Hits 94.3 95 43 93.7 96.3 44.9 JL1 
Intensity  49958 33468 30832 29989 17903 16789 JL1 
2.958  43 42 94.9 60.5 91.2 67 JL1 
Intensity  343372 75329 14355 13112 11333 10835 JL1 
3.259 cyclohexane 
derivative 
68.8 110.5 40.8 54.8 39.9 109.5 JL2 
Intensity  200828 98286 56486 43800 21650 20192 JL2 
3.293 No Hits 68.8 110.5 40.7 54.9 72.9 109.5 JL1 
Intensity  187022 93645 51954 45164 38777 33595 JL1 
3.295 cyclohexane 
derivative 
82.8 81.5 40.8 55 68.8 67.1 JL2 
Intensity  57543 54604 44200 37752 27266 16509 JL2 
3.385 No Hits 68.8 110.6 40.8 81 80 40 JL2 
Intensity  65605 42256 38196 22157 20869 16820 JL2 
3.388 No Hits 82.7 81.2 54.8 40.7 94.4 67.1 JL1 
Intensity  71342 49425 46212 32104 24388 21198 JL1 
3.401 No Hits 68.7 110.7 40.7 95.1 54.8 82.9 JL1 
Intensity  79123 46302 32926 25437 17563 15417 JL1 
3.694 cyclohexane 
derivative 
68.8 110.6 40.9 54.9 55.7 69.8 JL2 
Intensity  420667 263212 134452 75528 51784 45857 JL2 
3.718 Cyclohexane 
based structure 
68.8 110.5 40.8 54.9 69.5 55.8 JL1 
Intensity  557060 313287 154414 90250 58606 53022 JL1 
3.853 o-xylene 91.1 105.9 51.1 95 92.1 50.1 JL1, JL2 
Intensity  178467 31359 22155 20926 18778 15835 JL1, JL2 
3.892 No Hits 91 42.9 40.9 68.9 39.9 56.8 JL2 
Intensity  39824 38583 37137 17122 16658 11727 JL2 
3.928 No Hits 42.9 91.1 40.9 56.7 39.9 68.9 JL2 
Intensity  40776 34587 33285 21944 16551 14095 JL2 
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4.037 p-xylene 91.1 106 105.2 77 79.1 63.1 JL1, JL2 
Intensity  986701 673788 203207 125484 89969 89466 JL1, JL2 
4.208 cyclohexane 
derivative 
68.7 110.6 40.8 54.8 109.6 55.8 JL1, JL2 
Intensity  242073 140196 91611 70897 48670 47192 JL1, JL2 
4.298 cyclohexane 
derivative 
68.8 110.6 40.9 55 69.7 55.8 JL1, JL2 
Intensity  234336 150607 90181 61144 52457 45460 JL1, JL2 
4.38 cyclohexane 
derivative 
68.8 40.9 110.6 54.9 96.8 55.6 JL1, JL2 
Intensity  134391 62426 61584 41977 31677 30650 JL1, JL2 
4.403 No Hits 96.7 54.9 40.9 68.7 95 81.1 JL1, JL2 
Intensity  386988 159513 88429 69592 61835 55288  
4.56 No Hits 91.1 106 104.1 103.1 51 78.1 JL2 
Intensity  496872 282183 273617 114632 109333 104686 JL2 
4.584 No Hits 91.1 96.7 95.9 95.2 54.9 106 JL1 
Intensity  123852 118046 81973 73509 61148 55015 JL1 
4.819 methylated 
alkane 
56.8 40.8 42.8 84.3 56 69.6 JL1, JL2 
Intensity  219390 210265 167512 110838 77514 69293 JL1, JL2 
4.918 long-chain 
alcohol 
40.9 95.9 68.8 69.7 95 54.9 JL1, JL2 
Intensity  80773 70373 64078 60966 58243 52783 JL1, JL2 
4.99 ring structure 
hex/pent? 
96.7 54.9 96 40.8 68.8 81.1 JL1, JL2 
Intensity  354015 143703 138952 119654 110705 52697 JL1, JL2 
5.065 No Hits 96.7 40.8 54.7 95.6 68.8 81.3 JL2 
Intensity  71914 44296 42097 37619 25441 16411 JL2 
5.315 hydrocarbon 81.1 67.1 95 40.8 79.1 54.8 JL1, JL2 
Intensity  138357 101463 50289 39826 32399 22631 JL1, JL2 
5.292 No Hits 81.1 67.1 40.8 95.1 79.2 82.7 JL2 
Intensity  114456 76152 41499 32179 26439 25109 JL2 
5.626 No Hits 81.3 82.7 54.8 40.9 67 80.1 JL2 
Intensity  252663 232464 150312 123647 91454 43895 JL2 
5.641 hydrocarbon 81.4 82.8 54.8 67.1 40.9 42.7 JL1 
Intensity  258208 219386 170555 107408 89729 29573 JL1 
5.743 No Hits 56.7 40.8 70.2 42.7 55.8 69 JL2 
Intensity  76799 67353 53884 436110 43079 29600 JL2 
5.767 methylated 
alkane 
70.6 40.9 56.8 69.8 42.7 56.1 JL2 
Intensity  84270 81475 67379 51185 50615 43765 JL2 
5.888 methylated 
alkane 
68.7 40.8 56.7 69.8 110.7 54.8 JL1, JL2 
Intensity  94801 57368 51100 46479 38399 31745 JL1, JL2 
5.951 No Hits 68.8 40.8 69.6 55 40 123.9 JL2 
Intensity  37730 34090 15989 14523 13962 13904 JL2 
6.101 methylated 
alkane 
67.1 81.2 95 40.9 68.8 91.1 JL1 
Intensity  37957 36486 31509 26964 19809 16199 JL1 
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6.259 No Hits 68.8 40.8 109 40 81 54.9 JL2 
Intensity  35764 26351 18319 17004 13661 13551 JL2 
6.444 No Hits 68.8 40.9 69.8 124.1 82.6 54.9 JL1 
Intensity  102491 79972 63519 57792 56967 55572 JL1 
6.548 No Hits 105.1 68.7 40.8 110.5 42.7 39.8 JL2 
Intensity  78147 56681 50850 35728 26467 23242 JL2 
6.62 No Hits 105.1 77 68.8 51.1 50.1 40.9 JL1, JL2 
Intensity  369808 127277 101328 84515 71609 53668 JL1, JL2 
6.759 No Hits 40.8 56.8 81.1 42.8 94.1 69.7 JL1, JL2 
Intensity  70699 59519 59219 35049 30223 30092 JL1, JL2 
6.81 No Hits 105.2 40.8 39.9 120.1 77 56.8 JL2 
Intensity  37096 26752 18061 15052 11954 11811 JL2 
6.955 No Hits 81.1 40.8 95.6 54.9 56.7 96.6 JL1, JL2 
Intensity  85814 82037 57815 56125 54329 53652 JL1, JL2 
7.057 No Hits 68.8 95.1 40.8 93.1 81 43 JL1, JL2 
Intensity  62912 39001 35089 28456 28160 27256 JL1, JL2 
7.355 No Hits 96.6 95.9 54.9 68.9 40.9 81 JL1 
Intensity  159496 88711 87586 65683 57867 44802 JL1 
7.649 1,2,3-
trimethylbenze
ne 
105.1 120.1 40.9 78.9 91.1 81.1 JL2 
Intensity  87025 40835 20708 19599 19591 17172 JL2 
7.748 No Hits 96.6 68.8 40.9 54.9 69.8 81.1 JL2 
Intensity  62380 45061 34919 28566 20692 18409 JL2 
7.993 methylated 
alkane 
56.7 40.8 42.6 70.6 55.8 69.6 JL1, JL2 
Intensity  244921 224585 171377 115562 87022 84462 JL1, JL2 
8.146 No Hits 40.8 68.8 81 67.1 42.8 55.7 JL1, JL2 
Intensity  112893 82726 67777 61728 59046 55369 JL1, JL2 
8.78 No Hits 40.8 119.1 68.9 70.6 82.6 81.2 JL1, JL2 
Intensity  43589 29976 26175 24792 24648 23696 JL1, JL2 
8.952 Limonene 93 67.1 79.1 93.9 67.9 91.1 JL1, JL2 
Intensity  256339 183602 121910 115308 113682 85016 JL1, JL2 
9.096 methylated 
alkene 
40.8 56.8 82.7 69.8 54.8 55.9 JL2 
Intensity  269060 233240 159255 145344 138924 119930 JL2 
9.124 No Hits 56.7 40.8 82.7 69.7 54.9 55.8 JL1 
Intensity  170952 162019 147143 96162 84410 71105 JL1 
9.25 Benzyl Alcohol 79 107 108 77.1 91 51 JL2 
Intensity  365225 147843 145629 108074 64417 46995 JL2 
9.412 No Hits 40.9 78.9 69.3 54.8 55.8 39.8 JL2 
Intensity  28730 13418 13289 12641 12585 12151 JL2 
9.939 cyclohexane 
derivative 
81 95.1 67.1 137.5 40.9 81.8 JL1, JL2 
Intensity  53469 43313 41422 28893 24595 22413 JL1, JL2 
10.038 No Hits 40.8 119.2 42.8 56.8 54.9 40 JL2 
Intensity  32811 19861 13861 13150 12623 11208 JL2 
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10.22 No Hits 40.9 70 42.7 39.8 91.2 54.9 JL2 
Intensity  22795 13971 12043 12010 10354 10318 JL2 
10.283 No Hits 40.8 81.1 105.2 68.9 54.8 91.1 JL2 
Intensity  27329 14759 15640 13112 12305 12253 JL2 
10.374 2-chloro-
acetophenone 
105.1 77.1 51.1 95.1 106.1 50.1 JL1, JL2 
Intensity  229381 89340 51799 14471 14130 12957 JL1, JL2 
10.682 No Hits 40.9 68.9 56.8 39.8 91.1 67 JL2 
Intensity  37139 14832 14186 13278 13012 11882 JL2 
10.818 No Hits 40.9 68.9 81.1 58.9 56 43 JL1, JL2 
Intensity  31806 24958 20556 16968 16250 15479 JL1, JL2 
11.245 No Hits 43 121 91 40.8 40 77 JL2 
Intensity  40442 23593 14095 13205 12044 11346 JL2 
11.545 No Hits 57.9 43 40.8 56.6 39.9 68.8 JL2 
Intensity  39401 34853 27887 13695 13186 9835 JL2 
11.891 methylated 
Alkane 
40.8 56.8 42.8 70.5 69.8 68.8 JL1, JL2 
Intensity  71550 47530 36284 31987 27841 16323 JL1, JL2 
12.117 3-nonen-1-ol 40.9 81 95 69.6 68.7 67.2 JL1, JL2 
Intensity  235463 160904 154245 144443 113063 112285 JL1, JL2 
12.653 No Hits 40.9 82 39.8 91.1 68.9 79.2 JL2 
Intensity  14242 13378 9817 5914 5862 5771 JL2 
14.971 No Hits 128.2 81.1 40.9 95 67.2 68.8 JL2 
Intensity  42683 37222 29641 27860 21420 17054 JL2 
16.337 No Hits 81 40.9 82.7 67.1 95 67.9 JL1, JL2 
Intensity  218626 199072 174301 128542 108009 96154 JL1, JL2 
19.797 2-
methylnaphtha
lene 
141.3 142.2 115.2 81.1 40.8 39.8 JL2 
Intensity  65327 50861 15975 10199 10117 9889 JL2 
20.571 methylated 
alkane 
40.9 42.6 56.8 70.6 69.7 83.7 JL2 
Intensity  43598 36564 35702 31053 15271 14384 JL2 
20.598 methylated 
alkane 
56.8 40.9 42.7 70.6 69.9 84.5 JL2 
Intensity  45326 38008 31033 26728 19453 16188 JL2 
22.413 No Hits 42.7 82.8 40.9 70.4 69.2 88.9 JL1, JL2 
Intensity  96902 92545 76988 41989 37459 34836 JL1, JL2 
23.368 No Hits 93.9 105.2 91 119.2 93.1 107.1 JL2 
Intensity  45970 34948 32052 24639 23591 22704 JL2 
23.631 No Hits 88.8 42.8 40.9 70.1 55.8 68.8 JL1, JL2 
Intensity  103350 99539 86780 75326 71340 39594 JL1, JL2 
23.643 No Hits 40.8 88.8 42.7 70.3 55.8 68.8 JL1 
Intensity  88160 84659 79915 46974 46501 26877 JL1 
24.988 No Hits 161.2 91.2 79 93.1 105.2 133.1 JL1 
Intensity  72989 42819 29905 29126 28524 27920 JL1 
27.418 No Hits 43 107.1 40.9 68.8 93.1 79.1 JL1, JL2 
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Intensity  65600 57528 44351 44051 31443 25708 JL1, JL2 
30.01 No Hits 40.9 56.9 70.6 42.8 84.4 39.9 JL1 
Intensity  29122 24595 23659 20017 19184 11434 JL1 
30.847 No Hits 102.2 40.8 121.1 173.9 103.1 91.2 JL1 
Intensity  50195 15511 10265 10032 9290 7424 JL1 
34.613 No Hits 56.9 40.9 70.5 42.8 84.2 69 JL1, JL2 
Intensity  29535 22613 21327 14579 11505 9736 JL1, JL2 
35.14 Benzophenone 105.1 182.2 77.1 51.1 181.3 50.1 JL1 
Intensity  104985 67135 56582 42688 34883 13854 JL1 
35.43 No Hits 173.2 110.8 82.8 55 155.1 99 JL1 
Intensity  317669 86004 73003 72804 50985 44676 JL1 
 
Table 3 Compounds found in the breath of participant CV-16 
 Compound M/Z Observed in 
1.359 Benzene 78.4 43.1 41.2 51.4 50.4 77.3 RA1, RA2 
Intensity  167682 80205 75927 61182 55601 50478 RA1, RA2 
1.413 No Hits 41.1 43.2 55.9 40.2 69.9 42.1 RA1 
Intensity  68451 45102 38185 23808 20769 16188 RA1 
1.566 No Hits 77.3 73.1 74.1 45.3 56.1 57 RA1 
Intensity  152462 142383 119111 76360 75779 62934 RA1 
1.675 No Hits 45.2 43.3 88.9 41.2 77.3 42.4 RA1 
Intensity  223741 199863 173564 24454 23078 22765 RA1 
1.781 No Hits 43.2 45.2 55.2 73.3 83 41.2 RA1, RA2 
Intensity  65559 54428 42507 28555 25778 23060 RA1, RA2 
1.928 No Hits 40.3 41.2 43.3 55.1 69.5 45.2 RA1 
Intensity  17707 16002 14648 10108 8684 8553 RA1 
2.016 Methylated Alkane 45.3 43.3 44.1 73.3 40.2 42.2 RA2 
Intensity  119508 74213 24773 23217 21513 14024 RA2 
2.052 No Hits 45.3 73.2 43.3 41.3 40.3 67.3 RA2 
Intensity  90346 53775 42877 33801 29258 18276 RA2 
2.092 No Hits 40.3 43.3 73.2 41.2 44.3 91.3 RA1 
Intensity  20815 18734 18122 13337 8822 6296 RA1 
2.223 Toluene 91.4 92.3 63.4 65.3 62.4 89.3 RA1, RA2 
Intensity  677180 433847 107300 77830 43887 43412 RA1, RA2 
2.431 No Hits 60.1 73.3 41.1 42.3 43.2 45.3 RA1, RA2 
Intensity  64522 54809 31008 28678 24572 19705  
2.485 No Hits 151.4 149.3 45.1 73.2 133.4 43.3 RA2 
Intensity  131887 120765 110944 70647 51549 45616 RA2 
2.683 Hexanal 41.2 44.1 55.9 43.3 71.7 57 RA1, RA2 
Intensity  115768 93759 76929 40271 33689 29085  
3.317 No Hits 80.3 81.3 40.3 73.3 50.3 45.4 RA2 
Intensity  67990 43569 24569 15611 13128 9599  
3.743 o-xylene 91.4 106.2 51.4 105.4 40.3 69.4 RA1, RA2 
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Intensity  111122 27550 19411 15544 13456 11919 RA1, RA2 
3.943 p-xylene 91.4 106.2 105.4 77.3 103.4 79.5 RA1, RA2 
Intensity  166965 89719 50127 24691 18443 17061 RA1, RA2 
4.098 No Hits 102.4 40.2 43.4 73.2 91.6 50.5 RA1 
Intensity  23020 14459 9399 8701 7716 6648  
4.457 No Hits 91.5 106.3 105.4 104.4 45.3 51.4 RA1, RA2 
Intensity  134068 118495 61236 43994 38290 30726 RA1, RA2 
4.575 No Hits 42.2 55.2 69 80.2 41.1 83.2 RA1, RA2 
Intensity  58192 48782 41449 35444 34081 27704 RA1, RA2 
4.618 No Hits 40.3 41.1 69.1 55.2 42.1 43.2 RA1 
Intensity  13840 12374 9500 7402 7400 7309  
4.719 No Hits 72 81.9 43.3 83.4 41.2 56.9 RA1, RA2 
Intensity  69724 69310 62619 39450 32061 20549 RA1, RA2 
4.782 No Hits 151.4 44.2 133.5 41.2 156.7 69.5 RA1, RA2 
Intensity  180946 49986 48212 47621 46917 39108 RA1, RA2 
4.863 No Hits 57 41.1 45.3 56 69.4 40.4 RA2 
Intensity  71915 48794 34117 26340 24845 22037 RA2 
4.891 No Hits 41.2 57.1 40.3 81.3 56.4 45.2 RA1, RA2 
Intensity  25030 17856 12827 9856 9670 9203 RA1, RA2 
5.128 No Hits 60.2 48.5 40.3 151.5 59.1 43.2 RA1, RA2 
Intensity  33718 13477 12185 10143 8897 5991 RA1, RA2 
5.54 No Hits 93.3 91.4 77.3 92.3 79.4 121.4 RA1, RA2 
Intensity  159830 79559 53401 49165 46103 27073 RA1, RA2 
5.888 No Hits 41.1 45.3 56.8 40.4 86.8 56 RA1, RA2 
Intensity  20023 15817 13191 11008 10319 6570 RA1, RA2 
6.172 No Hits 91.4 40.2 73.1 41.1 69.2 43.3 RA1 
Intensity  15872 12685 7260 5537 4530 4396 RA1 
6.41 No Hits 105.4 40.3 41.1 91.4 84.3 83.3 RA1, RA2 
Intensity  29121 18470 16872 10082 9969 9407 RA1, RA2 
6.482 2-chloro-acetophenone 105.4 77.4 51.3 50.3 78.3 106.3 RA1, RA2 
Intensity  1043236 299777 221100 136591 75560 54373 RA1, RA2 
6.792 No Hits 93.2 41.2 79.3 91.3 40.2 77.4 RA2 
Intensity  86125 39225 38488 37583 25677 22004 RA2 
6.801 No Hits 91.4 93.3 41 40.2 77.5 71 RA1 
Intensity  22256 20919 19685 19409 14637 10942 RA1 
6.91 No Hits 93.3 41.1 79.4 69 91.4 121.3 RA1, RA2 
Intensity  93621 43385 29989 25231 24874 23371 RA1, RA2 
7.155 Phenol 94.3 66.4 65.4 62.4 63.4 51.4 RA1, RA2 
Intensity  452523 137881 81757 42279 42193 34080 RA1, RA2 
7.236 No Hits 103.3 76.3 94.4 60.2 41 55.2 RA1, RA2 
Intensity  77405 24076 18155 16553 15171 12695 RA1, RA2 
7.835 methylated alkane 57 41.1 43.1 70.9 69.9 56 RA1, RA2 
Intensity  101972 99890 47307 45052 40633 34758 RA1, RA2 
7.998 No Hits 41.2 69.1 81.3 55.9 57.1 67.4 RA1, RA2 
Intensity  75195 51170 50998 48362 45255 45103 RA1, RA2 
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8.218 No Hits 146.5 148.4 111.4 149.4 75.4 73.3 RA2 
Intensity  59014 27676 26955 18618 18170 16471 RA2 
8.628 No Hits 119.4 41.2 91.4 71.1 57 42.9 RA1, RA2 
Intensity  105840 27499 22047 18549 16186 15107 RA1, RA2 
8.889 No Hits 93.2 81.3 95.4 111.2 43.3 139.2 RA1 
Intensity  546703 256940 205239 191667 177075 176090 RA1 
9.101 Benzyl Alcohol 79.3 107.2 108.2 77.4 91.4 51.4 RA1, RA2 
Intensity  778113 395168 375799 301143 169092 160781 RA1, RA2 
9.861 No Hits 41.1 56.9 43.1 70.4 119.4 84.1 RA1 
Intensity  40201 20914 19839 16468 14868 12956  
9.904 No Hits 93.3 91.4 41 92.5 121.3 79.4 RA2 
Intensity  53582 40045 27304 27117 26889 26808  
10.058 No Hits 41.1 70.1 40.3 43 42.2 69.2 RA1, RA2 
Intensity  68413 58863 34869 33124 32119 31238 RA1, RA2 
10.211 2-chloro-acetophenone 105.3 77.3 51.3 50.4 106.3 95.4 RA1, RA2 
Intensity  508393 180397 97145 48787 47465 37072 RA1, RA2 
10.501 No Hits 41.1 57 70.7 69.9 69 81.5 RA2 
Intensity  48100 45721 27571 22748 19342 17284 RA2 
10.627 No Hits 55.1 41.1 82.7 68.9 56.1 70.1 RA2 
Intensity  84179 59058 45655 40651 38578 37357 RA2 
10.643 No Hits 41.2 83.1 55.2 69.1 56.1 119.4 RA1 
Intensity  28897 23552 18361 18096 14927 14787 RA1 
11.06 No Hits 43.3 121.3 51.4 77.3 105.3 50.4 RA1, RA2 
Intensity  93717 61762 43982 40010 22192 20463 RA1, RA2 
11.171 No Hits 132.4 117.5 91.4 115.5 40.3 105.3 RA1 
Intensity  43248 32562 16896 15958 9702 8811  
11.702 Methylated Alcohol 41 57.1 43.1 71 70 83.9 RA1, RA2 
Intensity  149946 128221 103834 90628 65338 53610 RA1, RA2 
11.928 No Hits 41.2 57.1 81.3 56.1 69 95.3 RA1, RA2 
Intensity  411506 343323 315509 295921 274926 274240 RA1, RA2 
12.262 No Hits 119.5 41.1 40.3 69.3 120.5 91.4 RA1, RA2 
Intensity  99919 27630 16354 16201 14707 13828 RA1, RA2 
12.641 No Hits 73.2 87.2 88.2 40.3 43.1 41.1 RA2 
Intensity  107520 57964 22298 19325 19134 17890 RA2 
14.783 No Hits 95.3 81.4 71.2 41.1 82.2 67.4 RA1, RA2 
Intensity  900051 868788 353468 345704 295341 254346 RA1, RA2 
14.981 No Hits 73.3 41.2 60.1 95.4 105.3 55 RA2 
Intensity  44321 43510 41052 22590 20152 19777 RA2 
15.857 2-ethyl-1-hexanol 57 41.1 43 70.4 55.8 84.3 RA1, RA2 
Intensity  135166 125500 85880 71356 46303 41683 RA1, RA2 
16.128 No Hits 41.1 81.9 55.1 67.3 83 95.4 RA1, RA2 
Intensity  452382 402663 278819 256199 244959 236906 RA1, RA2 
16.39 No Hits 41.1 56.8 69.9 43 68.7 40.2 RA2 
Intensity  59396 37661 32375 25268 18748 16889 RA2 
16.489 No Hits 94.3 138.1 95.2 77.4 66.3 41.2 RA2 
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Intensity  209706 105105 65379 57509 46632 32507 RA2 
16.552 No Hits 135.5 69.3 94.4 136.4 137.4 40.3 RA2 
Intensity  206287 56232 47340 30396 30092 25171 RA2 
17.566 No Hits 82.1 93.3 41.2 73.3 81.4 40.3 RA2 
Intensity  50474 33296 26542 21257 19982 19820 RA2 
19.086 Methylated Alkane 41.1 70.7 43 57 69.9 84.4 RA2 
Intensity  92824 92681 79533 73611 48408 48195 RA2 
19.555 5-methyl-quinoline 141.5 142.5 115.5 139.5 143.5 75.3 RA1, RA2 
Intensity  478993 425855 140653 49365 41754 39350 RA1, RA2 
20.206 No Hits 141.5 142.6 115.5 69.1 40.3 70.2 RA2 
Intensity  149043 129517 44541 30225 26942 21314 RA2 
20.323 Methylated Alkane 57 41.2 70.8 43 70.1 84.5 RA2 
Intensity  162248 123927 106150 86515 58996 46103 RA2 
20.374 No Hits 104.3 76.3 57.1 70.3 43.1 50.5 RA1 
Intensity  101772 28671 19155 18047 16575 16009 RA1 
22.134 No Hits 83 42.9 41.2 69.7 70.8 56 RA1 
Intensity  215689 114222 74839 51081 44030 43688 RA1 
21.244 Methylated Alkane 57 41.2 70.6 42.9 84.7 56.2 RA2 
Intensity  55092 53794 39481 38065 34416 27336 RA2 
22.148 No Hits 83 43 41.2 70.4 55.9 69 RA2 
Intensity  562367 287236 237081 163623 150926 135802 RA2 
23.079 No Hits 105.4 94.2 133.4 91.4 119.5 107.3 RA2 
Intensity  89114 84024 83368 79969 75192 66832 RA2 
23.367 No Hits 56 89 43 41.1 70.7 73.2 RA1, RA2 
Intensity  381667 329238 301476 262738 211881 134619 RA1, RA2 
24.577 No Hits 156.6 141.6 155.5 93.4 69 91.3 RA2 
Intensity  106471 105281 52131 34369 33246 30657 RA2 
24.702 No Hits 161.5 105.3 93.3 91.3 107.4 119.5 RA2 
Intensity  259685 184383 147051 137724 125338 113185 RA2 
25.18 3-ethyl-quinoline 141.6 156.6 155.5 115.4 128.4 142.5 RA2 
Intensity  264001 180990 64159 58821 38210 33296 RA2 
25.369 No Hits 156.5 141.5 155.4 157.7 41.2 91.3 RA2 
Intensity  128866 122792 46724 26763 24802 22116 RA2 
27.14 No Hits 69.1 41.2 107.3 43.3 67.3 93.3 RA1, RA2 
Intensity  128336 119089 113552 101241 55101 48643 RA1, RA2 
29.71 Methylated Alkane 41.1 56.8 70.9 43 84.5 70 RA1, RA2 
Intensity  84855 82719 81063 54019 50932 45876 RA1, RA2 
29.728 No Hits 57.1 41.2 70.8 43 40.2 84.3 RA2 
Intensity  109004 92782 86014 62611 45026 44756 RA2 
34.29 Methylated Alkane 41.2 57 71 43 84.6 70 RA2 
Intensity  99120 88914 64675 64021 32339 32200 RA2 
34.857 No Hits 105.4 182.4 77.4 51.4 181.5 50.4 RA1 
Intensity  90887 58721 36862 29704 19477 10697 RA1 
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Table 4 Compounds found in the breath of participant CV-17 
 Compound M/Z Observed 
in 
1.27 No Hits 79.3 80.3 77.3 41.2 67.3 50.3 KK1 
Intensity  253586 145899 67618 60507 50527 47436 KK1 
1.387 3,4-
dimethyl-1-
hexene 
41 55.9 56.9 42.9 42.1 83.1 KK1 
Intensity  1373344 107955 1022205 824792 605590 592496 KK1 
1.431 methylated 
alkane 
69.9 56.9 41 42.9 56 70.7 KK1 
Intensity  1577545 1273441 1184770 1153572 814900 811904 KK1 
1.494 methylated 
alkene 
69.9 41 42.8 55 56 68.9 KK1 
Intensity  464957 276879 208032 192053 187425 146212 KK1 
1.521 No Hits 77.2 55.9 69.9 41.1 55.1 69.1 KK1 
Intensity  568793 293009 289184 275076 194275 186828 KK1 
1.584 methylated 
alkane 
41 57 42.9 70.2 55.9 42 KK1 
Intensity  1090641 995691 970485 925615 557512 422619 KK1 
1.683 No Hits 88.8 45.1 43.2 89.8 41.2 42.1 KK1 
Intensity  440460 367199 223747 59508 53243 34586 KK1 
1.8 methylated 
alkane 
82.8 55 41.1 81.3 56 69.9 KK1 
Intensity  185380 144828 116760 67287 56137 49170 KK1 
1.89 No Hits 88 45.2 73.1 69.2 41 89 KK1 
Intensity  377468 311388 189930 114548 96942 78144 KK1 
1.935 No Hits 79.3 77.3 41 43.2 69.9 93.9 KK1 
Intensity  55039 44200 42223 25032 22631 20261  
1.971 No Hits 45.2 59 43.2 75 44.2 41.1 KK2 
Intensity  402929 343738 148143 134595 101905 78643  
2.223 Toluene 91.3 92.3 63.3 65.3 93.4 50.4 KK1,KK2 
Intensity  1278693 834978 175314 146742 116700 86115 KK1,KK2 
2.65 No Hits 41 43 84.5 95.3 57 40.2 KK1,KK2 
Intensity  61106 40101 23720 20170 17666 17609 KK1,KK2 
2.686 hexanal 41.1 55.8 44.1 43.3 57 67.3 KK1,KK2 
Intensity  90925 66033 56541 49190 41007 36987 KK1,KK2 
3.706 No Hits 67.3 41.1 81.9 40.3 43.3 69.2 KK1,KK2 
Intensity  71272 59417 35296 21855 17649 16406 KK1,KK2 
3.733 o-xylene 91.3 106.2 105.6 67.4 41.2 77.3 KK1,KK2 
Intensity  149688 41975 31094 28207 26285 17772 KK1,KK2 
3.803 No Hits 43.3 41.1 91.4 69.4 93.3 40.3 KK1 
Intensity  51480 31552 30248 24860 18777 15620 KK1,KK2 
3.942 p-xylene 91.3 106.2 105.3 51.3 103.4 92.4 KK1,KK2 
Intensity  238625 128158 82450 33208 25170 24581 KK1,KK2 
4.032 No Hits 41.1 56 43 55.2 42 69.1 KK1,KK2 
Intensity  47106 28693 27308 16115 15093 12823 KK1,KK2 
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4.105 No Hits 102.4 40.2 41.1 73.2 43.2 51.4 KK1,KK2 
Intensity  28778 11126 8574 7567 7447 6846 KK1,KK2 
4.263 No Hits 43.3 81.3 41.1 45.2 69.1 40.2 KK1 
Intensity  37803 30005 26921 20542 19431 17006  
4.315 No Hits 43.2 81.2 79.4 41.2 40.2 109.3 KK2 
Intensity  30428 20419 16174 15652 13497 8329  
4.371 No Hits 43.2 56.9 73.3 41.1 45.2 40.3 KK1 
Intensity  33756 29905 20629 17593 16970 13328  
4.46 No Hits 91.4 104.3 106.2 41.1 103.4 78.3 KK1,KK2 
Intensity  87277 53364 49941 44546 39400 32404 KK1,KK2 
4.587 No Hits 81.3 41.2 55.1 69.8 42 79.3 KK1,KK2 
Intensity  316098 86984 80328 56391 49511 33956 KK1,KK2 
4.687 methylated 
alkane 
41.1 57 43 69.3 40.2 84.6 KK1,KK2 
Intensity  51778 43339 25282 21891 19032 16949 KK1,KK2 
4.714 No Hits 43.2 72.1 81.8 41.1 83.6 56.8 KK2 
Intensity  63354 44906 39349 31729 28490 24511 KK2 
4.786 No Hits 41.1 69.8 43 44.2 54.8 81.2 KK2 
Intensity  69434 57806 36150 35727 35656 31862 KK2 
4.795 No Hits 41.1 69.9 81.4 55.1 43.2 40.2 KK1 
Intensity  63743 37568 34642 32015 24542 24161 KK1 
4.886 No Hits 56.9 41.1 40.3 82.1 81.3 45.1 KK1,KK2 
Intensity  35390 22189 16808 15056 13088 11530 KK1,KK2 
5.16 No Hits 93.2 41.1 91.4 67.4 40.1 79.3 KK1,KK2 
Intensity  37600 24193 17205 16507 12866 12422 KK1,KK2 
5.365 No Hits 93.3 91.4 92.4 77.4 79.3 94.4 KK1 
Intensity  479952 256913 188136 110931 85918 66559 KK1 
5.572 No Hits 93.3 135.2 81.4 91.4 121.4 136 KK1 
Intensity  2081773
8 
7847619 7131190 3844762 3710714 361714
3 
KK1 
6.031 No Hits 93.3 121.1 107.3 79.4 94.4 91.3 KK1,KK2 
Intensity  549522 283649 176787 175878 133037 124753 KK1,KK2 
6.093 No Hits 81.3 96 41.1 71.1 57.1 70.2 KK1,KK2 
Intensity  110288 75805 66057 43033 31922 30751 KK1,KK2 
6.21 No Hits 69.2 41.1 94.2 972 91.4 55.1 KK1 
Intensity  135807 131657 75062 54094 51799 51117  
6.418 No Hits 105.4 41 43.3 55.1 83.2 69.2 KK1,KK2 
Intensity  125735 56303 39302 34085 27876 24012 KK1,KK2 
6.508 2-chloro-
acetopheno
ne 
105.3 77.3 51.4 50.3 106 74.3 KK1,KK2 
Intensity  773336 237527 188190 97011 96876 56858 KK1,KK2 
6.701 No Hits 105.4 40.2 120.3 91.3 119.4 41.1 KK2 
Intensity  39199 15745 12372 8722 8636 7804  
7.21 No Hits 95.3 81.3 67.3 41.2 93.2 54.9 KK1,KK2 
Intensity  98013 82806 68556 56572 44448 40508  
7.99 No Hits 41.1 81.9 43 56 67.2 95.3 KK1,KK2 
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Intensity  145317 83380 80780 68487 66074 60629  
8.343 No Hits 121.3 93.1 91.4 79.3 136.2 122.4 KK1,KK2 
Intensity  189372 156293 107414 58621 52678 43198  
8.442 No Hits 105.3 59.2 119.4 79.4 91.4 73.2 KK1 
Intensity  61965 34558 33282 26608 25769 22702  
8.634 1-methyl-3-
(1-
methylethyl)
-benzene 
119.4 91.4 117.3 120.5 140.7 63.3 KK1,KK2 
Intensity  651901 134176 74152 61814 55161 48163  
9.187 Benzyl 
Alcohol 
79.3 108.2 93.3 107.2 91.4 77.3 KK1,KK2 
Intensity  766773 502977 486066 426052 350001 316912 KK1,KK2 
9.565 No Hits 93.3 80.3 79.4 91.4 105.3 77.3 KK1,KK2 
Intensity  222290 128861 115447 97289 66157 56833 KK1,KK2 
9.925 No Hits 93.3 121.3 77.3 91.4 135.8 92.3 KK1,KK2 
Intensity  356225 161290 109860 103800 70295 57100 KK1,KK2 
10.061 No Hits 70 41.2 83.1 55 42.9 82.1 KK1 
Intensity  66400 65482 45262 35273 33952 33192 KK1 
10.232 No Hits 105.3 77.4 51.3 106.4 50.4 120.5 KK1 
Intensity  550210 134638 69771 52581 48124 46162 KK1 
10.439 No Hits 93.2 79.4 93.9 91.4 121.2 81.3 KK1 
Intensity  156528 92507 71774 65962 60750 55370  
10.668 Octanol? 41.1 68.9 82.9 55.1 56.1 69.8 KK2 
Intensity  85830 69947 61385 59358 51102 46673  
10.709 methylated 
alkane 
41.1 56.1 69.1 55.1 69.8 82.8 KK1 
Intensity  199065 124848 117741 105368 99947 91318  
10.961 No Hits 121.4 93.3 79.3 91.4 136.2 77.5 KK1,KK2 
Intensity  254627 219781 105301 96968 92549 58267  
11.094 No Hits 43.2 121.2 93.3 94.1 79.4 51.4 KK2 
Intensity  52310 29869 25162 21042 18254 17374  
11.177 No Hits 117.5 132.4 115.5 43.2 91.4 121.3 KK1,KK2 
Intensity  294459 197609 144943 99965 98229 72375 KK1,KK2 
11.799 No Hits 93.2 41 80.3 71.2 121.3 55.1 KK1,KK2 
Intensity  512393 282326 200794 190843 155585 124176 KK1,KK2 
11.943 No Hits 41.1 81.3 70 57 56 95.2 KK1,KK2 
Intensity  398453 336968 276864 267341 216246 190056 KK1,KK2 
15.643 No Hits 81.4 95.3 41.2 67.4 82.3 123.2 KK1 
Intensity  785862 547121 450446 348858 281348 240374 KK1 
15.75 No Hits 93.2 121.5 136.1 81.5 95.4 59.2 KK1 
Intensity  1008598 674669 468121 364815 329101 277579 KK1 
16.217 methylated 
alcohol 
81.4 41 95.3 83.2 67.4 43.1 KK1,KK2 
Intensity  595069 422703 370705 335543 317941 261862 KK1,KK2 
16.397 No Hits 81.4 43.2 126.1 41.1 169.7 71.1 KK1,KK2 
Intensity  553676 472926 408267 229797 178913 141362 KK1,KK2 
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16.412 methylated 
alkane 
41 82.9 69 43.2 57.1 55.1 KK1,KK2 
Intensity  99846 74899 69027 64789 50030 49831  
16.468 No Hits 41.2 70.1 83 43.3 68.8 55.9 KK1 
Intensity  181351 141874 132076 131403 128660 113873  
16.63 2-phenoxy-
ethanol 
94.4 138.2 95.2 66.4 51.3 77.3 KK1,KK2 
Intensity  595976 215404 185352 169894 153552 134795  
17.386 No Hits 153.3 81.3 152.3 109.4 137.1 67.3 KK1 
Intensity  2353570 1712552 1649672 1392099 1206058 103625
4 
KK1 
17.484 No Hits 81.9 67.3 82.9 41.1 57 84.4 KK1 
Intensity  1983667 1437238 856714 709762 625714 427000 KK1 
17.601 No Hits 82 93.2 41.1 107.3 54 91.4 KK2 
Intensity  156617 86242 67694 67212 58386 48542  
17.655 No Hits 82 93.3 107.4 79.5 106.4 54.2 KK1 
Intensity  329160 193283 136391 136390 113149 106948 KK1 
17.799 No Hits 41.1 56.1 84.9 56.9 82.9 103.2 KK1 
Intensity  80112 56744 51713 45709 41996 39422 KK1 
18.059 No Hits 110.3 82.1 95.3 153.2 137.5 109.3 KK1 
Intensity  2428741 1611139 1448978 1253995 1003400 876273 KK1 
18.93 No Hits 81.3 95.3 67.3 41.1 43.1 123 KK2 
Intensity  81185 75222 46273 41409 40578 34762 KK2 
19.14 No Hits 41.1 57.1 70.9 70 73.2 84.2 KK1 
Intensity  125526 113215 92367 78987 63390 61845 KK1 
19.599 No Hits 142.6 141.5 115.6 63.4 143.6 41 KK1 
Intensity  700266 650877 168667 87700 57459 53539 KK1 
19.796 No Hits 95.3 81.4 137.7 83 123.2 96.2 KK1 
Intensity  5810952 4831429 2629643 2319881 2305714 125904
8 
KK1 
20.255 No Hits 141.5 142.6 41 115.4 83.1 43 KK2 
Intensity  225189 205512 58080 47695 34727 32900 KK2 
20.354 No Hits 43 57 41.2 95.3 70.8 81.2 KK1,KK2 
Intensity  243315 199414 186532 181933 181508 113473 KK1,KK2 
20.524 No Hits 93.3 121.4 135.8 107.3 94.2 79.4 KK1,KK2 
Intensity  101086 77591 67525 55445 49132 44519 KK1,KK2 
21.262 methylated 
alkane 
57.1 41.2 43.1 70.7 70 56 KK1 
Intensity  89576 70759 68017 60875 51673 41133 KK1 
22.181 No Hits 83.1 43.1 41.1 88.9 70.7 70 KK1,KK2 
Intensity  763093 415957 410552 226542 221426 159716  
23.1 No Hits 119.5 94.1 91.3 105.4 107.3 95.2 KK1 
Intensity  165243 163296 98639 95910 93528 93405 KK1 
23.397 No Hits 89.2 43 56 41.2 68.9 70.7 KK1 
Intensity  472747 418595 416375 376832 288996 274000 KK1 
23.693 No Hits 79.4 80.2 123.4 81.4 161.3 41.2 KK1 
Intensity  150571 129269 89877 86401 66553 53352 KK1 
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24.603 No Hits 156.5 141.5 155.5 95.2 79.4 161.3 KK1,KK2 
Intensity  229401 197566 110750 65721 57090 47985  
25.205 7-ethyl-
quinoline  
141.5 156.5 155.6 153.5 115.4 128.6 KK1,KK2 
Intensity  368888 309986 121740 69060 53551 48735 KK1,KK2 
27.159 No Hits 43.3 107.3 93.3 41.2 69.2 95.4 KK1,KK2 
Intensity  237623 204044 194110 146202 143227 95465 KK1,KK2 
29.74 methylated 
alkane 
41.1 70.9 57.1 43 84.7 70.1 KK1,KK2 
Intensity  184029 155381 147124 123352 104086 91267 KK1,KK2 
34.307 No Hits 57 41.2 70.9 84.6 43 56.1 KK1,KK2 
Intensity  174338 125401 105985 102678 84231 69217 KK1,KK2 
34.867 benzopheno
ne 
105.3 182.4 77.3 51.4 181.5 183.2 KK1,KK2 
Intensity  247643 119727 113589 63777 51284 21112 KK1,KK2 
 
Table 5 Compounds found in the breath of all participants included in the preliminary evaluation 
 
Compounds M/Z Observed in 
1.27 No Hits 79.3 80.3 77.3 41.2 67.3 50.3 CV-17 
1.359 Benzene 78.4 43.1 41.2 51.4 50.4 77.3 CV-14, CV-08, CV-16 
1.387 3,4-dimethyl-1-hexene 41 55.9 56.9 42.9 42.1 83.1 CV-17 
1.413 No Hits 41.1 43.2 55.9 40.2 69.9 42.1 CV-16 
1.431 methylated alkane 69.9 56.9 41 42.9 56 70.7 CV-17 
1.494 methylated alkene 69.9 41 42.8 55 56 68.9 CV-17 
1.521 No Hits 77.2 55.9 69.9 41.1 55.1 69.1 CV-17 
1.548 No Hits 40.9 43 73 74 54.9 69.7 CV-14 
1.566 No Hits 77.3 73.1 74.1 45.3 56.1 57 CV-16 
1.584 methylated alkane 41 57 42.9 70.2 55.9 42 CV-17 
1.608 No Hits 72.8 73.8 54.7 56.7 55.6 74.7 CV-08 
1.611 No Hits 40.8 42.9 77.1 39.9 69.7 70.5 CV-14 
1.675 No Hits 45.2 43.3 88.9 41.2 77.3 42.4 CV-16 
1.683 No Hits 88.8 45.1 43.2 89.8 41.2 42.1 CV-17 
1.683 No Hits 76.9 44.9 72.8 77.8 69.3 56.5 CV-08 
1.728 No Hits 44.9 43 88.7 40.8 42 60.9 CV-14 
1.739 No Hits 93.9 92.3 44.9 96.4 91.2 94.9 CV-08 
1.781 No Hits 43.2 45.2 55.2 73.3 83 41.2 CV-16 
1.8 methylated alkane 82.8 55 41.1 81.3 56 69.9 CV-17, CV-14 
1.826 
1-ethyl-1-methyl-
cyclopentane 82.7 54.9 40.9 81.6 68.9 69.8 CV-13 
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1.89 No Hits 88 45.2 73.1 69.2 41 89 CV-17 
1.926 No Hits 82.4 54.6 80.8 66.9 93.7 79.7 CV-08 
1.927 No Hits 45 39.9 40.9 87.9 43 73 CV-14 
1.928 No Hits 40.3 41.2 43.3 55.1 69.5 45.2 CV-16 
1.935 No Hits 79.3 77.3 41 43.2 69.9 93.9 CV-16, CV-17 
1.971 No Hits 45.2 59 43.2 75 44.2 41.1 CV-16, CV-17 
1.972 No Hits 43.1 40.9 69.7 40.1 54.9 73.1 CV-13 
1.982 No Hits 79.1 40.9 42.9 95 39.9 77.1 CV-14 
2.016 Methylated Alkane 45.3 43.3 44.1 73.3 40.2 42.2 CV-16 
2.052 No Hits 45.3 73.2 43.3 41.3 40.3 67.3 CV-16 
2.054 No Hits 43.1 40.9 40 69.7 72.9 55 CV-13 
2.092 No Hits 40.3 43.3 73.2 41.2 44.3 91.3 CV-16 
2.272 Toluene 91.1 92.1 63.1 65 50.1 51.1 
CV-14, CV-08, CV-16, 
CV-17, CV-13 
2.429 No Hits 43.1 60 96.7 73 40 40.9 CV-13 
2.431 No Hits 60.1 73.3 41.1 42.3 43.2 45.3 CV-16 
2.434 No Hits 96.6 40.9 54.8 40 68.9 91.2 CV-14 
2.485 No Hits 151.4 149.3 45.1 73.2 133.4 43.3 CV-16 
2.65 No Hits 41 43 84.5 95.3 57 40.2 CV-17 
2.695 No Hits 43 40.9 40 42 84.5 55.8 CV-13 
2.706 No Hits 40.8 42.6 96.7 84.2 55 41.8 CV-14 
2.741 No Hits 40.9 43 43.9 55.9 40 81.8 CV-13 
2.742 Hexanal 40.8 55.8 42.9 43.9 71.6 54.8 
CV-14, CV-08, CV-16, 
CV-17 
2.75 No Hits 93.9 175 176.9 176 93 91.8 CV-08 
2.824 
1,1-dimethyl-
cyclohexane 96.6 40.8 54.9 39.9 43 55.7 CV-14 
2.841 No Hits 96.1 42.9 95.1 54.9 40.9 91.1 CV-14 
2.877 No Hits 94.3 95 43 93.7 96.3 44.9 CV-14 
2.958 No Hits 43 42 94.9 60.5 91.2 67 CV-14 
3.003 No Hits 94.4 96.7 44.9 95.6 92.6 76.8 CV-08 
3.259 cyclohexane derivative 68.8 110.5 40.8 54.8 39.9 109.5 CV-14 
3.293 No Hits 68.8 110.5 40.7 54.9 72.9 109.5 CV-14 
3.295 cyclohexane derivative 82.8 81.5 40.8 55 68.8 67.1 CV-14 
3.317 No Hits 80.3 81.3 40.3 73.3 50.3 45.4 CV-16 
3.385 No Hits 68.8 110.6 40.8 81 80 40 CV-14 
3.388 No Hits 82.7 81.2 54.8 40.7 94.4 67.1 CV-14 
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3.401 No Hits 68.7 110.7 40.7 95.1 54.8 82.9 CV-14 
3.434 No Hits 94.4 72.8 73.7 44.9 54.8 96.7 CV-08 
3.694 cyclohexane derivative 68.8 110.6 40.9 54.9 55.7 69.8 CV-14 
3.718 
Cyclohexane based 
structure 68.8 110.5 40.8 54.9 69.5 55.8 CV-14 
3.706 No Hits 67.3 41.1 81.9 40.3 43.3 69.2 CV-17 
3.853 o-xylene 91.1 105.9 51.1 95 92.1 50.1 
CV-14, CV-08, CV-16, 
CV-17, CV-13 
3.892 No Hits 91 42.9 40.9 68.9 39.9 56.8 CV-14 
3.803 No Hits 43.3 41.1 91.4 69.4 93.3 40.3 CV-14, CV-17 
4.037 p-xylene 91.1 106 105.2 77 79.1 63.1 
CV-14, CV-08, CV-16, 
CV-17, CV-13 
4.032 No Hits 41.1 56 43 55.2 42 69.1 CV-17 
4.105 No Hits 102.4 40.2 41.1 73.2 43.2 51.4 CV-16, CV-17 
4.208 cyclohexane derivative 68.7 110.6 40.8 54.8 109.6 55.8 CV-14 
4.263 No Hits 43.3 81.3 41.1 45.2 69.1 40.2 CV-17 
4.298 cyclohexane derivative 68.8 110.6 40.9 55 69.7 55.8 CV-14 
4.315 No Hits 43.2 81.2 79.4 41.2 40.2 109.3 CV-17 
4.38 cyclohexane derivative 68.8 40.9 110.6 54.9 96.8 55.6 CV-14 
4.371 No Hits 43.2 56.9 73.3 41.1 45.2 40.3 CV-17 
4.403 No Hits 96.7 54.9 40.9 68.7 95 81.1 CV-14 
4.422 No Hits 102 75.9 73.9 49.9 63 74.9 CV-08 
4.457 No Hits 91.5 106.3 105.4 104.4 45.3 51.4 
CV-14, CV-08, CV-16, 
CV-17, CV-13 
4.575 No Hits 42.2 55.2 69 80.2 41.1 83.2 CV-16 
4.584 No Hits 91.1 96.7 95.9 95.2 54.9 106 CV-14, CV-08 
4.587 No Hits 81.3 41.2 55.1 69.8 42 79.3 CV-17 
4.618 No Hits 40.3 41.1 69.1 55.2 42.1 43.2 CV-16 
4.687 methylated alkane 41.1 57 43 69.3 40.2 84.6 CV-17 
4.714 No Hits 43.2 72.1 81.8 41.1 83.6 56.8 CV-17 
4.719 No Hits 72 81.9 43.3 83.4 41.2 56.9 CV-16 
4.782 No Hits 151.4 44.2 133.5 41.2 156.7 69.5 CV-16 
4.786 No Hits 41.1 69.8 43 44.2 54.8 81.2 CV-17 
4.792 styrene 104 78 91 103 105.9 50.9 CV-08 
4.795 No Hits 41.1 69.9 81.4 55.1 43.2 40.2 CV-17 
4.819 methylated alkane 56.8 40.8 42.8 84.3 56 69.6 CV-14 
4.851 No Hits 72.9 55.7 54.8 69.7 68.8 96.5 CV-08 
308 
 
4.863 No Hits 57 41.1 45.3 56 69.4 40.4 CV-16 
4.878 No Hits 43 41 40 69.8 44 54.9 CV-13 
4.886 No Hits 56.9 41.1 40.3 82.1 81.3 45.1 CV-16, CV-17 
4.918 long-chain alcohol 40.9 95.9 68.8 69.7 95 54.9 CV-14 
4.99 
ring structure 
hex/pent? 96.7 54.9 96 40.8 68.8 81.1 CV-14 
5.065 No Hits 96.7 40.8 54.7 95.6 68.8 81.3 CV-14 
5.076 No Hits 56.7 55.8 84.5 54.8 73 69.8 CV-08 
5.128 No Hits 60.2 48.5 40.3 151.5 59.1 43.2 CV-16 
5.16 No Hits 93.2 41.1 91.4 67.4 40.1 79.3 CV-17 
5.292 No Hits 81.1 67.1 40.8 95.1 79.2 82.7 CV-14 
5.315 hydrocarbon 81.1 67.1 95 40.8 79.1 54.8 CV-14 
5.365 No Hits 93.3 91.4 92.4 77.4 79.3 94.4 CV-16, CV-17 
5.572 No Hits 93.3 135.2 81.4 91.4 121.4 136 CV-17 
5.626 No Hits 81.3 82.7 54.8 40.9 67 80.1 CV-14 
5.641 hydrocarbon 81.4 82.8 54.8 67.1 40.9 42.7 CV-14 
5.654 No Hits 93.1 92.1 91.2 40 79.2 43 CV-13 
5.743 No Hits 56.7 40.8 70.2 42.7 55.8 69 CV-14 
5.767 methylated alkane 70.6 40.9 56.8 69.8 42.7 56.1 CV-14 
5.888 No Hits 41.1 45.3 56.8 40.4 86.8 56 CV-16 
5.888 methylated alkane 68.7 40.8 56.7 69.8 110.7 54.8 CV-14 
5.951 No Hits 68.8 40.8 69.6 55 40 123.9 CV-14 
5.962 No Hits 92.9 91 91.9 78.9 151 77 CV-08 
6.031 No Hits 93.3 121.1 107.3 79.4 94.4 91.3 CV-17 
6.093 No Hits 81.3 96 41.1 71.1 57.1 70.2 CV-17 
6.101 methylated alkane 67.1 81.2 95 40.9 68.8 91.1 CV-14 
6.172 No Hits 91.4 40.2 73.1 41.1 69.2 43.3 CV-16 
6.21 No Hits 69.2 41.1 94.2 109 91.4 55.1 CV-14, CV-17 
6.418 No Hits 105.4 41 43.3 55.1 83.2 69.2 CV-16, CV-17 
6.444 No Hits 68.8 40.9 69.8 124.1 82.6 54.9 CV-14 
6.482 
2-chloro-
acetophenone 105.4 77.4 51.3 50.3 78.3 106.3 CV-16, CV-17 
6.548 No Hits 105.1 68.7 40.8 110.5 42.7 39.8 CV-14 
6.597 Benzoyl Bromide 105.2 77.1 51.1 50.1 78.2 74.2 CV-13 
6.608 No Hits 90.9 149 72.9 91.9 151 119.6 CV-08 
6.62 No Hits 105.1 77 68.8 51.1 50.1 40.9 CV-14 
6.701 No Hits 105.4 40.2 120.3 91.3 119.4 41.1 CV-17 
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6.759 No Hits 40.8 56.8 81.1 42.8 94.1 69.7 CV-14 
6.792 No Hits 93.2 41.2 79.3 91.3 40.2 77.4 CV-16 
6.801 No Hits 91.4 93.3 41 40.2 77.5 71 CV-16 
6.81 No Hits 105.2 40.8 39.9 120.1 77 56.8 CV-14 
6.9 
2-chloro-
acetophenone 104.9 76.9 50.9 94.9 49.9 105.7 CV-08 
6.91 No Hits 93.3 41.1 79.4 69 91.4 121.3 CV-16 
6.955 No Hits 81.1 40.8 95.6 54.9 56.7 96.6 CV-14 
7.057 No Hits 68.8 95.1 40.8 93.1 81 43 CV-14 
7.143 No Hits 94 105 120 66 95 63 CV-08 
7.155 Phenol 94.3 66.4 65.4 62.4 63.4 51.4 CV-16 
7.21 No Hits 95.3 81.3 67.3 41.2 93.2 54.9 CV-17 
7.236 No Hits 103.3 76.3 94.4 60.2 41 55.2 CV-16 
7.251 Phenol 94.2 66.2 65.1 63.2 40 50.1 CV-13 
7.355 No Hits 96.6 95.9 54.9 68.9 40.9 81 CV-14 
7.378 Phenol 94 66 92.9 64.9 91 63 CV-08 
7.416 No Hits 94 66 105 92.9 64.9 91 CV-08 
7.597 Phenol 93.9 66 64.9 62.9 61.9 94.9 CV-08 
7.649 1,2,3-trimethylbenzene 105.1 120.1 40.9 78.9 91.1 81.1 CV-14 
7.668 Benzonitrile 103 75.9 66 93.9 50 75 CV-08 
7.748 No Hits 96.6 68.8 40.9 54.9 69.8 81.1 CV-14 
7.835 methylated alkane 57 41.1 43.1 70.9 69.9 56 CV-16 
7.99 No Hits 41.1 81.9 43 56 67.2 95.3 CV-16, CV-17 
7.993 methylated alkane 56.7 40.8 42.6 70.6 55.8 69.6 CV-14 
8.134 No Hits 41 42.8 81.4 55.8 67.2 41.9 CV-13 
8.146 No Hits 40.8 68.8 81 67.1 42.8 55.7 CV-14 
8.218 No Hits 146.5 148.4 111.4 149.4 75.4 73.3 CV-16 
8.343 No Hits 121.3 93.1 91.4 79.3 136.2 122.4 CV-17 
8.442 No Hits 105.3 59.2 119.4 79.4 91.4 73.2 CV-17 
8.628 No Hits 119.4 41.2 91.4 71.1 57 42.9 CV-16 
8.634 
1-methyl-3-(1-
methylethyl)-benzene 119.4 91.4 117.3 120.5 140.7 63.3 CV-17 
8.78 No Hits 40.8 119.1 68.9 70.6 82.6 81.2 CV-14 
8.889 No Hits 93.2 81.3 95.4 111.2 43.3 139.2 CV-16 
8.952 Limonene 93 67.1 79.1 93.9 67.9 91.1 CV-14, CV-13 
9.083 methylated alkane 56.8 40.9 69.8 82.7 55.8 54.9 CV-13 
9.096 methylated alkene 40.8 56.8 82.7 69.8 54.8 55.9 CV-14 
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9.101 Benzyl Alcohol 79.3 107.2 108.2 77.4 91.4 51.4 CV-16, CV-17 
9.124 No Hits 56.7 40.8 82.7 69.7 54.9 55.8 CV-14 
9.229 Benzyl Alcohol 79.1 108 107.1 77.1 51.2 91.1 CV-13 
9.249 No Hits 56.7 55.7 69.8 54.8 82.7 57.7 CV-08 
9.25 Benzyl Alcohol 79 107 108 77.1 91 51 CV-14 
9.332 Limonene 92.9 79 67 93.8 67.8 90.9 CV-08 
9.412 No Hits 40.9 78.9 69.3 54.8 55.8 39.8 CV-14 
9.509 Hydrocarbon 56.7 69.8 70.6 55.7 54.8 82.7 CV-08 
9.565 No Hits 93.3 80.3 79.4 91.4 105.3 77.3 CV-17 
9.646 Benzyl Alcohol 78.9 76.9 106.9 107.9 72.8 50.9 CV-08 
9.861 No Hits 41.1 56.9 43.1 70.4 119.4 84.1 CV-16 
9.925 No Hits 93.3 121.3 77.3 91.4 135.8 92.3 CV-16, CV-17 
9.939 cyclohexane derivative 81 95.1 67.1 137.5 40.9 81.8 CV-14 
10.038 No Hits 40.8 119.2 42.8 56.8 54.9 40 CV-08 
10.058 No Hits 41.1 70.1 40.3 43 42.2 69.2 CV-16, CV-17 
10.075 No Hits 56.8 69.8 70.6 55.8 54.8 82.7 CV-14 
10.211 
2-chloro-
acetophenone 105.3 77.3 51.3 50.4 106.3 95.4 CV-16, CV-17 
10.22 No Hits 40.9 70 42.7 39.8 91.2 54.9 CV-14 
10.283 No Hits 40.8 81.1 105.2 68.9 54.8 91.1 CV-14 
10.374 
2-chloro-
acetophenone 105.1 77.1 51.1 95.1 106.1 50.1 CV-14, CV-13 
10.439 No Hits 93.2 79.4 93.9 91.4 121.2 81.3 CV-17 
10.501 No Hits 41.1 57 70.7 69.9 69 81.5 CV-16 
10.643 No Hits 41.2 83.1 55.2 69.1 56.1 119.4 CV-16 
10.668 Octanol? 41.1 68.9 82.9 55.1 56.1 69.8 CV-16, CV-17, CV-14 
10.709 methylated alkane 41.1 56.1 69.1 55.1 69.8 82.8 CV-17 
10.746 
2-chloro-
acetophenone 104.9 76.9 50.9 94.9 49.9 105.9 CV-08 
10.798 No Hits 40.9 68.9 55.8 40 82.7 43 CV-13 
10.818 No Hits 40.9 68.9 81.1 58.9 56 43 CV-14 
10.961 No Hits 121.4 93.3 79.3 91.4 136.2 77.5 CV-17 
11.06 No Hits 43.3 121.3 51.4 77.3 105.3 50.4 CV-16, CV-17 
11.094 No Hits 43.2 121.2 93.3 94.1 79.4 51.4 CV-17 
11.171 No Hits 132.4 117.5 91.4 115.5 40.3 105.3 CV-16, CV-17 
11.177 No Hits 117.5 132.4 115.5 43.2 91.4 121.3 CV-17 
11.214 No Hits 43.1 121.1 40 77.2 51.2 73 CV-13 
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11.245 No Hits 43 121 91 40.8 40 77 CV-14 
11.545 No Hits 57.9 43 40.8 56.6 39.9 68.8 CV-14 
11.702 Methylated Alcohol 41 57.1 43.1 71 70 83.9 CV-14, CV-16 
11.799 No Hits 93.2 41 80.3 71.2 121.3 55.1 CV-17 
11.87 No Hits 40.9 42.7 56.9 70.6 68.8 69.6 CV-13 
11.928 No Hits 41.2 57.1 81.3 56.1 69 95.3 CV-16 
11.943 No Hits 41.1 81.3 70 57 56 95.2 CV-17 
12.091 Nonanal 40.9 81.1 69.8 55.7 56.8 67.2 CV-13 
12.117 3-nonen-1-ol 40.9 81 95 69.6 68.7 67.2 CV-14 
12.262 No Hits 119.5 41.1 40.3 69.3 120.5 91.4 CV-16 
12.52 No Hits 81.1 66.9 69.7 95 55.7 56.8 CV-08 
12.641 No Hits 73.2 87.2 88.2 40.3 43.1 41.1 CV-16 
12.653 No Hits 40.9 82 39.8 91.1 68.9 79.2 CV-14 
14.783 No Hits 95.3 81.4 71.2 41.1 82.2 67.4 CV-16 
14.971 No Hits 128.2 81.1 40.9 95 67.2 68.8 CV-14 
14.981 No Hits 73.3 41.2 60.1 95.4 105.3 55 CV-16 
15.643 No Hits 81.4 95.3 41.2 67.4 82.3 123.2 CV-17 
15.75 No Hits 93.2 121.5 136.1 81.5 95.4 59.2 CV-17 
15.857 2-ethyl-1-hexanol 57 41.1 43 70.4 55.8 84.3 CV-16 
16.128 No Hits 41.1 81.9 55.1 67.3 83 95.4 CV-16 
16.217 methylated alcohol 81.4 41 95.3 83.2 67.4 43.1 CV-17 
16.311 hydrocarbon 81.2 40.9 82 54.9 82.8 95.1 CV-13 
16.337 No Hits 81 40.9 82.7 67.1 95 67.9 CV-14 
16.39 No Hits 41.1 56.8 69.9 43 68.7 40.2 CV-16 
16.397 No Hits 81.4 43.2 126.1 41.1 169.7 71.1 CV-17 
16.412 methylated alkane 41 82.9 69 43.2 57.1 55.1 CV-17 
16.489 No Hits 94.3 138.1 95.2 77.4 66.3 41.2 CV-16 
16.468 No Hits 41.2 70.1 83 43.3 68.8 55.9 CV-17 
16.552 No Hits 135.5 69.3 94.4 136.4 137.4 40.3 CV-16 
16.63 2-phenoxy-ethanol 94.4 138.2 95.2 66.4 51.3 77.3 CV-17 
16.79 No Hits 80.9 67 67.9 82.8 54.8 81.9 CV-08 
16.813 methylated alkane 80.9 67 67.9 54.7 82.8 81.8 CV-08 
17.386 No Hits 153.3 81.3 152.3 109.4 137.1 67.3 CV-17 
17.484 No Hits 81.9 67.3 82.9 41.1 57 84.4 CV-17 
17.601 No Hits 82 93.2 41.1 107.3 54 91.4 CV-16, CV-17 
17.655 No Hits 82 93.3 107.4 79.5 106.4 54.2 CV-17 
17.799 No Hits 41.1 56.1 84.9 56.9 82.9 103.2 CV-17 
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18.059 No Hits 110.3 82.1 95.3 153.2 137.5 109.3 CV-17 
18.93 No Hits 81.3 95.3 67.3 41.1 43.1 123 CV-17 
19.086 Methylated Alkane 41.1 70.7 43 57 69.9 84.4 CV-16 
19.14 No Hits 41.1 57.1 70.9 70 73.2 84.2 CV-17 
19.555 5-methyl-quinoline 141.5 142.5 115.5 139.5 143.5 75.3 CV-16, CV-17 
19.796 No Hits 95.3 81.4 137.7 83 123.2 96.2 CV-17 
19.797 2-methylnaphthalene 141.3 142.2 115.2 81.1 40.8 39.8 CV-14 
20.255 No Hits 141.5 142.6 41 115.4 83.1 43 CV-16, CV-17 
20.296 No Hits 117.1 90 141.1 142.1 88.9 62.9 CV-08 
20.323 Methylated Alkane 57 41.2 70.8 43 70.1 84.5 CV-16, CV-17 
20.524 No Hits 93.3 121.4 135.8 107.3 94.2 79.4 CV-17 
20.556 No Hits 104.1 40.9 56.9 42.8 76.1 70.5 CV-13 
20.571 methylated alkane 40.9 42.6 56.8 70.6 69.7 83.7 CV-14 
20.598 methylated alkane 56.8 40.9 42.7 70.6 69.9 84.5 CV-14 
21.244 Methylated Alkane 57 41.2 70.6 42.9 84.7 56.2 CV-16 
21.262 methylated alkane 57.1 41.2 43.1 70.7 70 56 CV-17 
22.148 No Hits 83 43 41.2 70.4 55.9 69 CV-16 
22.181 No Hits 83.1 43.1 41.1 88.9 70.7 70 CV-16, CV-17 
22.385 No Hits 82.9 42.8 41 70.2 69.5 55.9 CV-13 
22.413 No Hits 42.7 82.8 40.9 70.4 69.2 88.9 CV-14 
23.079 No Hits 105.4 94.2 133.4 91.4 119.5 107.3 CV-16 
23.1 No Hits 119.5 94.1 91.3 105.4 107.3 95.2 CV-17 
23.368 No Hits 93.9 105.2 91 119.2 93.1 107.1 CV-14 
23.397 No Hits 89.2 43 56 41.2 68.9 70.7 CV-16, CV-17 
23.611 No Hits 40.9 88.9 42.8 55.7 70.4 73 CV-13 
23.631 No Hits 88.8 42.8 40.9 70.1 55.8 68.8 CV-14 
23.643 No Hits 40.8 88.8 42.7 70.3 55.8 68.8 CV-14 
23.693 No Hits 79.4 80.2 123.4 81.4 161.3 41.2 CV-17 
23.958 No Hits 91 119 105 92.9 72.9 93.9 CV-08 
24.577 No Hits 156.6 141.6 155.5 93.4 69 91.3 CV-16, CV-17 
24.702 No Hits 161.5 105.3 93.3 91.3 107.4 119.5 CV-16 
24.988 No Hits 161.2 91.2 79 93.1 105.2 133.1 CV-14 
25.205 7-ethyl-quinoline 141.5 156.5 155.6 153.5 115.4 128.6 CV-16, CV-17 
25.369 No Hits 156.5 141.5 155.4 157.7 41.2 91.3 CV-16 
27.14 No Hits 69.1 41.2 107.3 43.3 67.3 93.3 CV-16 
27.159 No Hits 43.3 107.3 93.3 41.2 69.2 95.4 CV-17 
27.418 No Hits 43 107.1 40.9 68.8 93.1 79.1 CV-14 
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28.027 No Hits 107 93 69 79 151 91 CV-08 
29.74 methylated alkane 41.1 70.9 57.1 43 84.7 70.1 CV-16, CV-17 
29.993 No Hits 56.9 41 70.7 42.8 40 84.1 CV-13 
30.01 No Hits 40.9 56.9 70.6 42.8 84.4 39.9 CV-14 
30.847 No Hits 102.2 40.8 121.1 173.9 103.1 91.2 CV-14 
34.29 Methylated Alkane 41.2 57 71 43 84.6 70 CV-16, CV-17 
34.613 No Hits 56.9 40.9 70.5 42.8 84.2 69 CV-14 
34.857 benzophenone 105.4 182.4 77.4 51.4 181.5 50.4 CV-16, CV-17, CV-14 
35.122 Benzophenone 105.2 182.2 77.1 181.4 51.2 40 CV-13 
35.43 No Hits 173.2 110.8 82.8 55 155.1 99 CV-14 
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